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General Introduction

General introduction 11
1.1. LEUKEMIA
– In science the credit goes to the man who convinces the world, not to the
 man to whom the idea fi rst occurs. – 
William Osler (1849–1919) Canadian physician.
In 1845 both the British pathologist John Hughes Bennett and the German pathologist 
Rudolf Virchow described leukemia as a lethal disease characterized by enlargement of 
the spleen, and an excess of cells in the blood.1-3 Although both claimed to have been 
the fi rst to describe leukemia, and current textbooks usually ascribing the discovery 
of this disease to either one of them, it was in fact the French physician Alfred Donné 
who published the fi rst description of leukemia in his book Complimentary course on 
microscopy for medical studies in 1844.4,5 Although merely armed with a microscope, 
Donné actually believed that the excess of cells he observed in the blood of patients 
with this mysterious disease was a result of an arrest in maturation of intermediate 
blood cells.4,5 Nowadays we know that Donné could not have been more right, as leuke-
mia (Greek for “white blood”) is a type of cancer that is characterized by uncontrolled 
accumulation of immature white blood cells in the bone marrow.
Normally, the bone marrow is responsible for the formation of new blood cells 
(hematopoiesis), which is a tightly balanced and highly organized process of prolifera-
tion, diff erentiation, maturation, and cell survival. In case of leukemia, malignant cells 
eventually replace the entire population of healthy blood cells, resulting in anemia (low 
number of red blood cells), internal bleeding (low number of platelets), and increased 
susceptibility to infections (low number of normal white blood cells). Ultimately, leu-
kemic cells enter the peripheral blood circulation and infi ltrate other organs like the 
spleen, liver, and kidneys. When left  untreated, leukemia is a lethal disease. 
1.1.2. Types of leukemia
Like cancer is not simply a disease, but rather a generic term for over a hundred of 
diff erent diseases, leukemia is a collective noun for over a dozen of diff erent leukemias. 
First and foremost, diff erent types of leukemia are defi ned by the type of blood cell 
that was subject to malignant transformation. Driven by cytokines or hematopoietic 
growth factors, all types of blood cells develop from a communal pool of self-renewing 
pluripotent hematopoietic stem cells (HSCs). Th ese pluripotent HSCs are able to 
diff erentiate towards either lymphoid or non-lymphoid committed stem cells. Lym-
phoid stem cells have the ability to diff erentiate and mature into either B- or T-lym-
phocytes, whereas non-lymphoid stem cells eventually diff erentiate towards myeloid 
cells like granulocytes (i.e. neutrophils, eosinophils, and basophils), monocytes, and 
macrophages, or towards megakaryocytes, platelets and erythrocytes. Depending on 
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the lineage of the cell in which the leukemia originates, leukemia can be divided into 
lymphoid (or lymphocytic) and non-lymphoid (or myeloid) leukemia. Accordingly, 
lymphoid leukemias can be subdivided into B- and T-cell leukemias. Likewise, based 
upon the type of non-lymphoid cell that is aff ected, several subgroups of non-lymphoid 
(or myeloid) leukemias can be identifi ed. 
Both lymphoid and myeloid leukemias can further be classifi ed into acute and 
chronic leukemias. Acute leukemias are rapidly progressing leukemias involving highly 
immature hematopoietic progenitors that are diff erentiated only limitedly. In contrast, 
chronic leukemias involve well-diff erentiated (but immunologically incompetent) cells, 
and usually develop more slowly. 
1.1.3. Childhood acute lymphoblastic leukemia (ALL) 
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, rep-
resenting about one quarter of all childhood cancers. Annually, 3-4 per 100.000 children 
are diagnosed with this type of leukemia. In approximately 75% of the childhood ALL 
cases, the leuke mic cells are characterized by recurrent chromosomal abnormalities, 
including balanced chromosomal translocations and numerical anomalies.6 Based on 
these recurrent abnormalities, ALL can even be further subdivided into a variety of 
genetic subtypes, all with distinct etiologies, biological and clinical features, treatment 
outcomes, and genetic constitutions.6,7 Fortunately, the prognosis for childhood ALL 
in general nowadays is favorable, with approximately 80% of the children treated with 
combination chemotherapy surviving their disease.6
1.2. INFANT ACUTE LYMPHOBLASTIC LEUKEMIA
Unfortunately, for some subgroups of patients the prognosis still remains poor. In 
approximately 4% of the childhood cases, ALL is diagnosed in an infant (i.e. a child 
less than 1 year of age). Infants with ALL form the most striking example of a subgroup 
of ALL patients who did not benefi t from the greatly improved treatment regimens. 
Although complete remission (CR) is achieved in the vast majority (~95%) of these 
very young children8,9, a good outcome usually is hampered by an exceedingly high 
relapse rate, typically occurring within the fi rst year upon diagnosis. Consequently, the 
overall survival for infant ALL patients to date remains a dismal 40-50%.10,11
1.2.1. MLL gene rearrangements and infant ALL
ALL in infants is characterized by an exceptionally high incidence of leukemia specifi c 
chromosomal translocations involving the Mixed Lineage Leukemia (MLL, ALL-1 or 
HRX) gene, which occur in approximately 80% of the cases.12,13 Such chromosomal 
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translocations arise during illegitimate recombination events that result in the inter-
change of fragments between non-homologous chromosomes. Th e MLL gene comprises 
a so-called breakpoint cluster that behaves like a hot-spot for chromosomal transloca-
tions which reciprocally fuse the N-terminal portion of the MLL gene to the C-terminal 
region of one of its translocation partner genes (Figure 1), of which over 50 have been 
described.14 Remaining in-frame, these gene fusions encode chimeric transcripts which 
give rise to oncogenic fusion proteins with pronounced transforming potential (ex-
tensively reviewed in ref.15,16). Th e genesis of these MLL fusion proteins are believed 
to be initiating events in the development of infant ALL, and take place in utero (see 
chapter 2). By far the most common MLL rearrangements found in infant ALL patients 
are translocations t(4;11) (~50%), t(11;19) (~20%) and t(9;11) (~10%), fusing the MLL
gene to the transcription factors AF417, ENL18 and AF919 respectively. 
1.2.2. The immunophenotype of infant ALL
Leukemic cells from Infant ALL patients carrying MLL rearrangements typically dis-
play an immature CD19-positive (CD19+), CD10 negative (CD10–) precursor B-lineage 
(pro-B) immunophenotype, and are oft en characterized by co-expression of myeloid-
associated antigens like CD15 and CDw65. Mature B-cell or T-cell phenotypes are 
observed only sporadically20,21. In contrast, infant ALL cells carrying germ line MLL
genes far more oft en resemble common (CD19+,CD10+) or pre-B (CD19+,CyIgμ+) im-
munophenotypes.
1.2.3. Prognostic factors in infant ALL
Among many prognostic factors identifi ed for infant ALL, including the presence of 
translocations involving MLL, age less than 6 months, high white blood cell counts, lack 
of CD10 expression, myeloid antigen co-expression, central nervous system involve-
ment, and a poor in vivo response to prednisone, the presence of MLL rearrangements 
seems to be the most important independent predictor for an adverse outcome (see 
chapter 2). Several studies have demonstrated that particularly those infant ALL cases 
carrying MLL rearrangements experience a poor prognosis, whereas the prognosis for 
infant ALL patients bearing germ line MLL genes is much more favorable, with long-
term survival rates easily exceeding 60%.22-26
1.2.4. Cellular drug resistance in infant ALL
Considerably contributing to the dismal prognosis of the majority of infant ALL patients 
seems to be cellular drug resistance. Leukemic cells from infant ALL patients are sig-
nifi cantly more resistant in vitro to several important chemotherapeutic drugs com-
pared to cells from older children with ALL, especially to glucocorticoids (prednisone 
and dexamethasone) and L-asparaginase.27,28 Since the in vitro and in vivo response to 
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prednisone is highly predictive for clinical outcome in childhood ALL in general25,29,30, 
the poor prognosis for infant ALL may to a large extent be associated with the observed 
resistance to glucocorticoids, and presumably with resistance to other drugs as well. 
Th us, with current treatment protocols for childhood ALL failing in over 50% of the 
infant ALL cases, more eff ective (innovative) therapeutic strategies are urgently needed 
in order to improve prognosis for this aggressive type of leukemia.
Although relatively resistant to several important chemotherapeutic drugs, in-
fant ALL cells appeared to respond remarkably well to the cytidine analogue Ara-C 
(cytosine arabinoside). Infant ALL cells are signifi cantly more sensitive to Ara-C as 
compared to cells from older children with ALL.27,28  Th is observation suggested that 
infant ALL might resemble a subclass of childhood ALL that may well benefi t from 
intensifi ed treatment with Ara-C. Th erefore, in 1999 a novel collaborative treatment 
protocol (INTERFANT-99) was developed with intensifi ed use of Ara-C throughout 
the protocol, in order to provide a more specifi c treatment for infant ALL patients.
Figure 1.1 
AF4
MLL
MLL-AF4 
AF4-MLL 
BEFORE TRANSLOCATION                                       AFTER TRANSLOCATION 
Chromosome 11 
Chromosome 4 t(4;11)(q21;q23) 
Figure 1. MLL rearrangement.
Schematic representation of chromosomal translocation t(4;11)(q21;q23), fusing the N-terminal region of the MLL gene on chromosome 11 to 
the C-terminal region of the AF4 gene on chromosome 4, and vice versa.
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1.3. OUTLINE OF THIS THESIS
Chapter 2 of this thesis comprises a review describing important aspects of infant ALL, 
including MLL rearrangements, the cell of origin, the prenatal origin of this type of 
leukemia, the etiology and risk factors, prognostic factors, cellular drug resistance, 
and putative therapeutic approaches to improve prognosis (mostly based on studies 
described elsewhere in this thesis). 
Chapter 3 describes a study investigating the mechanism underlying the remarkable 
sensitivity of infant ALL cells to Ara-C. Th is study demonstrates that elevated expres-
sion of the gene encoding the human equilibrative nucleoside transporter 1 (ENT1), on 
which Ara-C is mainly dependent to permeate the cell membrane, provides a plausible 
explanation for this phenomenon. Since Ara-C is a drug that is typically used in the 
treatment of acute myeloid leukemia (AML), and MLL rearranged infant ALL cells 
oft en display myeloid characteristics, a reasonable hypothesis would be that Ara-C 
sensitivity (as a result of increased ENT1 expression) is associated with the presence of 
MLL rearrangements. In chapter 4 we address this hypothesis, and show that there is 
no direct association of the presence of MLL rearrangements and sensitivity to Ara-C. 
In chapter 5 we investigated whether the mechanism underlying Ara-C sensitivity in 
infant ALL (i.e. increased ENT1 expression), also applies to childhood AML. Th is study 
revealed that elevated expression of ENT1 in childhood AML samples not only predicts 
sensitivity to Ara-C, but also appeared to be associated with sensitivity towards other 
nucleoside analogue drugs such as cladribine, decitabine, and gemcitabine.
Since infant ALL cells in vitro are resistant to multiple chemotherapeutic drugs27,28, 
infant ALL patients may legitimately be classifi ed as multidrug resistant. Th erefore, a 
plausible explanation for the chemo-resistant character of infant ALL cells could be the 
involvement of multidrug resistance proteins that function as specialized membrane 
pumps capable of traffi  cking chemotherapeutic drugs out of the cell. In chapter 6 we 
investigated whether drug resistance in infant ALL is a consequence of increased drug 
effl  ux mediated by multidrug resistance pumps.
Given the poor response of infant ALL patients to current chemotherapeutic regimes, 
it is of utmost importance to explore innovative therapeutic strategies. For this, we set 
out to search for molecular targets suitable to direct therapy against. In collaboration 
with Dr. Scott Armstrong (Dana Farber Cancer Institute, Harvard Medical School, 
Boston, MA, USA) we observed that the gene encoding Fms-like tyrosine kinase recep-
tor 3 (FLT3) is highly expressed in MLL rearranged ALL samples31. As a consequence of 
high-level expression we demonstrated that FLT3 is constitutively activated in an MLL
rearranged ALL cell line, promoting leukemic cell proliferation and survival.32 In chap-
ter 7 we studied whether high-level expression of FLT3 is associated with constitutive 
FLT3 signaling in primary MLL rearranged infant ALL cells. Moreover, we investigated 
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whether inhibition of FLT3 using a small molecule FLT3 inhibitor may represent a 
novel therapeutic approach against this type of leukemia.
Constitutively activated FLT3 also frequently occurs in primary AML cells, predom-
inantly caused by specifi c mutations within the FLT3 gene. In chapter 7 and chapter 
8 we studied whether these activating mutations also occur in MLL rearranged infant 
ALL, and if so, how frequently these genetic abnormalities occur. For this we screened 
the entire FLT3 gene for the presence of known and novel mutations, and demonstrate 
that the main etiology for constitutive FLT3 signaling in MLL rearranged infant ALL 
cells is over-expression of wild-type FLT3. 
In addition to exploring the use of over-expressed genes as therapeutic targets for 
infant ALL, we also studied genes that appeared to be under-expressed in infant ALL 
as compared to other ALL subtypes. Chapter 9 describes a study demonstrating that 
MLL rearranged infant ALL is characterized by the silencing of the tumor suppressor 
gene FHIT, and how this phenomenon provides a rationale for the use of demethylating 
agents as therapeutic intervention for these patients.
Finally, chapter 10 summarizes the work presented in this thesis, accommodated 
with general conclusions and future perspectives. Chapter 11 comprises a concise 
layman’s summary of this thesis in Dutch. 
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ABSTRACT
Despite the greatly improved treatment regimes for childhood acute lymphoblastic 
leukemia (ALL) in general, resulting in long-term survival in approximately 80% of 
cases, current therapies still fail in >50% of ALL cases diagnosed within the fi rst year of 
life (i.e. in infants). Th erefore, more adequate treatment strategies are urgently needed 
to also improve prognosis for these very young patients with ALL. Here we review the 
current acquaintance with the biology of infant ALL and describe how this knowledge 
may lead to innovative therapeutic approaches.
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INTRODUCTION
Current treatment strategies for childhood acute lymphoblastic leukemia (ALL) now-
adays result in long-term survival in approximately 80% of the cases.1 Unfortunately, 
for some subgroups of patients the prognosis still remains poor. Infants (i.e. children 
less than 1 year of age) form the most striking example of ALL patients who have not 
benefi ted from the greatly improved treatment regimens that have developed over 
recent decades. Although morphological complete remission (CR) is achieved in the 
vast majority (~95%) of these very young children2,3, a favorable outcome usually is 
hampered by an exceedingly high relapse rate, typically within the fi rst year aft er CR. 
Consequently, the overall survival for infant ALL patients to date remains at best a 
dismal 40-50%4 (Table 1). Th erefore, novel therapeutic strategies are urgently needed 
for this aggressive type of leukemia. Here we review the current knowledge on infant 
ALL and discuss how this information may translate into therapeutic possibilities that 
may improve prognosis.
Table 1. Treatment results in infant ALL.
Study group 4yr-EFS Sample size Reference
DFCI 85-01 54% n=23 Silverman, et al (1997)5
BFM 43% n=105 Dordelmann, et al (1999)6
EORTC-CLCG 43% n=25 Ferster, et al (1994)7
CCG-1883 39% n=135 Reaman, et al (1999)3
CCG-107 33% n=99 Reaman, et al (1999)3
UKALL-92 33% n=86 Chessells, et al (2002)8
POG 8493 28% n=82 Frankel, et al (1997)2
POG (Alternating drugs) 17% n=33 Lauer, et al (1998)9
MLL GENE REARRANGEMENTS 
Infant ALL is characterized by an exceptionally high incidence of leukemia-specifi c 
rearrangements involving the Mixed Lineage Leukemia (MLL, ALL-1 or HRX) gene 
on chromosome band 11q23, which occur in about 80% of the cases.10,11 Th ese chro-
mosomal abnormalities, believed to be initiating events in leukemogenesis, usually 
involve reciprocal translocations fusing the N-terminal portion of the MLL gene to 
the C-terminal region of one of its translocation partner genes, of which over 50 have 
been described.12,13 Remaining in-frame, such gene fusions encode chimeric transcripts 
which give rise to oncogenic fusion proteins with pronounced transforming potential 
(extensively reviewed in refs. 14 and 15). By far the most common MLL translocations 
found in infant ALL patients are t(4;11), t(11;19) and t(9;11), fusing MLL to the tran-
scription factors AF416, ENL17 and AF918 respectively. Among several prognostic factors 
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identifi ed in infant ALL (described below), the presence of MLL rearrangements seems 
to be the most important independent predictor of an adverse outcome. In particular, 
infant ALL cases carrying MLL rearrangements experience a poor prognosis, whereas 
the prognosis for infant ALL patients bearing germ line MLL genes is much more 
favorable, with long-term survival rates easily exceeding 60%.19-22 Th is, together with 
recent micro-array studies demonstrating that MLL rearranged leukemias display char-
acteristic gene expression profi les that distinguish them from other childhood ALL 
subtypes23,24, suggests that MLL rearranged ALL represents a unique biological entity 
that is frequently diagnosed at very young age (i.e. within the fi rst year of life). In this 
review we will specifi cally focus on MLL rearranged ALL (from here on abbreviated as 
MLL) in infants. 
THE CELL OF ORIGIN
Infant MLL cells typically display an immature CD19-positive (CD19+) and CD10 
negative (CD10-) precursor B-lineage (i.e. pro-B) immunophenotype, and are oft en 
characterized by co-expression of myeloid-associated antigens like CD15 and CDw65. 
Mature B-cell or T-cell phenotypes are observed only sporadically.25,26 In contrast, infant 
ALL cells carrying germ line MLL genes more oft en resemble common (CD19+,CD10+) 
or pre-B (CD19+,CyIgμ+) immunophenotypes. Recently Fais et al demonstrated that 
the expression of CD1d, a monomorphic molecule involved in glycolipid presentation, 
is associated with infant age (<1 year), the pro-B immunophenotype and the presence 
of translocation t(4:11).27
Co-expression of myeloid markers on highly immature B-cell progenitors in addi-
tion to observed lineage switches from ALL to acute myeloid leukemia (AML)28 and 
vice versa29,30 in MLL rearranged leukemias, strongly points to a type of B-cell/myeloid 
progenitor31,32 as the cell from which infant MLL originates. Th e characteristic gene ex-
pression profi le associated with MLL rearranged ALL seems to support this (reviewed 
by Armstrong, et al33). However, increasing evidence is emerging that the self-renewal 
properties of certain types of high-risk acute leukemias are sustained by the presence 
of a minor sub-population of leukemic stem cells from which the leukemia originates. 
Hotfi lder et al recently reported the presence of leukemia-specifi c translocations in 
primitive lymphoid-restricted CD34+CD19– cells purifi ed from primary t(4;11) positive 
infant ALL samples which predominantly consist of leukemic B-lineage CD34+CD19+
cells. Th is indicated that t(4;11) positive ALL actually originates in a primitive lym-
phoid-restricted progenitor/stem cell34, which give rise to leukemic cells that, to some 
extent, retain the ability to diff erentiate towards the pro-B (CD34+CD19+CD10–) com-
partment. In support of this latter is a study demonstrating that CD34+CD19– cells 
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purifi ed from primary human B-lineage ALL samples injected into non-obese diabetic/
severe combined immunodefi cient (NOD/SCID) mice, induced leukemia in vivo with 
both immunophenotypes and karyotypes similar to that of the primary leukaemia.35
Whether a CD34+CD19– progenitor/stem cell also lies at the basis of infant MLL carry-
ing other types of MLL translocations remains to be confi rmed.
PRENATAL ORIGIN OF INFANT ALL 
It is believed that the fi rst genetic event necessary for the development of childhood 
ALL frequently originates in utero, following additional postnatal mutations that lead 
to clinically overt leukemia. Th is seems particularly true for children ≤3 years of age as 
leukemic cells from these patients predominantly exhibit fetal-type DJ
H
 junctions of the 
complementarity determining region 3 (CDR3) of the immunoglobulin H chain that 
lack so called N regions, which are added during DJ
H
 recombination events later in fetal 
development36. Surprisingly, Fasching et al did fi nd N regions to be present in infant 
ALLs specifi cally carrying t(4:11) translocations, suggesting that the initial transform-
ing events took place at a later developmental stage when compared to children who 
developed leukemia between 1 and 3 years of age.37 Th e prenatal origin for t(4:11) 
positive infant leukemias, however, has been well established by studies identifying 
unique clonotypic MLL-AF4 fusion sequences in neonatal blood spots from children 
developing ALL within the fi rst two years of life.38 Moreover, detection of identical 
clonal non-constitutive MLL translocations in the leukemic cells from several identi-
cal twins, strongly suggests that malignant cells with acquired MLL rearrangements 
of one twin were transferred to the other fetus by intra-placental metastasis.39-42 Th us, 
with infant MLL indisputably originating in utero, but yet diplaying N-region positive 
DJ
H
 junctions strongly suggests an exquisitely short latency period for these leukemias 
to develop into overt disease. Th is implies that upon the development of the fi rst ge-
netic hit (presumably the MLL translocation) only limited mutagenic events are further 
required. Alternatively, the initial genetic event in infant MLL may create genetically 
highly instable genomes that are particularly susceptible to additional genetic altera-
tions, additionally required to fully develop this type of leukemia.
ETIOLOGY AND RISK FACTORS 
As with most cancers, the cause of infant ALL largely remains unknown. However, 
several factors have been noted that increase the risk to develop infant ALL. As the 
initiating event of most (if not all) infant leukemias occur in utero, factors that promote 
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malignant transformation in these children most likely strike shortly before or during 
pregnancy. For example, both maternal alcohol consumption during pregnancy and 
paternal smoking one month prior to pregnancy have been shown to be associated with 
increased risk of infant ALL.43 Moreover, there are indications that maternal exposure 
during pregnancy to low-dose radiation from the Chernobyl accident has been respon-
sible for an excess of infant ALL cases in contaminated areas (reviewed by Moysich 
et al44). Furthermore, several studies in children <4 years of age suggested that a high 
birth weight and a maternal history of fetal loss are associated with increased risk of 
developing ALL.45-47 However, Ross et al showed that only high birth weight, complied 
as a signifi cant risk factor for developing ALL within the fi rst year of life.48
Rearrangements involving the MLL gene frequently arise in therapy-related second-
ary leukemias in older children exposed to drugs that function as topoisomerase II 
inhibitors like epipodophyllotoxins (such as etoposide) and anthracyclines. At fi rst 
intensive treatment with topo-II inhibitors appeared to predominantly result in the 
development MLL rearranged AML49,50, however, increasing numbers of cases of ther-
apy-related MLL rearranged ALL are emerging (reviewed by Anderson et al51). Th ese 
fi ndings led to the hypothesis that transplacental exposure to topo-II inhibitors may 
be involved in the etiology of infant MLL.52 Th is hypothesis is strongly supported by 
the fi nding that both primary infant MLL and therapy-related secondary acute leuke-
mias characterized by translocation t(4;11) show MLL breakpoints that are similarly 
distributed within the MLL breakpoint cluster region.53 Several dietary biofl avonoids 
like quercetin (found in certain fruits and vegetables) and genistein (soy) are known 
topo-II inhibitors, and are capable of crossing the placenta54, and were shown to induce 
MLL cleavage in vitro.55 Th ese data led to the postulation that maternal consumption 
of dietary biofl avonoids may potentially lead to MLL translocations in utero and con-
tribute to the development of infant MLL. However, as yet only an increased risk of 
infant AML, but not of ALL, has actually been linked to maternal consumption of food 
containing topo-II inhibitors.56 Moreover, recently reported contradicting results dem-
onstrate that maternal consumption of fresh vegetables and fruits during pregnancy 
was associated with a decreased instead of increased, risk of infant MLL.57
A common structural feature shared by many topo-II inhibitors (including fl avo-
noids) is a quinone moiety. Metabolites generated as by-products of the metabolism of 
quinone-containing compounds within the fetal liver, thus include quinones58, which 
have been shown to cleave both the MLL gene as well as its fusion partner AF4 at topo-
II cleavage sites.59 Th us, apart from intact topo-II inhibitors, their quinone-containing 
metabolites may also be involved in the development of infant MLL. Nevertheless, the 
window of opportunity for quinones to induce DNA cleavage usually is rather small as 
they are normally detoxifi ed by NAD(P)H:quinone oxidoreductase 1 (NQO1). How-
ever, the NQO1 gene, is subject to a C‡T polymorphism at nucleotide 609 in exon 6 
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which results in an amino-acid change (Pro187Ser) and gives rise to a NQO1 protein 
with signifi cantly decreased enzymatic activity.60,61 Interestingly, the occurrence of al-
leles generating low activity variants of NQO1 have been associated with increased risk 
of infant MLL62, but not with ALL without MLL rearrangements in older children.63
Taken together this suggests that elongated exposure to quinones may specifi cally in-
duces MLL rearranged leukemias. More recently, however, a similar study has been re-
ported in which this polymorphism appeared to be associated with infant ALL without 
MLL rearrangements, but not with infant MLL.64
PROGNOSTIC FACTORS IN INFANT ALL
In infant ALL, many prognostic factors have been described. All of these factors, 
summarized in Table 2, have been shown to confer a poor outcome mostly in uni-
variate analyses, but also are closely related to each other.19,20,65 In multivariate analysis 
including these factors, the presence of MLL rearrangements oft en remains the only 
independent factor predicting a poor outcome.19,21,65 Th e event-free survival (EFS) for 
MLL rearranged infant cases (5–34%) is signifi cantly worse than for their MLL germ 
line counterparts (42-92%) (Table 2). Some studies reported that only t(4;11) positive 
infant ALL patients experience a poor prognosis, whereas patients carrying other types 
of MLL rearrangements fare equally well as MLL germ line cases.3,65 However, in a large 
cohort of infant MLL cases all types of MLL rearrangements were associated with a 
poor prognosis at this age66, which also appears to be true for the majority of studies 
identifying MLL rearrangements as a prognostic factor (Table 2). 
Although CD10 negativity (or a so-called pro-B phenotype), age less than 6 months, 
high white blood cell (WBC) counts, and central nervous system (CNS) involvement 
are strongly associated with the presence of MLL rearrangements, several studies also 
identifi ed these clinical features as independent predictors of a poor prognosis (Table
2). Nevertheless, it can be concluded that the presence of MLL rearrangements and 
young age are the strongest independent prognostic factors. Th is is confi rmed by 
preliminary results from the very large collaborative infant ALL study Interfant-99, 
which is currently in progress (coordinated by Dr. R. Pieters). Finally, Dordelmann 
et al demonstrated that a poor in vivo response to prednisone appeared to be a strong 
adverse prognostic factor, even among MLL rearranged cases.6
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Table 2. Prognostic factors in infant ALL (<1 year of age).
Prognostic 
factor 
Unfavorable / 
favorable feature
Sample 
size
Outcome (≥3yr-EFS) Type of analysis References
MLL gene 
rearrangements
Present / absent n=96
n=40
n=37
n=59
n=55
n=28
n=38#
n=27
n=56
n=82
19% (n=78) vs. 46% (n=18)
28% (n=29) vs. 100% (n=11)§
5% (n=27) vs. 89% (n=10)¶
28% (n=29) vs. 42-56% (n=30)
34% (n=42) vs. 92% (n=13)
13% (n=19) vs. 67% (n=9)
9% (n=24) vs. 57% (n=14)
6% (n=18) vs. 56% (n=9)
5% (n=21) vs. 47% (n=28)*
3% (n=33) vs. 50% (n=49)*
Univariate
Univariate
Univariate
Univariate
Univariate
Multivariate
Multivariate
Multivariate
Multivariate*
Multivaraite*
Rubnitz, et al (1994)131
Hilden, et al (1995)132
Taki, et al (1996)20
Dordelmann, et al (1999)6
Isoyama, et al (2002)133
Pui, et al (1994)134
Cimino, et al (1995)19
Pui, et al (1996)21
Heerema, et al (1999)65
Reaman, et al (1999)3
Age <6 / ≥6 months n=30
n=29
n=82
n=23
n=56
n=44**
n=88
n=106
n=222
15% (n=13) vs. 44% (n=17)
8% (n=13) vs. 42% (n=16)
18% (n=26) vs. 57% (n=56)
30% (n=9) vs. 71% (n=14)
Not specifi ed
28% (n=25) vs. 63% (n=19)
8% (n=38) vs. 44% (n=50)
32% (n=50) vs. 56% (n=56)
13% vs. 26-49%
Univariate
Univariate
Univariate†
Univariate
Univariate
Univariate
Multivariate
Multivariate
Multivariate‡
Pui, et al (1994)134
Pui, et al (1996)21
Frankel, et al (1997)2
Silverman, et al (1997)5
Heerema, et al (1999)65
Kosaka, et al (2004)135
Chessells, et al (1994)136
Dordelmann, et al (1999)6
Reaman, et al (1999)3
WBC count ≥100 / <100 x109/L n=24
n=88
n=23
n=106
n=222
Not specifi ed
24% (n=45) vs. 33% (n=43)
36% (n=14) vs. 86% (n=9)
37% (n=60) vs. 52% (n=46)
Not specifi ed
Univariate||
Univariate||
Univariate
Univariate
Multivariate||
Ishii, et al (1991)137
Chessells, et al (1994)136
Silverman, et al (1997)5
Dordelmann, et al (1999)6
Reaman, et al (1999)3
Immuno-
phenotype
CD10 negative / 
positive
Myeloid antigen co-
expression present 
/ absent
n=106#
n=71
n=28
n=37
n=21
n=104
n=45
n=152
n=43
n=22
27% (n=37) vs. 50% (n=69)
21% (n=47) vs. 54% (n=24)
28% (n=16) vs. 57% (n=12)
10% (n=27) vs. 86% (n=10) ¶
40% (n=10) vs. 73% (n=11)
35% (n=62) vs. 55% (n=42)
30% (n=28) vs. 56% (n=17)
27% (n=98) vs. 56% (n=54)
17% (n=14) vs. 39% (n=29)
10% (n=10) vs. 67% (n=12)
Univariate
Univariate
Univariate
Univariate
Univariate
Univariate
Univariate
Multivariate
Univariate
Univariate
Basso, et al (1992)26
Chessells, et al (1994)136
Ferster, et al (1994)7
Taki, et al (1996)20
Silverman, et al., (1997)5
Dordelmann et al (1999)6
Heerema, et al (1999)65
Reaman, et al (1999)3
Basso, et al (1992)26
Pui, et al (1994)134
CNS 
involvement
Present / absent n=41**
n=106
10% (n=10) vs. 57% (n=31)
19% (n=45) vs. 51% (n=81)
Univariate
Multivariate
Kosaka, et al (2004)135
Dordelmann, et al (1999)6
In vivo
prednisone 
response
Poor response / 
good response∝
n=105 15% (n=27) vs. 53% (n=78) Multivariate Dordelmann, et al (1999)6
§2-yr EFS. ¶Overall survival (OS) instead of event free survival (EFS). #Patients aged between 0 and 18 months. *t(4;11) cases only. †Age less than 9 months. 
‡Age less than 3 months. ||White blood cell count ≥50 x109/L. **MLL rearranged cases only. ∝Poor prednisone response is defi ned as the presence of ≥1000 
blasts/μL after a 7-day prednisone window (including one intrathecal dose of methotrexate on day one).
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CELLULAR DRUG RESISTANCE AND WHY CURRENT THERAPY FAILS
Cellular drug resistance seems to signifi cantly contribute to the dismal prognosis 
of infant ALL. About 30% of infant ALL patients show a poor in vivo response to 
prednisone6, compared with ~10% of all children with ALL.67 In addition, we showed 
that, compared with cells from older children diagnosed with ALL, leukemic cells from 
infant ALL patients are highly resistant to glucocorticoids (prednisone and dexametha-
sone) and L-asparaginase in vitro.68,69 As the in vitro and in vivo response to prednisone 
is highly predictive for clinical outcome in childhood ALL in general6,70,71, the poor 
prognosis for infant ALL may to a large extent be associated with cellular resistance 
to glucocorticoids. Interestingly, regardless of age, childhood pro-B ALL, which is the 
most commonly observed immunophenotype in infants with ALL (particularly in pa-
tients carrying translocation involving MLL), shows a similar drug resistance profi le as 
observed for infant ALL.69 Given that glucocorticoids generally fail to induce leukemic 
cell death in AML cells72,73, the unfavorable response to these drugs, especially in pro-
B/infant MLL may well be an epiphenomenon related to the diff erentiation stage of 
immature MLL rearranged pro-B ALL cells, that still display myeloid characteristics 
like the expression of myeloid-associated antigens (e.g. CD15 and CDw65).
Although infant MLL cells are relatively resistant to glucocorticoids when compared 
with other ALL subtypes, glucocorticoids should not be excluded from infant MLL 
treatment protocols, as the vast majority of leukemic cells are eliminated by prednisone6, 
and complete remission (CR) is achieved in virtually all cases (~95%) on glucocorti-
coid-containing induction therapies.2,3 Th e duration of these CRs, however, usually is 
rather short and typically occur within the fi rst year following diagnosis. Th is sug-
gests that small numbers of surviving cells rapidly give rise to a re-emerging leukemia. 
Surviving therapy, these cells presumably are even more resistant than the bulk of the 
leukemic cell population that was eliminated, simply as a result of selection. Refl ecting 
this latter point, most patients who experienced a relapse do not survive their disease.3
As immature (leukemic) stem cells usually are not prone (yet) to undergo apoptosis74, 
the self-renewing CD34+CD19– leukemic stem cells from which t(4;11) positive infant 
ALL seems to originate34, most likely are some of the few residual cells surviving initial 
therapy. Th erefore, adequate treatment for infant MLL may not only require more ef-
fi cient targeting of the bulk of the leukemic population, but may also demand targeting 
of the self-renewing leukemic stem cell. 
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THE CONUNDRUM OF CELLULAR DRUG RESISTANCE
An essential step of glucocorticoid-induced leukemic cell death, is binding to the in-
tracellular glucocorticoid receptor (GR).75 Possibly, the presence of either mutations 
or polymorphisms within the GR gene may lead to impaired binding of the gluco-
corticoid-GR complex, and as a result, to increased resistance to these drugs. To test 
this hypothesis, we recently screened the entire GR gene for the presence of genetic 
alterations in a large group of pediatric ALL patients, including a number of infant ALL 
samples. Several polymorphisms but not mutations were found in the coding region 
of the GR gene of childhood ALL cells. Correlating these data to both in vitro and in 
vivo glucocorticoid cytotoxicity, however, showed that these genetic variations did not 
contribute to glucocorticoid resistance.76
L-asparaginase exerts its cytotoxic eff ects by depleting cells of asparagine and glu-
tamine. It is believed that ALL cells are specifi cally sensitive to L-asparaginase due to 
their impaired capacity to synthesize asparagine as a result of reduced expression of 
asparagine synthetase (AS).77,78 However, the hypothesis that resistance of infant ALL 
cells towards L-asparaginase may be explained by elevated expression levels of AS, 
could not be confi rmed (R.W. Stam, unpublished observations). 
Finally, the chemo-resistant character of infant MLL cells may suggest the involve-
ment of multidrug resistance (MDR) proteins, which are specialized membrane trans-
porters capable of traffi  cking multiple drugs out of the cell. Nevertheless, we recently 
showed that drug resistance in infant ALL is not likely a result of increased drug effl  ux 
mediated by MDR pumps, such as P-glycoprotein (P-gp), multidrug resistance pro-
tein 1 (MRP1), lung resistance-related protein/major vault protein (LRP/MVP), and 
breast cancer resistance protein (BCRP), as the expression of the genes encoding these 
proteins is not elevated in infant ALL cells when compared with ALL cells from older 
children.79
Although highly informative, studies like these exclude only limited numbers of 
possible explanations for drug resistance in infant ALL at a time. As described later 
in this review, the rapidly advances in gene expression profi ling techniques nowadays 
available may notably accelerate our progress in understanding cellular drug resistance 
in infant ALL. 
NUCLEOSIDE ANALOGUE SENSITIVITY AND THERAPEUTIC POSSIBILITIES FOR 
INFANT ALL
Although relatively resistant to several chemotherapeutic drugs, we showed that infant 
ALL cells are more sensitive to the cytidine analogue cytosine arabinoside (Ara-C) 
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when compared with cells from older children with ALL.68,69 Sensitivity to Ara-C in 
infant ALL appeared not to be associated with rearrangements of the MLL gene, as 
both MLL rearranged and MLL germ line infant ALL cases appeared equally sensitive 
to this drug in vitro (Stam, et al manuscript submitted). Th e remarkable sensitivity to 
Ara-C seems most likely to be due to elevated expression of the human equilibrative 
nucleoside transporter 1 (hENT1)80, on which Ara-C is mainly dependent to perme-
ate the cell membrane.81-83 However, at high-dose Ara-C regimens generating high 
extracellular drug concentrations, Ara-C also enters the cell by passive diff usion and 
membrane transport via ENT1 is circumvented. Th us, infant ALL patients may benefi t 
from their elevated ENT1 expression when treated with low to moderate dosages of 
Ara-C, whereas this advantage presumably is lost when treated with high-dose Ara-C 
regimens. Nevertheless, improved outcomes have been reported for infant ALL patients 
treated with protocols in which high-dose Ara-C had been implemented during the 
consolidation phase.3,5 Moreover, improved outcome for adult pro-B ALL cases (both 
MLL rearranged and germ line) was noted with intensifi ed post-remission therapy 
including high-dose Ara-C.84 In 1999 the collaborative Interfant-99 treatment protocol 
for infant ALL was initiated that included the intensive use of both low and high-dose 
Ara-C throughout the duration of the treatment. 
In addition to Ara-C, infant ALL cells also appeared to be highly sensitive to the 
adenosine analogue 2-CdA (2-chlorodeoxyadenosine or cladribine).69 Whether 2-CdA 
sensitivity in infant ALL can also be attributed to increased ENT1 expression remains 
uncertain. Wright et al showed that 2-CdA does not seem to enter pediatric ALL cells 
via the same membrane nucleoside transport system responsible for cellular Ara-C 
infl ux85. However, the number of ALL samples used in that study was rather small. In 
contrast, we recently observed a signifi cant correlation between ENT1 expression and 
sensitivity to 2-CdA in a large cohort of childhood AML patients.86 Interestingly, in 
several studies synergistic eff ects between Ara-C and 2-CdA have been observed in 
vitro87-89, and the addition of 2-CdA to Ara-C containing regimens have been shown to 
increase the complete remission rates in AML.90,91 Taken together these observations 
support that regimens combining the use of Ara-C and 2-CdA may potentially be ben-
efi cial for infant ALL patients. Moreover, given the apparent sensitivity of infant ALL 
cells to nucleoside analogues, the use of newly developed nucleoside analogous like for 
example clofarabine92,93 and troxacitabine (troxatyl)94,95, may be interesting candidate 
drugs for further testing on infant MLL cells. 
Another specifi c class of nucleoside analogue drugs that may additionally be 
eff ective against infant MLL cells are DNA demethylating cytidine analogues, such 
as 5-azacytidine, 5-aza-2’-deoxycytidine (decitabine), or the recently identifi ed agent 
zebularine.96 Gutierrez et al showed that among several pediatric ALL subtypes, MLL
rearranged cases had the highest methylation index (i.e. number methylated genes/
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number of genes studied).97 Th us, MLL seems to be characterized by aberrant DNA 
hypermethylation. In concordance with this, we recently observed that the tumor sup-
pressor gene FHIT was silenced by 5’CpG island methylation in 100% of the infant MLL 
cases tested, whereas silencing of this gene in older children with ALL carrying germ 
line MLL genes was observed in only ~50% of the cases.98 Furthermore, we observed 
that ectopic expression of FHIT in the MLL cell line RS4;11, which lacks endogenous 
FHIT expression, induced leukemic cell death. Likewise, exposing MLL cells to the 
demethylating agent decitabine resulted in re-expression of FHIT protein expression 
and induced apoptosis. Th erefore, inhibition of DNA methylation may be an eff ective 
therapeutic strategy in the treatment of infant MLL, especially since we recently found 
that decitabine (like other cytosine analogues) depend on ENT1 to cross the cell mem-
brane,86 which is highly expressed in infant ALL cells.80
Nevertheless, as combinations of multiple chemotherapeutic drugs rather than single 
(types of) agents are required to cure acute leukemias, extending the drug repertoire 
against infant MLL with several nucleoside analogues will probably not be suffi  cient 
to signifi cantly improve the prognosis. Th us, in addition to exploring the use of eff ec-
tive nucleoside analogues, other innovative treatment strategies are needed that either 
overcome resistance to conventional drugs or which involve alternative novel agents 
that more eff ectively target infant MLL cells.
NOVEL THERAPEUTIC TARGETS
Th e rapidly advanced gene expression profi ling technologies, nowadays allow compari-
sons of multiple patient groups for the expression of vast numbers of genes, by approach 
covering the entire genome. Recently, we demonstrated how such a gene expression 
profi ling study can be a suitable approach in gaining new insights in drug resistance 
mechanisms at a genetic level. Comparing gene expression patterns in childhood 
ALL patients either resistant or sensitive to prednisone, vincristine, L-asparaginase, 
and daunorubicin in vitro, we found 124 diff erentially expressed genes to be related to 
resistance to one of these drugs.99 Moreover, this gene expression signature associated 
with drug resistance appeared to be highly predictive for clinical outcome. Interest-
ingly, only three of the 124 diff erentially expressed genes had been associated with drug 
resistance before, indicating that the mechanisms underlying resistance to these drugs 
are complex and largely unknown. Validation studies are now needed to determine the 
exact mechanisms that are involved, and whether these genes are causally involved in 
resistance. Some of these genes may represent universal determinants of drug resis-
tance that apply to all types of leukemia, including infant MLL. For example, one of the 
genes that appeared to be over-expressed in prednisone-resistant ALL cells was MCL-1, 
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an anti-apoptotic member of the BCL-2 family.99 Interestingly, we observed increased 
MCL-1 expression in infant MLL samples when compared with samples from older 
children with ALL, and found the expression of this gene to correlate with resistance 
to prednisone both in infant and non-infant ALL (Stam, et al unpublished data). MCL-
1 plays an important role in the survival of B-cell chronic lymphoblastic leukaemia 
(B-CLL)100, and multiple myeloma (MM) cells101, in which MCL-1 also is abundantly 
expressed. Recently, honokiol (a natural phenolic compound extracted from the root 
and stem bark of several Magnolia species) was found to induce leukemic cell death 
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Figure 1. Schematic and simplifi ed representation of putative therapeutic strategies against infant ALL.
FLT3 activation involves receptor dimerization and phosphorylation. Constitutively activated FLT3 promotes proliferation and leukemic cell 
survival. Additionally contributing to apoptotic resistance are elevated expression levels of MCL-1, which seems to particularly mediate 
resistance to glucocorticoid induced cell death. Nucleotides (depicted as hexagons) and their analogues are hydrophilic molecules and therefore 
require specialized membrane transport proteins (e.g. ENT1) to permeate leukemic cells. Inside the cell, nucleosides are being phosphorylated to 
form nucleotide triphosphates, and become incorporated into the DNA. Incorporated nucleoside analogue drugs such as Ara-C and 2-CdA induce 
apoptosis by blocking DNA synthesis. Incorporated demethylating cytidine analogues inhibit DNA (hyper)methylation by forming covalent 
complexes with DNA methyltransferases (like DNMT1), depleting the cell of functional DNMTs. 
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in primary B-CLL cell, by down-regulating MCL-1.102 Likewise, two synthetic MCL-1 
inhibitors, i.e. Seliciclib (CYC202 or R-roscovitine) and the R-etodolac (SDX-101) were 
shown to induce apoptosis in MM cells by directly targeting MCL-1.103,104 Interestingly, 
sub-cytotoxic doses R-etodolac sensitized MM cells to dexamethasone-induced cell 
death. Th erefore, glucocorticoid resistance in infant MLL cells might be overcome by 
compounds like Seliciclib and R-etodolac, or may directly induce leukemic cell death. 
Hence, inhibition of MCL-1 may be another therapeutic possibility for infant MLL. Im-
portantly, MCL-1 also plays an important role in the development of B and T lympho-
cytes105 as wells as in the survival of hematopoietic stem cells.105,106 Th erefore, targeting 
MCL-1 in infant MLL cells may also induce leukemic cell death of CD34+CD19– leu-
kemic stem cells. 
On the other hand, given the unique biological and clinical features associated with 
infant MLL, it seems likely that next to general drug resistance mechanisms, distinct 
mechanisms are also involved that are more specifi c for this type of leukemia. Hence, in 
addition to our micro-array studies in older children with ALL99, additional studies are 
being conducted on infant MLL patients in order to gain insights in the specifi c genes 
involved in drug resistance. 
Like the comparison of gene expression profi les from drug sensitive and resistant 
patients may lead to the identifi cation of genes involved in drug resistance, comparison 
of leukemia subtypes may identify genes that are uniquely expressed within certain 
types of leukemia, allowing the development of subtype-specifi c therapy. Several stud-
ies have demonstrated that based on their gene expression profi les, MLL rearranged 
ALL specifi es a unique type of leukemia displaying a gene expression pattern that is 
clearly distinguishable from other genetic subtypes of ALL.23,24,107,108 Soon aft er this 
fi nding, this MLL-specifi c gene expression signature proved to be of great value for the 
discovery of novel therapeutic targets. 
For example, FLT3, the gene encoding Fms-like tyrosine kinase 3, appeared to be 
one of the genes most consistently highly expressed in patients with MLL.23 FLT3 is 
important in early B-lineage development109 and as such is most abundantly expressed 
in immature B-cells110, which may explain the high expression of this gene in MLL cells, 
which typically display immature pro-B phenotypes. Normally FLT3 becomes activated 
upon binding of the hematopoietic growth factor FLT3 ligand (FLT3L). However, in 
AML the FLT3 gene is frequently subjected to mutations that constitutively activate 
this receptor in a ligand-independent manner, providing leukemic cells with a growth 
advantage and transforming capacity (reviewed in ref.111). As such, constitutively ac-
tivated FLT3 became a promising therapeutic target in AML. Several small molecule 
inhibitors (e.g. CEP-701, PKC412, and SU5416) effi  ciently inactivate FLT3 and induce 
leukemic cell death in vitro in AML cells depending on constitutive FLT3 signaling.112-
114 Th is fi nding prompted the initiation of several phase I/II clinical trials to determine 
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the effi  cacy of these inhibitors in refractory AML patients, and so far the results are 
promising.115-117 Interestingly, constitutively activated FLT3 also occurs in MLL patients 
carrying activating mutations, and in MLL patients merely displaying high-level ex-
pression of wild-type FLT3.118,119 We and others recently demonstrated that high-level 
wild-type FLT3 expression in primary infant MLL samples is associated with activated 
FLT3 and cytotoxic responsiveness to FLT3 inhibitors.119,120 Th ese data show that FLT3 
inhibition may represents a novel therapeutic strategy for infant MLL that urgently 
demands clinical testing. 
Interestingly, in combination with Ara-C, some FLT3 inhibitors display synergistic 
cytotoxic eff ects in leukemic cells that are dependent on FLT3 activation.121,122 Th is, 
together with the in vitro responsiveness of MLL cells to FLT3 inhibition, suggests that 
the addition of FLT3 inhibitors to Ara-C containing regimens may possibly improve 
treatment response for infant MLL. Th e sequence of administration, however, seems 
rather important. In order to achieve a synergistic eff ect, Ara-C and the FLT3 inhibitor 
CEP-701 should be administered simultaneously, or CEP-701 should be given directly 
following Ara-C. In contrast, pre-exposure to CEP-701 followed by Ara-C administra-
tion led to antagonistic eff ects.121
Noteworthy is the recent fi nding that FLT3 activating internal tandem duplications 
(ITDs) as observed in primary AML samples123, are also present in the CD34+/CD39–
leukemic stem cell fraction of these samples.124 Moreover, exposing these FLT3/ITD 
positive stem cells to the FLT3 inhibitor CEP701, inhibited engraft ment of these cells.124
Th ese data indicate that FLT3 inhibition in AML patients carrying this type of activating 
FLT3 mutation may be highly eff ective, as the leukemic stem cell is targeted as well. If 
constitutively activated FLT3 as a consequence of over-expression can be demonstrated 
in the CD34+CD19– leukemic stem cell fraction in primary infant MLL samples34, FLT3 
inhibition may also eff ectively target these leukemic stem cells.
Another example of a potential therapeutic target for infant MLL identifi ed by gene 
expression profi ling may be CD44. CD44 is a cell surface antigen that is strongly ex-
pressed on leukemic blasts from most AML patients.125 Interestingly, several studies 
reported apoptosis-inducing eff ects of specifi c monoclonal antibodies (e.g. HI44a and 
A3D8) against CD44 on both AML cell lines and primary AML cells.126-129 Gene expres-
sion profi ling revealed that CD44 also is highly expressed on MLL cells as compared 
to other ALL subtypes.23,130 Th is similarity to AML cells again stresses the biphenotypic 
character of infant MLL, and imply that antibody based treatment approaches targeting 
CD44 on infant MLL cells, may have therapeutic potential. Th e possible value of CD44, 
as well as of other candidate genes identifi ed by gene expression profi ling, as therapeu-
tic targets for infant MLL are currently being studied in our laboratory. 
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CONCLUDING REMARKS AND FUTURE PERSPECTIVES
Infant ALL is a rare malignancy that is characterized by an exceedingly high incidence 
(~80%) of MLL gene rearrangements, which is a strong predictor of an adverse out-
come. Current therapies fail in >50% of the MLL rearranged infant ALL (MLL) cases, 
indicating that innovative therapeutic strategies are urgently needed to improve prog-
nosis. It is, therefore, of utmost importance to unravel the unique molecular biological 
properties of this malignancy. As shown in this review, this already provides insights 
into what type(s) of drugs may be eff ective against infant MLL, and may provide a 
sense for why other classes of drugs are highly ineff ective. Furthermore, genome-wide 
analysis has led to the identifi cation of genes specifi cally expressed in infant MLL that 
may serve as therapeutic targets. Th erefore, continued molecular studies designed to 
validate the potential of such targets, or to further gain insight in the biology of infant 
MLL, should ultimately lead to the development of eff ective treatment regimens for this 
aggressive type of leukemia. 
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ABSTRACT
Infant acute lymphoblastic leukemia (ALL) is characterized by a high incidence of 
MLL gene rearrangements, a poor outcome, and resistance to chemotherapeutic drugs. 
One exception is cytosine arabinoside (Ara-C), to which infant ALL cells are highly 
sensitive. To investigate the mechanism underlying Ara-C sensitivity in infants with 
ALL, mRNA levels of Ara-C metabolizing enzymes were measured in infants (n=18) 
and non-infants with ALL (n=24). In the present study, infant ALL cells were 3.3-fold 
more sensitive to Ara-C (p=0.007) and accumulated 2.3-fold more Ara-CTP (p=0.011) 
upon exposure to Ara-C, compared with older children with ALL. Real-time quantita-
tive RT-PCR (TaqMan) analysis revealed that infants express 2-fold less of the Ara-C 
phosphorylating enzyme deoxycytidine kinase (dCK) mRNA (p=0.026) but 2.5-fold 
more mRNA of the equilibrative nucleoside transporter 1 (hENT1), responsible for 
Ara-C membrane transport (p=0.001). Th e mRNA expression of pyrimidine nucleo-
tidase I (PN-I), cytidine deaminase (CDA) and deoxycytidylate deaminase (dCMPD) 
did not diff er signifi cantly between both groups. hENT1 mRNA expression inversely 
correlated with in vitro resistance to Ara-C (r
s
=-0.58, p=0.006). Th e same diff erences 
concerning dCK and hENT1 mRNA expression were observed between MLL gene rear-
ranged (n=14) and germline MLL cases (n=25). An oligonucleotide microarray screen 
(Aff ymetrix) comparing MLL gene rearranged ALL with non-rearranged ALL patients, 
showed a 1.9-fold lower dCK (p=0.001) and a 2.7-fold higher hENT1 (p=0.046) mRNA 
expression in MLL gene rearranged ALL patients. We conclude that an elevated expres-
sion of hENT1, which transports Ara-C across the cell membrane, contributes to Ara-C 
sensitivity in MLL gene rearranged infant ALL. 
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INTRODUCTION
Although the treatment of childhood acute lymphoblastic leukemia (ALL) has improved 
tremendously over the last few decades, for some subgroups of patients the prognosis 
still remains poor. Infants (i.e. children ≤12 months of age) form such a subgroup. In-
fant ALL is characterized by a high incidence of rearrangements of the Mixed Lineage 
Leukemia (MLL, ALL-1 or HRX) gene on chromosome band 11q23. Th e frequency of 
these MLL gene rearrangements is possibly as high as 75% when detected with mo-
lecular techniques.1 Th e most common MLL abnormalities found in infants with ALL 
are the translocations t(4;11) and t(11;19) occurring in approximately 70% and 15% of 
the MLL gene rearranged cases, respectively.2,3,4,5 Th e immunophenotype of MLL gene 
rearranged infant ALL is usually that of an immature precursor B-lineage lacking CD10 
expression and co-expressing myeloid associated antigens. Furthermore, infants with 
ALL have a poor prognosis compared with older children with ALL, with an event-free 
survival (EFS) of ~35%.6 Th e most important reason for this poor prognosis is cellular 
drug resistance. Pieters et al7 showed that leukemic cells from infants with ALL are in 
vitro signifi cantly more resistant, especially to prednisone and L-asparaginase, than 
cells from older children with ALL. One exception, however, is cytosine arabinoside 
(Ara-C) to which infant ALL cells are highly sensitive.7 Th ese fi ndings have led to the 
development of a new treatment protocol for infants with ALL i.e. the INTERFANT-99 
protocol. 
Ara-C is a deoxycytidine analogue that is phosphorylated into its active form Ara-
CTP which competes with dCTP for incorporation into DNA. When incorporated, 
Ara-C blocks DNA synthesis and as a consequence the cell is subjected to programmed 
cell death (Figure 1). Nucleosides and their analogues are hydrophilic molecules and 
therefore require specialized membrane transport proteins to be transported into cells8. 
To permeate the cell membrane, Ara-C is mainly dependent on the human equilibra-
tive nucleoside transporter 1 (hENT1).9,10 Inside the cell, deoxycytidine kinase (dCK) 
phosphorylates Ara-C to form Ara-CMP, which is thought to be the rate-limiting 
activation step of Ara-C.11 Subsequently, Ara-CMP is further phosphorylated into Ara-
CDP by (deoxy)cytidylate kinase (UMP-CMPK) and fi nally into its active, cytotoxic 
form Ara-CTP by nucleotide diphosphate kinases (NDPKs). Pyrimidine nucleotidase 
I (PN-I) catalyzes the dephosphorylation of Ara-CMP12, thereby opposing the action 
of dCK. Cytidine deaminase (CDA) and deoxycytidylate deaminase (dCMPD) convert 
Ara-C to Ara-U and Ara-CMP to Ara-UMP, respectively, by deaminating the cytosine 
base. Inactivation of Ara-C and Ara-CMP by these deaminating enzymes decreases the 
amount of Ara-CTP and thus the cytotoxic eff ects of Ara-C.13,14
Th e mechanism underlying the remarkable Ara-C sensitivity in infants with ALL is 
unknown. Hypothetically, increased activation of the pro-drug Ara-C to its active, cyto-
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toxic form Ara-CTP caused by aberrant expression of the above described enzymes may 
be involved. Accordingly we determined the mRNA levels of these Ara-C metabolizing 
enzymes in a group of 18 infants and 24 children older than 12 months of age diagnosed 
with ALL, using real-time quantitative RT-PCR (Taqman) analysis. In addition we used 
an oligonucleotide microarray screen15 to compare the expression levels of these en-
zymes in MLL gene rearranged ALL patients and patients with conventional ALL. 
MATERIALS ANS METHODS
Patient samples
Bone marrow and/or peripheral blood samples from untreated infants (i.e. children 
≤12 months of age) initially diagnosed with ALL were collected from the University 
hospital Rotterdam / Sophia children’s hospital and other hospitals participating in the 
INTERFANT-99 treatment protocol. Samples from initially diagnosed ALL patients 
older than 12 months of age were obtained from the German COALL study group 
(Prof. Dr. G. E. Janka-Schaub, Hamburg, Germany). Within 24 hours aft er sampling, 
mononuclear cells were isolated by density gradient centrifugation using Lymphoprep 
(density 1.077 g/ml ; Nycomed Pharma, Oslo, Norway), centrifuged at 480 g for 15 
minutes at room temperature. Th e collected mononuclear cells were washed twice and 
kept in culture medium consisting of RPMI 1640 medium (Dutch modifi cation with-
out L-glutamine ; Gibco BRL, Life Technologies), 20% fetal calf serum (FCS ; Integro, 
Zaandam , Th e Netherlands), 2 mM L-glutamine (Gibco BRL, Life Technologies) 5 
μg/ml insulin, 5 μg/ml transferrin, 5 ng/ml sodium selenite (ITS media supplement ; 
Sigma, St Louis MO, USA), 100 IU/ml penicillin, 100 μg/ml streptomycin, 0.125 μg/ml 
Figure 1. Cytosine arabinoside (Ara-C) metabolism within cells. 
Ara-C enters the cell mainly via (1) equilibrative nucleoside transporter 1 (hENT1). Inside the cell, Ara-C is phosphorylated to Ara-CMP by (2) 
deoxycytidine kinase (dCK). Subsequently, Ara-CMP is phosphorylated into its active form Ara-CTP. Incorporation of Ara-CTP into the DNA during 
DNA synthesis leads to programmed cell death or apoptosis. Ara-CTP formation can, however, be obstructed. (3) Pyrimidine nucleotidase I (PN-
I) inhibits Ara-CTP formation by opposing the action of dCK. (4) Cytidine deaminase (CDA) and (5) deoxycytidylate deaminase (dCMPD) convert 
Ara-C to Ara-U and Ara-CMP to Ara-UMP respectively, thereby decreasing the amount of Ara-CTP that can be formed.
Cell membrane
                         1                      2 
Ara-C        Ara-C   Ara-CMP    Ara-CDP    Ara-CTP    DNA             Cell death 
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fungizone (Gibco BRL, Life Technologies) and 0.2 mg/ml gentamycin (Gibco BRL, Life 
Technologies). Contaminating non-leukemic cells were removed by immunomagnetic 
beads as described by Kaspers et al.16 All samples contained ≥90% leukemic cells, as de-
termined morphologically on May-Grünwald-Giemsa (Merck, Darmstadt, Germany) 
stained cytospins. For RNA extraction, a minimum of 5 x106 cells were lysed in TRIzol 
reagent (Gibco BRL, Life Technologies) and stored at -80 °C until extraction.
In vitro Ara-C cytotoxicity assay
In vitro Ara-C cytotoxicity was determined using the MTT assay as described by 
Pieters et al.17 Briefl y, 100 μl aliquots of cell suspension (~1.6 x105 cells) were cultured 
in round-bottomed 96-well microtitre plates (Greiner bio-one) in the presence of six 
diff erent concentrations of Ara-C (Cytosar, Pharmacia & Upjohn BV, Woerden, Th e 
Netherlands) ranging from 0.009 – 10 μg/ml, in duplicate. Control cells were cultured 
in eight wells without Ara-C. Four wells containing 100 μl culture medium were used 
as blanks. Aft er incubating the plates for four days at 37°C in humidifi ed air containing 
5% CO
2
, 10 μl of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazoliumbromide (MTT, 
5 mg/ml ; Sigma Aldrich, Zwijndrecht, Th e Netherlands) was added and the plates were 
incubated for an additional six hours under the same conditions. During this fi nal 6-
hour incubation, the yellow MTT tetrazolium salt is reduced to purple-blue formazan 
crystals by viable cells only. Th e formazan crystals were dissolved by adding 100 μl 
acidifi ed isopropanol (0.04 N HCl-isopropyl alcohol) and the optical density (OD), 
which is linearly related to the number of viable cells,18 was measured spectrophoto-
metrically at 562 nm. Aft er subtraction of the blank values, the leukemic cell survival 
(LCS) was calculated by the equation : 
LCS = (OD
Day 4
 treated well / mean OD
 Day 4
 control wells) x 100%
Drug sensitivity was assessed by the LC
50
, the drug concentration lethal to 50% of the 
cells. Evaluable assay results were obtained when a minimum of 70% leukemic cells 
was present in the control wells aft er 4 days of incubation and when the control optical 
density (OD) was ≥ 0.050.17
Ara-CTP accumulation
Leukemic cells from patients, prepared as described above, were incubated at 37°C for 
24 hours in the presence of 1 μM (0.25 μg/ml) of Ara-C. Aft er exposure to Ara-C, cells 
were washed in drug-free medium, centrifuged for 3 minutes at 5000 rpm and rapidly 
frozen and stored at -80 °C. Ara-CTP was extracted as described by Noordhuis et al.19
Cell pellets were resuspended in 150 μl ice-cold phosphate buff ered saline (pH 7.4) 
and subsequently 50 μL of 40% ice-cold trichloroacetic acid (TCA) (w/v) was added. 
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Th e suspension was kept on ice for 20 minutes. Aft er centrifugation for 5 minutes at 
13000 rpm and 4°C, the supernatant was removed and neutralized by adding 400 μl 
of tri-octylamine/1,1,2-tri-chloro-trifl uorethane (1/4, v/v). Aft er further centrifuga-
tion for 1 minute, the upper layer (the nucleotide extract) was collected and stored 
at -20°C. Nucleotides were separated using anion-exchange high-performance liquid 
chromatography (HPLC)19 on a Partisphere Sax column (Whatman; i.d. 4.6 mm, length 
12.5 cm, particle size 5 μm). A 1000S diode-array detector was set at 280 and 254 nm 
(Applied Biosystems, Foster City, CA, USA) and a Chromeleon V 4.30 data acquisition 
system (Dionex, Breda, the Netherlands) was used for quantitation of the peaks. Elu-
tion was performed isocratically with 0.25 M KH
2
PO
4
 containing 0.5 M KCl (pH 4.5) at 
a fl ow of 1.5 ml/min. Th e retention time of Ara-CTP was 5.4 minutes.
RNA extraction and cDNA synthesis
Total cellular RNA was extracted from a minimum of 5 x106 cells using TRIzol reagent 
(Gibco BRL, Life Technologies) according to the manufacturer’s protocol, except for 
minor modifi cations. An additional phenol-chloroform extraction was performed and 
the isopropanol precipitation at –20°C was facilitated by adding 1 μL (20 μg/ml) gly-
cogen (Roche, Almere, Th e Netherlands). Aft er precipitation with isopropanol, RNA 
pellets were dissolved in 20 μl RNAse-free TE-buff er (10 mM Tris-HCl, 1 mM EDTA, 
pH=8.0). Th e RNA was quantitated spectrophotometrically. Following a denaturation 
step of 5 min at 70°C, 1 μg of RNA was reverse transcribed to single stranded cDNA 
using a mix of random hexamers (2.5 μM), and oligo dT primers (20 nM). Th e RT 
reaction was performed in a total volume of 25 μl containing 0.2 mM of each dNTP 
(Amersham Pharmacia Biotech, Piscataway NJ, USA), 200 U Moloney murine leukemia 
virus reverse transcriptase (M-MLV RT) (Promega, Madison Wisconsin, USA) and 25 
U RNAsin (Promega, Madison Wisconsin, USA), at 37°C for 30 minutes, 42°C for 15 
minutes and 94°C for 5 minutes. Th e obtained cDNA was diluted to a fi nal concentra-
tion of 8 ng/μl. Samples were stored at –80°C.
Quantitative real-time PCR (Taqman technology)
Th e mRNA expression levels of dCK, PN-I, CDA, dCMPD, hENT1 and an endogenous 
housekeeping gene encoding for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
as a reference, were quantifi ed using real-time PCR analysis (Taqman chemistry) on an 
ABI Prism 7700 sequence detection system (PE Applied Biosystems). Amplifi cation 
of specifi c PCR products was detected using dual-fl uorescent non-extendable probes 
labeled with 6-carboxyfl uorescein (FAM) at the 5’-end and with 6-carboxytetramethyl-
rhodamine (TAMRA) at the 3’-end. All primers and probe combinations (Table 1) were 
designed using the OLIGO 6.22 soft ware (Molecular Biology Insights, Cascade, CO, 
USA) and purchased from Eurogentec (Seraing, Belgium). All primers had a melting 
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temperature (T
m
 ; nearest neighbor method) of 65 ± 1°C. All internal probes had a T
m
 of 
75 ± 1°C. All PCRs performed with comparable effi  ciencies of ≥95%. Th e quantitative 
real-time PCR was performed in a total reaction volume of 50 μL containing 1x Taq-
man buff er A (Applied Biosystems), 4 mM MgCl
2
, 200 μM of each dNTP (Amersham 
Pharmacia Biotech, Piscataway NJ, USA), 300 nM forward and reverse primer, 50 nM 
dual-labeled fl uorogenic internal probe, 1.25 U AmpliTaq Gold DNA polymerase (Ap-
plied Biosystems) and 40 ng of cDNA (see above) from each patient as a template, 
in MicroAmp optical 96-well plates covered with MicroAmp optical caps (Applied 
Biosystems). Samples were heated for 10 minutes at 95°C and amplifi ed for 40 cycles of 
15 seconds at 95°C and 60 seconds at 60°C. A serial dilution of cDNA derived from a 
cell line RNA-pool (CEM, K562, and two EBV transformed lymphoblastic B-cell lines) 
in dH
2
O was amplifi ed in parallel as a control to verify amplifi cation effi  ciency within 
each experiment. Since all PCRs performed with equal effi  ciencies, relative mRNA ex-
pression levels of dCK, PN-I, CDA, dCMPD and hENT1 for each patient can directly be 
normalized for input RNA against the GAPDH expression of the patient. Th e relative 
mRNA expression levels of the target genes in each patient was calculated using the 
comparative cycle time (C
t
) method.20 Briefl y, the target PCR C
t
 values, i.e. the cycle 
number at which emitted fl uorescence exceeds 10 x the standard deviation (SD) of 
base-line emissions as measured from cycles 3 to 15, is normalized to the GAPDH PCR 
Table 1. Probe and primer combinations used for quantitative real-time PCR (Taqman). 
Gene Primer/probe Sequence
dCK forward
reverse
probe
5’-TGC AGG GAA GTC AAC ATT-3’
5’-TCC CAC CAT TTT TCT GAG-3’
5’-(FAM)-TAA ACA ATT GTG TGA AGA TTG GGA AG-(TAMRA)-3’
CDA forward 
reverse 
probe
5’-GGA GGC CAA GAA GTC AG-3’
5’-GAC GGC CTT CTG GAT AG-3’
5’-(FAM)-CAA CAT AGA AAA TGC CTG CTA CCC-(TAMRA)-3’
dCMPD forward 
reverse 
probe
5’-AAT GGG TGC AGT GAT GAC-3’
5’-CTT AGC GCA TTC ATT ACA AG-3’
5’-(FAM)-ATC ATG AAC AAA AAT TCG ACC GAT-(TAMRA)-3’
PN-I forward 
reverse 
probe
5’-AAT CGG CGA TGT ACT AGA G-3’
5’-CAT CTG CCA TTC TTA AGT CTC-3’
5’-(FAM)-ATG AAA CTG GGG TGC TCA AAG GA-(TAMRA)-3’
hENT1 forward 
reverse 
probe
5’-TGT TTC CAG CCG TGA CT-3’
5’-CAG GCC ACA TGA ATA CAG-3’
5’-(FAM)-CAG CAC CTG GGA ACG TTA CTT-(TAMRA)-3’
GAPDH forward 
reverse 
probe
5’-GTC GGA GTC AAC GGA TT-3’
5’-AAG CTT CCC GTT CTC AG-3’
5’-(FAM)-TCA ACT ACA TGG TTT ACA TGT TCC AA-(TAMRA)-3’
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C
t
 value by subtracting the GAPDH C
t
 value from the target PCR C
t
 value, which gives 
the Δ C
t
 value. From this Δ C
t
 value, the relative mRNA expression level to GAPDH for 
each target PCR can be calculated using the following equation : 
Relative mRNA expression = 2 –[Ct target – Ct GAPDH] x 100%.
Oligonucleotide microarray screen (Aff ymetrix)
A detailed material and method section for the oligonucleotide microarray screen (Af-
fymetrix) comparing MLL gene rearranged and non-rearranged ALL patients has been 
described elsewhere.15 In addition, further details regarding patient samples and data 
analysis can be found at http://www.dfci.harvard.edu/korsmeyer/MLL.htm.
Statistics
Diff erences in the distribution of Ara-C LC
50
 values and mRNA expression between two 
groups were analyzed using the Mann-Whitney U test. Correlations between mRNA 
expression of Ara-C metabolizing enzymes and Ara-C LC
50
 values were calculated us-
ing the Spearman’s rank correlation test. Statistical tests were performed at a two-tailed 
signifi cance level of 0.05. 
Table 2. Patient characteristics.
Infants Non-infants
Number (n) 18 24
Sex (male : female), (%) 67 : 33 67 : 33
Age, yrs. (median; P25 – P75§) 0.45 (0.198 – 0.65) 5.5 (2.93 – 8.3)
Immunophenotype, (%)
 Pro-B ALL
 Pre-B ALL
 c-ALL
 T-ALL
 Unknown
56
17
5
0
22
0
12
71
17
0
MLL gene status, (%)
MLL germline
MLL rearranged
 Unknown
11
78
11
100
0
0
§P25 – P75 = 25th and 75th percentile (i.e. quartiles).
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RESULTS
Leukemic cells from infants (n=18) and older children (n=24) newly diagnosed with 
ALL were used. Patient characteristics are listed in Table 2. Th e in vitro Ara-C cytotox-
icity was successfully tested in 9 infants and 14 samples from older children with ALL. 
Assay failure was mostly due to a poor survival of control leukemic cells, i.e. <70 % 
survival of leukemic cells aft er 4 days of culture in the absence of Ara-C, or an optical 
density (OD) at 562 nm of <0.050. Leukemic cells from infants with ALL were signifi -
cantly (p=0.007) more sensitive (3.3-fold) to Ara-C than cells from older children with 
ALL (Figure 2) with a median LC
50
 of 0.27 μg/ml Ara-C for the infant and 0.89 μg/ml 
Ara-C for the non-infant ALL samples. Th is is in concordance with results published 
before.7 Furthermore, we determined Ara-CTP accumulation upon a 24 hour exposure 
to 1 μM (0.25 μg/ml) of Ara-C in 15 infant and 8 non-infant ALL samples. In two of the 
non-infant samples, a limited number of cells were available in which no Ara-CTP was 
detectable. Th ese samples were considered to contain less than 30 pmol Ara-CTP per 
million leukemic cells. In leukemic cells from infants with ALL, 2.3-fold more Ara-CTP 
accumulated (p=0.011) (Figure 2).
Using quantitative real-time PCR (Taqman technology), the mRNA expression lev-
els of dCK, CDA, dCMPD, PN-I and hENT1 were measured in 18 infant ALL samples. 
In 23 non-infant samples the mRNA expression levels of dCK, CDA and dCMPD were 
determined. From 21 non-infants PN-I and hENT1 mRNA expression was determined. 
Figure 2. Ara-C cytotoxicity and Ara-CTP accumulation.
A. Ara-C sensitivity (LC50 Ara-C in μg/ml) of leukemic cells from infants (n=9) and non-infants (n=14) with newly diagnosed acute 
lymphoblastic leukemia (ALL). B. Ara-CTP accumulation (pmol/106 cells) in leukemic cells from infant (n=15) and non-infant (n=8) ALL 
patients upon ex vivo exposure to 1 μM of Ara-C for 24 h. The lines indicate the median values, circles (ο) represent individual patients.
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Infants expressed signifi cantly less dCK mRNA (p=0.026) compared with older children 
with ALL. Th e diff erence in the median relative dCK mRNA expression in the infant 
and non-infant group is 2-fold. No signifi cant diff erence in mRNA expression of PN-I, 
an enzyme opposing dCK activity, was found (Figure 3). Also, no signifi cant diff erences 
were found in the mRNA expression of the deaminating (Ara-C inactivating) enzymes 
Figure 4. Relative CDA and dCMPD mRNA expression (Taqman).
Relative mRNA expression of cytidine deaminase (CDA) and deoxycytidylate deaminase (dCMPD) in infants and non-infants with ALL. The lines 
indicate the median values, circles (ο) represent individual patients. N.S = not signifi cant.
Figure 3.4 
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Figure 3. Relative dCK and PN-I mRNA expression (Taqman).
Relative mRNA expression of deoxycytidine kinase (dCK) and pyrimidine nucleotidase (PN-I) in infants and non-infants with ALL. The lines 
indicate the median values, circles (ο) represent individual patients. N.S. = not signifi cant.
Figure 3.3 
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CDA and dCMPD between infants and non-infants with ALL (Figure 4). However, 
mRNA of the nucleoside transporter hENT1, on which Ara-C is mainly dependent 
to cross the cell membrane, was signifi cantly 2.5-fold higher expressed (p=0.001) in 
infants compared with non-infants with ALL (Figure 5).
Excluding the infant ALL samples from which the MLL status is unknown (n=2) and 
transferring the infant ALL samples with germ line MLL genes (n=2) to the non-infant (or 
rather MLL germ line) group (see Table 2), results in similar diff erences. MLL gene rear-
ranged infant ALL patients express signifi cantly 1.6-fold less dCK mRNA (p=0.043) and 2.5-
fold more hENT1 mRNA (p=0.001) compared to ALL patients with germ line MLL genes.
Th e oligonucleotide microarray screen comparing a group of MLL gene rearranged 
ALL patients (n=18), consisting of 15 infants and 3 older children, and a group of 
children older than 12 months of age with conventional ALL (n=23),15 revealed similar 
results. No signifi cant diff erences in mRNA expression between MLL gene rearranged 
ALL patients and ALL patients without MLL gene abnormalities were found for the de-
aminating enzymes CDA and dCMPD (data not shown). In contrast, the relative gene 
expression of dCK was signifi cantly (p=0.001) lower (1.9-fold) and hETN1 expression 
signifi cantly (p=0.046) higher (2.7-fold) in MLL gene rearranged ALL patients (Figure
6). Th e expression of PN-1 was not measured because no oligonucleotides representing 
this gene are present on the Aff ymetrix microarray chip used in this screen. 
Th e hENT1 mRNA expression inversely correlates with the LC
50
 values of Ara-C 
(r
s
=-0.58, p=0.006) (Figure 7). In other words, Ara-C sensitivity correlates with in-
creased hENT1 mRNA expression. In contrast, we found that increased dCK mRNA 
expression tends to correlate, although weakly, with increased resistance to Ara-C 
(r
s
=0.41, p=0.052). 
Figure 5. Relative hENT1 mRNA expression (Taqman).
Relative mRNA expression of the human equilibrative nucleoside transporter 
1 (hENT1) in infants and non-infants with ALL. The lines indicate the median 
values, circles (ο) represent individual patients.
Figure 3.5
(hENT1)
0
1
2
3
P = 0.001
    Infants     Non-infants
Re
lat
ive
 m
RN
A 
ex
pr
es
sio
n 
to
 G
AP
DH
 (%
)
Equilibrative nucleoside transporter 1 (hENT1) 
54
C
ha
pt
er
 3
DISCUSSION
Infant ALL is characterized by a high incidence of MLL gene rearrangements and a 
poor treatment outcome compared to older children with ALL. Th e poor prognosis for 
infants with ALL is associated with rearrangements of the MLL gene,4,21,22 and in vitro
Figure 7. Relation between Ara-C cytotoxicity and hENT1 mRNA expression (Taqman). 
Correlation between the Ara-C cytotoxicity (log LC50 in ug/ml) and the relative mRNA expression of the human equilibrative nucleoside 
transporter 1 (hENT1). Open circles indicate individual infant ALL patients. Non-infants with ALL are indicated by black dots.
Figure 3.7 
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germ line (n=23) ALL patients measured on oligonucleotide microarrays. The lines indicate the median values, black dots represent individual 
patients.
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resistance to prednisone and L-asparaginase.7 However, infant ALL cells are highly sen-
sitive to cytosine arabinoside (Ara-C).7 Th is knowledge has recently been implemented 
in a new international collaborative treatment protocol, i.e. INTERFANT-99, for infants 
with ALL in order to give a more specifi c treatment to infant ALL patients. 
Th e necessity of an exclusive treatment protocol for infants diagnosed with ALL 
has recently been stressed by a gene expression profi ling study comparing (mostly) 
infants with MLL gene rearranged ALL, and older children with conventional ALL and 
acute myeloid leukemia (AML) without MLL gene rearrangements, using oligonucle-
otide microarrays.15 Th is resulted in a gene expression profi le for MLL gene rearranged 
ALL patients that is clearly distinguishable from the gene expression profi les found for 
conventional ALL and AML. Th is fi nding suggests that MLL gene rearranged leukemia 
needs to be classifi ed as an unique leukemia for which urgently molecular targets need 
to be found to explore the possibilities of developing an appropriate treatment protocol 
for these patients.
In the present study we analyzed the mechanism of Ara-C sensitivity in infant MLL
gene rearranged ALL. Because aberrant expression of key enzymes in Ara-C metabo-
lism (Figure 1) might explain the remarkable sensitivity to Ara-C characteristic for 
these patients, we used quantitative real-time PCR analysis (Taqman chemistry) and 
an oligonucleotide microarray screen15 to determine the mRNA levels of several Ara-
C metabolizing enzymes in both infants and in older children with newly diagnosed 
ALL. Quantitative RT-PCR analysis revealed that infants with ALL express signifi cantly 
2-fold less dCK and 2.5-fold more hENT1 mRNA compared with older children with 
ALL. No signifi cant diff erences in PN-I, CDA and dCMPD mRNA expression were 
observed. Th e hENT1 mRNA expression correlated with sensitivity to Ara-C, whereas 
dCK mRNA expression tended to correlate, although weakly, with Ara-C resistance. 
In approximately 80% of the infant ALL samples, the MLL gene is rearranged (Table
2). Comparison between MLL gene rearranged infants and MLL germ line patients 
revealed the same diff erences in dCK and hENT1 expression as observed for the in-
fant versus non-infant group. Similar results were obtained from the oligonucleotide 
microarray screen. MLL gene rearranged ALL patients expressed 1.9-fold less dCK
and 2.7-fold more hENT1 mRNA compared to children with ALL without MLL gene 
rearrangements. Because MLL gene rearrangements are strongly associated with infant 
ALL, it is diffi  cult to determine whether the observed diff erences are related to MLL 
gene rearrangements or to infancy, or even to both. To answer this question, a large 
group of rather rare MLL germ line infant ALL samples is needed. However, since in-
fant ALL is so strongly associated with MLL gene rearrangements, observations found 
in a group of infants with ALL shall therefore resemble a group of MLL gene rearranged 
ALL samples and vice versa.
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Deoxycytidine kinase (dCK) generally phosphorylates deoxycytidine (dCyd) to form 
dCMP, but also phosphorylates a variety of deoxycytidine analogues, including Ara-
C.23 Reduced dCK mRNA expression and defi ciency of functional dCK has oft en been 
associated with Ara-C resistance.24,25,26,27 In addition, it has been demonstrated that re-
lapsed ALL and AML patients show decreased dCK mRNA expression28 and that initial 
childhood ALL patients expressing low levels of dCK mRNA are more likely to relapse 
than patients expressing higher levels of dCK mRNA.29 Aft er Ara-C is phosphorylated 
by dCK, Ara-CMP is further phosphorylated to Ara-CDP by (deoxy)cytidylate kinase 
(UMP-CMPK) and fi nally to its active, cytotoxic form Ara-CTP by nucleotide diphos-
phate kinases (NDPKs). Because dCK has the lowest cellular concentration of these 
three kinases, it is thought to be the rate-limiting enzyme in the activation of Ara-C11. 
However, we show that infants with ALL express signifi cantly 2-fold less dCK mRNA 
than older children with ALL, whereas no signifi cant diff erences in PN-I mRNA ex-
pression was found. Since PN-I opposes the action of dCK by dephosphorylating Ara-
CMP,12 the net phosphorylation of Ara-C into Ara-CMP may be considerably lower 
in infants with ALL. Yet, leukemic cells from these patients are signifi cantly 3.3-fold 
more sensitive to Ara-C and 2.3-fold more Ara-CTP was formed upon exposure to 
Ara-C. Moreover, we observed that dCK mRNA expression tends to correlate, although 
weakly, with the obtained LC
50
 values for Ara-C. In other words, higher dCK mRNA 
expression tends to correlate with increased resistance to Ara-C. Th ese data suggest 
that dCK is not a rate-limiting factor in the activation of Ara-C in infant ALL cells, 
which may support the fi ndings of White et al10 (see below). Another possibility could 
be that dCK is post-transcriptionally regulated and that despite of the lower mRNA 
expression, the amount of protein or the activity of the enzyme in infant ALL cells are 
comparable with, or even higher than in cells from older children with ALL. 
Cytidine deaminase (CDA) and deoxycytidylate deaminase (dCMPD) both inhibit 
the formation of Ara-CTP by converting Ara-C to Ara-U and Ara-CMP to Ara-UMP 
respectively. Increased CDA and dCMPD activity in several cell lines transfected with 
human CDA or human dCMPD cDNA has been shown to confer resistance to Ara-
C.13,14,30,31 Furthermore, CDA activity proofed to be signifi cantly higher in Ara-C refrac-
tory AML patients than in untreated patients.32 Our results did not show signifi cant 
diff erences in the mRNA expression of CDA and dCMPD between infants and older 
children with ALL, suggesting that Ara-C sensitivity in infant ALL can not be ascribed 
to decreased inactivation of Ara-C by these enzymes. 
Nucleosides and their analogues are hydrophilic molecules, and therefore dependent 
on specialized transport proteins to permeate cell membranes. Ara-C membrane trans-
port is mainly facilitated by a nitrobenzylmercaptopurine riboside (NBMPR) sensitive 
nucleoside transport system.9,10,33 Since the human equilibrative nucleoside transporter 
1 (hENT1) is the only known NBMPR sensitive nucleoside transporter capable of trans-
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porting pyrimidine nucleosides over the cell membrane,8 it is reasonable to assume that 
Ara-C mainly enters the cell via hENT1. In this study we show that infants with ALL 
express signifi cantly 2.5-fold more hENT1 mRNA compared to older children with ALL. 
In addition, we demonstrate a strong correlation between hENT1 mRNA expression 
and Ara-C sensitivity. Others showed that inhibition of Ara-C membrane transport 
with NBMPR confers Ara-C resistance in cells from both ALL and AML patients.9,10,33
Taken together, these data suggest that Ara-C sensitivity in infant ALL can, at least to 
some extent, be explained by a higher hENT1 mRNA expression, possibly resulting in 
more Ara-C membrane transport sites and thus an elevated uptake of Ara-C into the 
cell. Furthermore these data suggest that hENT1 mRNA expression may be a valuable 
predictor of Ara-C sensitivity in both infant and older ALL patients.
Our observation that Ara-C sensitivity may be a consequence of increased hENT1
mRNA expression and the fi nding that dCK apparently is not rate-limiting in the for-
mation of Ara-CTP in infants with MLL gene rearranged ALL, is in concordance with 
the fi ndings of White and co-workers.10 White et al, showed that Ara-C is phosphory-
lated by dCK almost as rapidly as it enters the cell at extracellular Ara-C concentrations 
below 1 μM, whereas at high Ara-C concentrations (>10 μM) unphosphorylated Ara-C 
accumulates inside cells. Th us at Ara-C concentrations <1 μM, the rate of Ara-C ac-
cumulation inside the cell is primarily determined by the transport rate or rather the 
number of transporter sites on the cell membrane (i.e. hENT1 expression). At extracel-
lular Ara-C concentrations exceeding 10 μM, dCK becomes the rate-limiting factor.10
Th e median LC
50
 values for Ara-C for the infant and non-infant group in this study 
are 0.27 μg/ml (1 μM) and 0.89 μg/ml (3.6 μM) Ara-C respectively. Th erefore, it is 
likely that the rate of Ara-C infl ux via hENT1 and not the level of dCK determines the 
amount of Ara-C phosphorylation by dCK and subsequently the sensitivity to Ara-C 
in these patient samples, even if dCK is post-transcriptionally regulated and the actual 
protein levels or enzyme activity in the infant samples are comparable or even higher 
than in cells from older children. Since infants with ALL who enter the INTERFANT-
99 treatment protocol receive both low-dose and high-dose Ara-C, corresponding to 
plasma levels <1 μM and >10 μM respectively34,35, these patients may benefi t from their 
increased hENT1 expression at least during treatment with low to normal doses of 
Ara-C. 
Based on these considerations we conclude that the observed increase in hENT1 
mRNA expression contributes to the remarkable sensitivity to Ara-C in infants diag-
nosed with ALL. 
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Chapter 4
MLL gene rearrangements have no direct impact 
on Ara-C sensitivity in infant acute lymphoblastic 
leukemia and childhood M4/M5 acute myeloid 
leukemia
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TO THE EDITOR
Th e anti-metabolite cytosine arabinoside (Ara-C) is a deoxycytidine analogue that is 
used as a therapeutic agent in many leukemia treatment regimens. In combination with 
anthracyclines, Ara-C is the most eff ective agent in the treatment of acute myeloid 
leukemia (AML). In the treatment of acute lymphoblastic leukemia (ALL) the use of 
Ara-C is limited. However, leukemic cells from infants (<1 year of age) with ALL, which 
are resistant to several chemotherapeutic drugs, are in vitro more sensitive to Ara-C as 
compared to older children with ALL.1,2 Th is observation suggested that infant ALL 
might resemble a subclass of childhood ALL which may benefi t from intensifi ed treat-
ment with Ara-C to improve the dismal prognosis for these patients who to date experi-
ence an event free survival (EFS) of ~35%. Th erefore, in 1999 a novel collaborative 
treatment protocol (INTERFANT-99) was designed with intensifi ed use of Ara-C, in 
order to provide a more specifi c treatment to infant ALL patients. 
Ara-C mainly depends on the human equilibrative nucleoside transporter 1 (ENT1) 
to permeate the cell membrane. Inside cells, the pro-drug Ara-C is phosphorylated into 
Figure 1. Ara-C metabolism. 
Ara-C enters the cell mainly via (1) equilibrative nucleoside transporter 1 (hENT1) and is subsequently phosphorylated to form Ara-CMP by (2) 
deoxycytidine kinase (dCK), followed by two more phosphorylation steps catalyzed by (deoxy)cytidylate kinase (UMP-CMPK) and nucleoside 
diphosphate kinases (NDKs), respectively, to form Ara-CTP. Incorporation of Ara-CTP into the DNA during DNA synthesis leads apoptosis. Ara-CTP 
formation can, however, be obstructed. (3) Pyrimidine nucleotidase I (PN-I) inhibits Ara-CTP formation by opposing the action of dCK. (4) 
Cytidine deaminase (CDA) and (5) deoxycytidylate deaminase (dCMPD) both are inactivating enzymes, which convert Ara-C to Ara-U and Ara-
CMP to Ara-UMP, respectively, thereby decreasing the amount of functional Ara-CTP that can be formed.
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its active, cytotoxic form Ara-CTP, as which it competes with dCTP for incorporation 
into the DNA. When incorporated, Ara-C blocks DNA synthesis and induces apoptosis 
(Figure 1). Ara-C is phosphorylated by deoxycytidine kinase (dCK) to form Ara-CMP. 
Subsequently, Ara-CTP is formed by two additional phosphorylations catalyzed by 
(deoxy)cytidylate kinase (UMP-CMPK) and nucleoside diphosphate kinases (NDKs) 
respectively (Figure 1). Several enzymes, however, oppose the formation of functional 
Ara-CTP, and thus the cytotoxic eff ects of this drug. Pyrimidine nucleotidase I (PN-I) 
for example preferentially dephosphorylates Ara-CMP to Ara-C.3 Cytidine deaminase 
(CDA) and deoxycytidylate deaminase (dCMPD) convert Ara-C to Ara-U and Ara-
CMP to Ara-UMP respectively, by deamination of the cytosine base of Ara-C. Recently 
we demonstrated that Ara-C sensitivity in infant ALL is related to increased expression 
of ENT1 (responsible for Ara-C transport across the cell membrane4), and not to the 
expression of other genes involved in Ara-C metabolism (mentioned above). 
Infant ALL is characterized by rearrangements of the Mixed Lineage Leukemia (MLL, 
ALL-1, or HRX) gene on chromosome band 11q23, in approximately 80% of the cases. 
Th e most common translocations involving MLL in infant ALL are t(4;11)(q21;q23) 
and t(11;19)(q23;p13.3) resulting in a fusion of MLL with AF-4 on chromosome 4 and 
ENL on chromosome 19, respectively. In childhood acute myeloid leukemia (AML), 
Table 1. Patient characteristics. 
Infant ALL Childhood AML
Number (n) 34 27
Sex ( : ) (%) 41 : 59 61 : 39 
Age, yrs. (median; P25-P75)§  0.47 (0.24 – 0.76) 10.4 (2.87 – 14.57)
Immunophenotype (%) :
AML : M4
 M5 
ALL : Pro-B
 Common
 Pre-B
 Pro-T
 AUL
 Unknown
-
-
68
17
6
3
3
3
61
39
-
-
-
-
-
-
MLL gene status (%) :
t(4;11)
t(11;19)
t(9:11)
11q23*
Germ line
47
29
-
-
24
-
-
29
21
50
§P25-P75 indicate the 25th and 75th percentiles
*11q23 indicates translocations involving MLL other than t(4;11), t(11;19), or t(9;11). 
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MLL gene rearrangements are mainly restricted to the FAB M4 and M5 subtypes, and 
occur in the majority of the infant cases. Interestingly, childhood M4/M5 AML har-
boring t(9;11)(q22;q23) in which MLL is fused to AF-9 on chromosome 9, has also 
been reported to be highly sensitive to Ara-C when compared to other AML subtypes 
without MLL rearrangements.5 Th e fact that Ara-C sensitivity is found in both MLL
rearranged infant ALL as well as MLL rearranged M4/M5 AML, raises an important 
question: is Ara-C sensitivity (or increased expression of ENT1) directly associated 
with rearrangements of the MLL gene? To answer this question we set out to determine 
the relationship between Ara-C sensitivity, expression of Ara-C metabolizing enzymes, 
and the presence of MLL gene rearrangements in both infant ALL and pediatric AML 
M4/M5. Patient characteristics are listed in Table 1.
Th e MTT-assay was used to determine in vitro Ara-C cytotoxicity. Within infant 
ALL, no signifi cant diff erence in Ara-C sensitivity was found between MLL rearranged 
(MLL+) and MLL germ line (MLL–) infant ALL cases (Figure 2a). Furthermore, no 
diff erences in Ara-C sensitivity were observed between infant ALL patients harboring 
either translocation t(4;11) or t(11;19) as compared to MLL germ line cases (Figure 2b). 
Also, no statistically signifi cant diff erence in Ara-C cytotoxicity was observed between 
MLL+ and MLL– AML M4/M5 cases (Figure 3a), nor between AML M4/M5 patients 
carrying t(9;11) or other translocations involving MLL (11q23) compared to AML M4/
M5 patients carrying germ line MLL genes (Figure 3b). 
Th e relative mRNA expression levels of ENT1, dCK, PN-I, CDA and dCMPD was mea-
sured using quantitative real-time PCR (TaqMan) as described before.4 Th e expression of 
genes important for membrane transport, and for the metabolism of Ara-C into its active, 
cytotoxic form Ara-CTP, did not signifi cantly diff er between MLL– and MLL+ infant ALL 
cases (Table 2), nor between MLL– and MLL+ M4/M5 AML cases (Table 3). Th e only excep-
tion was PN-I, which was signifi cantly higher expressed in infant ALL patients carrying 
germ line MLL genes as compared to MLL+ infant ALL samples (Table 2). Th is would be in 
line with the hypothesis that MLL rearrangements induce Ara-C sensitivity, as this would 
imply that increased dephosphorylation of Ara-CMP leads to increased resistance to Ara-C 
in leukemic cells from infant ALL patients carrying germ line MLL. However, increased 
PN-I expression does not seem to aff ect Ara-C sensitivity in these patients, as no signifi cant 
diff erence in Ara-C cytotoxicity could be observed between both patient groups (Figure 2). 
Our fi nding that Ara-C sensitivity is not directly associated with the presence of 
MLL rearrangements is in agreement with our recent study.2 No apparent diff erences 
in Ara-C sensitivity were found between MLL– and MLL+ ALL cases <1 year of age, 
nor between MLL– and MLL+ ALL above this age.2 Moreover, the same study further 
demonstrated no statistical diff erences in Ara-C cytotoxicity between t(4;11) positive 
ALL samples and samples carrying other translocations involving MLL.2 Furthermore, 
it appeared that among ALL patients ≥1 year of age, pro-B (CD10–, CD19+) cases are 
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more sensitive to Ara-C as compared to common (CD10+, CD19+) and pre-B (CD19+, 
CyIgμ+) ALL cases. However, in infant ALL patients (<1 year of age) the pro-B pheno-
type was not associated with sensitivity to Ara-C, but the number of infants with pre-B 
or common phenotypes was small.2 Th us, Ara-C sensitivity in ALL seems to be associ-
ated with age (i.e. <1 year) and immunophenotype, but not with the presence of MLL
rearrangements. Possibly, sensitivity to Ara-C as observed in childhood AML M4/M5 
cells is associated with the M4/M5 FAB type rather than with young age.
In conclusion, the present study does not provide data to support that MLL rear-
rangements are directly involved in the increased sensitivity to Ara-C as detected in 
infant ALL and M4/M5 AML.
Figure 2. Ara-C cytotoxicity in infant ALL. 
In vitro Ara-C cytotoxicity (LC50 Ara-C in μg/ml) in a. leukemic cells from MLL gene rearranged (n=26) and MLL germ line (n=8) infant ALL 
patients. Possible diff erences between both patient groups were statistically analyzed using the Mann-Whitney U test. b. In vitro Ara-C 
cytotoxicity in leukemic cells from infant ALL patients carrying either translocation t(4;11) (n=16), t(11;19) (n=10) or germ line MLL (n=8). 
Possible diff erences between these patient groups were statistically analyzed using the Kruskal-Wallis test. The box plots indicate the group 
medians, 25th/75th percentiles and the ranges of Ara-C cytotoxicity.
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Figure 3. Ara-C cytotoxicity in childhood M4/M5 AML. 
In vitro Ara-C cytotoxicity (LC50 Ara-C in μg/ml) in a. leukemic cells from MLL gene rearranged (n=14) and MLL germ line (n=13) childhood 
M4/M5 AML patients. Possible diff erences between both patient groups were statistically analyzed using the Mann-Whitney U test. b. In vitro
Ara-C cytotoxicity in cells from childhood M4/M5 AML patients carrying either translocation t(9;11) (n=8), unknown translocation involving 
MLL (11q23) (n=6) or germ line MLL (n=13). Possible diff erences between these patient groups were statistically analyzed using the Kruskal-
Wallis test. The box plots indicate the group medians, 25th/75th percentiles and the ranges of Ara-C cytotoxicity.
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Table 2. Comparison of expression levels of Ara-C metabolizing enzymes between infant ALL patients with and without MLL gene 
rearrangements. 
Gene Relative mRNA 
expression (%)
MLL rearranged
(n=22)
MLL germ line
(n=6)
Expression ratio†
ENT1 median
P25 – P75§
0.174
0.082 – 0.32
0.103
0.074 – 0.12
1.69
dCK median
P25 – P75§
0.483
0.284 – 0.882
0.869
0.273 –3.376
0.56
PN-I median
P25 – P75§
0.288
0.226 – 0.34
0.9736
0.477 – 1.167
0.3*
CDA median
P25 – P75§
0.006
0.0008 – 0.015
0.003
0.0003 – 0.045
2
dCMPD median
P25 – P75§
0.822
0.481 – 1.168
0.756
0.433 – 1.369
1.09
§P25 and P75 indicate the 25th and 75th percentiles respectively
†Median expression in MLL rearranged patie-nts divided by the median expression in MLL germ line patients. Values >1.0 indicate higher 
median expression in the MLL rearranged patient group.
*P=0.001 as determined by the Mann-Whitney U test
Table 3. Comparison of expression levels of Ara-C metabolizing enzymes between childhood AML M4/M5 patients with and without MLL
gene rearrangements. 
Gene Relative mRNA 
expression (%)
MLL rearranged 
(n=13)
MLL germ line
(n=12)
Expression ratio†
ENT1 Median
P25 – P75§
0.975
0.701 – 1.752
0.714
0.567 – 1.223
1.37
dCK Median
P25 – P75§
0.489
0.188 – 0.835
0.363
0.238 – 0.517
1.35
PN-I Median
P25 – P75§
0.297
0.106 – 0.767
0.343
0.15 – 0.55
0.87
CDA Median
P25 – P75§
0.149
0.055 – 0.44
0.22
0.05 – 0.505
0.68
dCMPD Median
P25 – P75§
0.989
0.637 – 1.931
0.921
0.775 – 1.517
1.07
§P25 and P75 indicate the 25th and 75th percentiles respectively
†Median expression in MLL rearranged patients divided by the median expression in MLL germ line patients. Values >1.0 indicate higher median 
expression in the MLL rearranged patient group.
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Chapter 5
The human equilibrative nucleoside transporter 
1 mediates in vitro cytarabine sensitivity in 
childhood acute myeloid leukemia
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ABSTRACT
Cytarabine (ara-C) is the most eff ective agent for the treatment of acute myeloid leuke-
mia (AML). Aberrant expression of enzymes involved in the transport/metabolism of 
ara-C may potentially explain resistance to this drug. We determined mRNA expres-
sion of these factors using quantitative-real-time-PCR in leukemic blasts from children 
diagnosed with de novo AML. Expression of the inactivating enzyme pyrimidine nucle-
otidase-I (PN-I) was 1.8-fold lower in FAB-M5 as compared to FAB-M1/2 (p=0.007). 
In vitro sensitivity to deoxynucleoside analogs was determined using the MTT-assay. 
Human equilibrative nucleoside transporter 1 (hENT1) mRNA expression and ara-C 
sensitivity were signifi cantly correlated (r
p
=-0.46, p=0.001), with 3-fold lower hENT1
mRNA levels in resistant patients (p=0.003). hENT1 mRNA expression also seemed 
to correlate inversely with the LC
50
 values of cladribine (r
p
=-0.30; p=0.04), decitabine 
(r
p
=-0.29; p=0.04) and gemcitabine (r
p
=-0.33; p=0.02). Deoxycytidine kinase (dCK) 
and cytidine deaminase (CDA) mRNA expression seemed to correlate with in vitro sen-
sitivity to gemcitabine (r
p
=-0.31; p=0.03) and decitabine (r
p
=0.33; p=0.03), respectively. 
Th e dCK/PN-I expression ratio correlated inversely with LC
50 
values for gemcitabine 
(r
p
=-0.45, p=0.001) and the dCK/CDA expression ratio seemed to correlate with LC
50 
values for decitabine (r
p
=-0.29; 0.04). In conclusion, decreased expression of hENT1, 
which transports ara-C across the cell membrane, appears to be a major factor in ara-C 
resistance in childhood AML.
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INTRODUCTION
Although the treatment of acute leukemia has improved signifi cantly over the past few 
decades, the prognosis of acute myeloid leukemia (AML) remains relatively poor. For 
newly diagnosed patients the compete remission (CR) rate reaches 85-90% with stan-
dard induction chemotherapy.1,2 However, about 30-50% of the patients that achieve 
CR relapse from minimal residual disease cells that apparently survived chemotherapy,2
giving rise to a more resistant leukemia. Resistance to chemotherapy therefore remains 
a major obstacle in the treatment of AML. 
In combination with anthracyclines, 1-ß-D-arabinofuranosylcytosine (cytosine 
arabinoside; cytarabine; ara-C), is the most eff ective agent for the treatment of AML. 
Ara-C is a deoxynucleoside analog that has to be converted into its active triphosphate 
derivative (ara-CTP) to exert its cytotoxic eff ect.3 Ara-CTP is then incorporated into the 
DNA causing chain termination, resulting in a block in DNA synthesis, and facilitates 
programmed cell death (Figure 1). Ara-C is a hydrophilic molecule and as such requires 
facilitated diff usion via nucleoside-specifi c membrane transport carriers to enter cells.4,5
Th e human equilibrative nucleoside transporter (hENT1) is responsible for ~80% of 
ara-C infl ux in human leukemic blast cells.5,6 Inside the cell, conversion of ara-C into 
ara-CMP by deoxycytidine kinase (dCK) is believed to be the rate-limiting step in the 
metabolism of ara-C.7,8 Subsequently, ara-CMP is phosphorylated into ara-CDP by 
nucleoside monophosphate kinases, which in turn is fi nally phosphorylated into ara-
CTP by diphosphate kinases.9 Inactivation of ara-C results from deamination by cyti-
dine deaminase (CDA).10 In addition, ara-CMP can be dephosphorylated by pyrimidine 
nucleotidase I (PN-I)11 as well as deaminated by deoxycytidylate deaminase (dCMPD).12
Inactivation by these enzymes decreases the amount of ara-CTP that can be formed, 
and thereby limits ara-C mediated cytotoxicity. Deoxycytidine triphosphate (dCTP) is 
thought to inhibit the phosphorylation of ara-C (by feedback inhibition of dCK) and the 
incorporation of ara-CTP into DNA (by competition for DNA polymerase). Increased 
intracellular dCTP pools therefore antagonize the formation of ara-CTP.13,14 dCTP can 
be synthesized directly via the de novo pathway by ribonucleotide reductase (RR).15
RR catalyzes the conversion of ribonucleotides into deoxyribonucleotides.15 Mamma-
lian RR is made up out of two subunits.16 Th e M1 subunit harbors the binding site for 
nucleotides and the second subunit, M2, contains a metal binding site that requires both 
a non-heme iron and a tyrosine free radical for its activity.15 CTP synthetase (CTPs) is 
responsible for the conversion of uridine triphosphate (UTP) into CTP and has high 
activity in several malignancies, including acute lymphoblastic leukemia.17
In addition to ara-C, a variety of other deoxynucleoside derivatives are active in both 
hematological and solid malignancies. Th e purine analogs 2-chlorodeoxyadenosine 
(cladribine; 2-CdA) and fl udarabine (F-ara-A) are active against indolent lymphoid 
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malignancies and are currently also used for the treatment of hairy-cell leukemias, and 
both chronic and acute leukemias, respectively.18 Th e pyrimidine analog gemcitabine 
(dFdC) has activity in various solid malignancies and some hematological disorders.19
Th e cytidine analog 5-aza-2’–deoxycytidine (decitabine; DAC) is a potent hypometh-
ylating agent and has shown to be active in the treatment of hematological malignan-
cies such as AML, chronic myeloid leukaemia (CML) and myelodysplastic syndrome.20
Th ese compounds are activated intracellularly via the same metabolic pathway as ara-C. 
Impaired transport, decreased activation of deoxynucleoside analogs to their cytotoxic 
tri-phosphate form, or increased dCTP levels may result in resistance to this clinically 
important group of compounds. Th e objective of our study was to identify possible 
mechanisms of resistance to deoxnucleoside analogs, particularly ara-C, in the leukemic 
blasts of pediatric AML patients. We therefore determined the mRNA level of the fol-
lowing targets: hENT1, dCK, PN-I, CDA, dCMPD, CTPs, and RR (subunit 1 and 2) in 
leukemic blasts from children with newly diagnosed AML. In addition, we studied the 
mRNA expression levels of the target enzymes in diff erent AML FAB-type subgroups. 
Finally, the expression levels of the above mentioned enzymes were correlated to in vitro
sensitivity to deoxynucleoside analogs (ara-C, 2-CdA, DAC, F-ara-A and dFdC).
Figure 5.1 
Figure 1. Metabolism of ara-C. 
Ara-C enters the cell mainly via the equilibrative nucleoside transporter 1 (hENT1; 1). Inside the cell, ara-C is phosphorylated into ara-CMP by 
deoxycytidine kinase (dCK; 2). Ara-CMP is subsequently phosphorylated to ara-CTP, the active metabolite. Incorporation of ara-CTP into the DNA 
blocks DNA synthesis and leads to programmed cell death (apoptosis). Ara-CTP formation can, however, be obstructed. Pyrimidine nucleotidase 
I (PN-I; 3) opposes the action of dCK by dephosphorylating ara-CMP to form ara-C. Cytidine deaminase (CDA; 4) and deoxycytidylate deaminase 
(dCMPD; 5) convert ara-C to ara-U, and ara-CMP to ara-UMP, respectively, decreasing the amount of functional ara-CTP that can be formed. 
Furthermore, increased intracellular dCTP pools are believed to antagonize the formation of ara-CTP. Both ribonucleotide reductase (6) and 
CTP synthetase (CTPs; 7) are involved in de novo dCTP synthesis. CTPs is capable of converting uridine triphosphate (UTP) into CTP. CTP can 
either become incorporated into RNA, or become deposphorylated to form CDP. In turn, ribonucleotide reductase converts CDP into dCDP, which 
competes with Ara-CDP for their fi nal phosphorylation into triphosphates (dCTP and ara-CTP). As such, increased expression of ribonucleotide 
reductase and CTPs inhibit ara-CTP formation either by competition or by feedback inhibition as a result of increasing dCTP pools. 
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MATERIALS AND METHODS
Patient samples
Bone marrow and/or peripheral blood samples were collected from untreated children 
diagnosed with de novo AML. Th e following groups participated in this study and 
provided patient samples: (1) Th e Dutch Childhood Oncology Group (DCOG), Th e 
Hague, Th e Netherlands; (2) MRC Childhood Leukaemia Working Party, UK and (3) 
Th e AML BFM-study Group, Münster, Germany. Central review of the diagnosis, data 
collection as well as review of FAB-classifi cation was performed by reference laborato-
ries and data centers of these groups. Th e FAB-classifi cation was performed according 
to the criteria by Bennett et al, including the modifi cations to diagnose FAB M0 and 
FAB M7.21 Samples were collected at the VU university medical center between Octo-
ber 1990 and September 2002.
Treatment protocols
Patients were treated on intensive ara-C/anthracyclines based protocols in the Neth-
erlands, Germany and the UK (protocols DCOG AML 87 and 97, BFM 93 and 98 and 
MRC AML 12). Th e treatment protocols have been reported in detail elsewhere.1,2,22,23
In the AML BFM 93 study, the patients were stratifi ed according to risk group. At 
diagnosis, patients were randomized between daunorubicin (plus ara-C and etoposide, 
ADE) and idarubicin (plus ara-C and etoposide, AIE) induction therapy. For high-
risk (HR) patients, one of the intensifi cation blocks was changed to high-dose ara-C 
with mitoxantrone (HAM). Sibling stem cell transplantations (SCT) was advised for 
HR patients in fi rst CR. Standard risk (SR) patients did not receive HAM. Protocol 
AML BFM 98 consisted of induction with the idarubicin block, followed by HAM. 
In the consolidation phase patients were randomized for either receiving the 6-week 
consolidation block followed by one intensifi cation block vs. three intensive courses of 
chemotherapy. 
Th e DCOG AML 87 protocol was based on the concurrent AML-BFM protocol. In 
brief, DCOG AML 87 started with an 8-day induction course followed by a 6-week 
consolidation block. Th en two intensifi cation courses were given. Intrathecal chemo-
therapy was given as central nervous system prophylaxis. In contrast to the AML BFM 
87 study, no maintenance therapy was given. Sibling donor allogeneic STC was advised 
for HR patients in fi rst CR. 
Patients enrolled in the DCOG AML 97, which was identical to the MRC AML12 
protocol, were stratifi ed according to cytogenetics. Good risk patients (defi ned as 
patients with t(8;21), inv(16) or t(15;17)) were not eligible for SCT. Patients were ran-
domized to induction treatment with either ADE (ara-C, daunorubicin and etoposide) 
or MAE (mitoxantrone, ara-C and etoposide), followed by a 4 or 5 (randomized) treat-
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ment courses. Th e fi ft h course was high-dose ara-C and L-asparaginase. If a matched 
sibling donor was available, then SCT was recommended as the fourth or fi ft h course 
(randomized).
Leukemic cells
Mononuclear cells were isolated by density gradient centrifugation using Lymphoprep 
(density 1.077 g/ml; Nycomed Pharma, Oslo, Norway), and centrifuged at 480 g for 15 
minutes at room temperature. Cells were washed and resuspended in culture medium 
consisting of RPMI 1640 medium (Dutch modifi cation without L-glutamine; Gibco 
BRL, Life Technologies, Breda, Th e Netherlands), 20% fetal calf serum (FCS; Integro, 
Zaandam, Th e Netherlands), 2 mM L-glutamine (Gibco BRL, Life Technologies), 5 
µg/ml transferrin, 5 ng/ml sodium selenite (ITS media supplement; Sigma, St Louis, 
MO), 100 IU/ml penicillin, 100 µg/ml streptomycin, 0.125 µg/ml fungizone (Gibco 
BRL, Life technologies), and 0.2 mg/ml gentamycin (Gibco BRL, Life technologies). 
Contaminating normal cells were removed by immunomagnetic beads (in case of lym-
phocytes) or by freezing in liquid nitrogen and thawing (in case of granulocytes).24
All samples contained at least 80% leukemic cells, as determined morphologically on 
May-Grunwald-Giemsa (Merck, Darmstadt, Germany) stained cytospins. A minimum 
of 5x106 cells were lysed in RNAzol or Trizol reagent (Gibco BRL, Life technologies) 
and stored at –80°C until RNA extraction. Th e majority of samples were received and 
processed within 24 hours (n=42), 8 samples, however, were received and processed 
within 48 hours.
RNA extraction and cDNA synthesis
Total cellular RNA was isolated from 5x106 cells using RNAzol or Trizol reagent accord-
ing to the manufacturer’s protocol. Aft er precipitation with ethanol, RNA pellets were 
dissolved in water. Th e RNA was quantifi ed spectrophotometrically. cDNA synthesis 
was performed as described by Stam et al.25 Briefl y, following a denaturation step of 5 
minutes at 70°C, 1 µg of RNA was reverse transcribed to single-stranded cDNA using 
a mix of random hexamers (2.5 µM) and oligo dT primers (20 nM). Th e RT reaction 
was performed in a total volume of 25 µl containing 0.2 mM of each dNTP (Amersham 
Pharmacia, Biotech, Piscataway, NJ) 200 U Moloney murine leukemia virus reverse 
transcriptase (M-ML RT; Promega, Madison, WI), and 25 U RNAsin (Promega) at 
37°C for 30 minutes, 42°C for 15 minutes and 94°C for 5 minutes. Th e obtained cDNA 
was diluted to a fi nal concentration of 8 ng/µl. Samples were stored at –80°C.
Quantitative real-time PCR (Taqman) 
Th e mRNA expression levels of dCK, PN-I, CDA, dCMPD, hENT1, RR1 and RR2, 
CTPs, and the endogenous housekeeping gene encoding glyceraldehyde-3-phosphate 
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dehydrogenase (GAPDH) as a reference, were quantifi ed using real-time PCR analysis 
(Taqman) on an ABI Prism 7700 sequence detection system (PE Applied Biosystems). 
Amplifi cation of specifi c PCR products was detected using dual-fl uorescent non-
extendable probes labeled with 6-carboxyfl uorescein (FAM) at the 5’ end, and with 
6-carboxytetramethylrhodamine (TAMRA) at the 3’ end. All primers and probe com-
binations were designed using the OLIGO 6.22 soft ware (Molecular Biology Insights, 
Cascade, CO) and purchased from Eurogentec (Seraing, Belgium). Primers and probes 
used to detect hENT1, dCK, PN-I, CDA and dCMPD have been reported before.25 For 
CTPs, RR1 and RR2 primers and probes are listed in Table 1.
Table 1. Primers and probe combinations used for quantitative real-time PCR (Taqman).
Gene Primer/probe Sequence
RR1 forward
reverse
probe
5’-GTG TGG GAA ATC TCT CAG A-3’
5’-CCA TGG CTG CTG TGT T-3’
5’-(FAM)-CAA ACT CAC TAG TAT GCA CTT CTA CGG-(TAMRA)-3’
RR2
forward
reverse
probe
5’-AGG GGC TCA GCT TGG-3’
5’-GGG GCA GCT GCT TTA G-3’
5’-(FAM)-CGT CCT GGC CAG CAA GAC-(TAMRA)-3’
CTPs forward
reverse
probe
5’-ATC CCG TGG TCG TAG AC-3’
5’-TGG CCA ACA AAC TTC AA-3’
5’-(FAM)-AAC ACA ACC CAG GGC AGA TG-(TAMRA)-3’
RR1: Ribonucleotide reductase subunit 1, RR2: Ribonucleotide reductase subunit 2, 
CTPs: CTP synthetase.
As described before,25 real-time PCR was performed in a total reaction volume of 
50 µl containing TaqMan buff er A (Applied Biosystems), 4 mM MgCl
2
, 200 µM of 
each dNTP (Amersham Pharmacia Biotech), 300 nM forward and reverse primer, 50 
nM dual-labeled fl uorogenic internal probe, 1.25 U AmpliTaq Gold DNA polymerase 
(Applied Biosystems) and 40 ng of cDNA as a template. Samples were heated for 10 
minutes at 95°C to activate the AmpliTaq Gold DNA polymerase and amplifi ed during 
40 cycles of 15 secondes at 95°C and 60 seconds at 60°C. Th e relative mRNA expression 
levels of the target genes in each patient were calculated using the comparative cycle 
time (C
t
) method.26 Briefl y, this PCR C
t
 value is the cycle number at which emitted fl uo-
rescence exceeds 10x the standard deviation (SD) of baseline emissions as measured 
from cycles 3-15. Th e C
t
 of the target gene is normalized to the GAPDH PCR C
t
 value 
by subtracting the GAPDH C
t
 value from the target C
t
 value. Th e mRNA expression 
level for each target PCR relative to GAPDH was calculated using the following equa-
tion: 
relative mRNA expression = 2 – (Ct target- Ct GAPDH) x 100%.
78
C
ha
pt
er
 5
In vitro cytotoxicity assay
In vitro cytotoxicity of the deoxynucleoside analogs ara-C (Cytosar; Pharmacia &Up-
john, Woerden, Th e Netherlands), 2-CdA (Leustatin, Ortho Biotech, USA), DAC 
(Decitabine, kindly provided by PCH Pharmachemie bv, Haarlem, Th e Netherlands), 
F-ara-A (Fludara, Schering AG, Th e Netherlands), Gemcitabine (Gemzar, Eli Lilly, 
Houten, Th e Netherlands) was determined using the MTT-assay as described previ-
ously.27 Briefl y, cells were cultured in round-bottomed 96-well microtitre plates in the 
presence of 6 concentrations of diff erent drugs, in the following ranges: ara-C (0.04-
41.0 µM); 2-CdA (0.001-140.0 µM); DAC (11.0 µM–11.0 mM); F-ara-A (0.04-44.0 µM) 
and dFdC (0.04-13.0 mM). Cells without drugs were included as controls and wells 
containing culture medium only were used as blanks. Th e plates were cultured for 4 
days at 37°C in humidifi ed air containing 5% CO
2, 
aft er which 10 µl of 3-[4,5-dimethyl-
thiazol-2-yl]-2,5 diphenyl tetrazoliumbromide (MTT; 5 mg/ml, Sigma Aldrich, Zwijn-
drecht, Th e Netherlands) was added and the plates were incubated for an additional 6 
hours. Only viable cells are able to reduce MTT tetrazolium salt to purple/blue forma-
zan crystals. Th e formazan crystals were dissolved using acidifi ed isopropanol (0.04 
N HCl-isopropyl alcohol) and the optical density (OD), which is linearly related to 
the number of viable cells,28 was measured spectrophotometrically at 562 and 720 nm. 
Aft er subtraction of the blank values, the leukemic cell survival (LCS) was calculated 
by the following equation: 
LCS = (OD
day4
 treated well/mean OD
day4
 control wells) x 100%. 
Drug sensitivity was expressed as the LC
50 
value, the drug concentration lethal to 50% 
of the leukemic cells. Reliable results were obtained when a minimum of 70% leukemic 
cells was present at day 4 and when the control OD was more than or equal to 0.05.29
Sample source (bone marrow or peripheral blood) and cryo-preservation do not infl u-
ence the results obtained by cellular drug resistance testing and were therefore analyzed 
together.30
Statistics
Th e distribution of measured values was characterized by median values and quartiles 
(25th-75th percentiles). Due to the strongly skewed character of the distributions, analy-
ses were performed on log-transformed measurements. For signifi cance, a two-tailed 
level of α=0.01 was used. P-values between 0.01 and 0.05 were considered to indicate 
a trend for signifi cance. Pearson correlations were used to describe relations between 
variables. AML patient samples were divided into thee sub-groups according to their 
sensitivity to ara-C: sensitive (LC
50
 <0.98 µM), intermediate (0.98< LC
50
 <5.18 µM) and 
resistant (LC
50
 >5.18 µM) (the cut-off  values are based on Zwaan et al (2000)31, and a 
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one-way Anova test was performed on hENT1 expression for these three sensitivity 
groups. Stepwise modeling on the log-transformed LC
50
 values was used to unravel the 
relative importance of the possible indicators.
RESULTS
Patient characteristics
Fift y-fi ve AML patient samples with LC
50 
values for ara-C, cladribine, decitabine, fl uda-
rabine and gemcitabine (determined by MTT-assay) were selected for RNA isolation. 
We were unable to isolate a suffi  cient amount of RNA from 5 of these samples. Th erefore, 
the study population consists of 50 newly diagnosed pediatric AML patients. Patient 
characteristics are listed in Table 2. Th is selected group of AML patients did not diff er 
signifi cantly regarding to age (p=0.30), white blood cell (WBC) count (p=0.14), sex 
(p=0.39), or in vitro sensitivity to ara-C (p=0.50) from a large group of AML samples 
that we have previously characterized for in vitro drug)31 and was therefore considered 
to be representative.
Table 2. Patient characteristics.
Number, (n) 50
Sex ( : ), (%) 62 : 38
Age, yrs. (median; range) 10.7 (0.1 – 16.8 )
WBC*, x109/L (median; range) 79.3 (2.1 – 524.0)
AML subtypes, (%)
FAB M0
FAB M1
FAB M2
FAB M3
FAB M4
FAB M5
Unknown
4
12
16
8
36
18
6
*WBC: White blood cell count
mRNA expression levels of enzymes involved in the metabolism of deoxynucleoside analogs in AML and FAB-type 
subgroups
Using quantitative real-time PCR the mRNA expression levels of hENT1, dCK, PN-
I, CDA, dCMPD, RR1, RR2 and CTPs were determined. Measurable amounts of all 8 
genes were found in all samples. Sample source (bone marrow (n=37) or peripheral 
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blood (n=13)) and the time interval between tissue acquisition and processing/storage 
of the cells (within 24 or 48 hrs) did not infl uence mRNA expression of the enzymes 
and all samples were therefore evaluated together in the following analyses. Genes were 
expressed with considerable variability between various patients (Figure 2). We investi-
gated the association between all 8 genes and several diagnostic features. Th ere was no 
diff erence in mRNA expression levels of target genes between boys and girls, nor was 
there a relation between the expression levels of these genes and initial WBC counts. 
For the analysis with FAB-type, patients were divided into 3 subgroups: FAB M1/
M2, FAB M4 and FAB M5. FAB M1 and M2 were taken together because they did not 
diff er in age, sex, WBC, drug resistance or mRNA expression levels (data not shown). 
FAB M0 and FAB M3 were excluded because of the limited number of samples. FAB M5 
expressed 1.8-fold (p=0.007) lower levels of PN-I compared to FAB M1/M2. We did not 
observe any other signifi cant diff erences (Table 3).
Table 3. Relative mRNA expression of hENT1 and enzymes involved in ara-C metabolism between AML FAB-type subgroups. 
Gene FAB M1/2
(n=14)
FAB M4
(n=18)
FAB M5
(n=9)
hENT1 0.68 (0.30 - 0.76) 0.51 (0.33 - 0.75) 0.57 (0.48 - 0.95)
dCK 0.61 (0.45 - 1.34) 0.52 (0.42 - 0.89) 0.55 (0.17 - 0.85)
CDA 0.069 (0.009 - 0.24) 0.14 (0.06 - 0.20) 0.16 (0.08 - 0.21)
dCMPD 1.09 (0.72 - 1.56) 0.89 (0.70 - 1.19) 0.60 (0.52 - 1.09)
PN-I 0.79 (0.51 - 1.37) 0.60 (0.39 - 0.85) 0.43 (0.16 - 0.50)*
RR1 0.18 (0.11 - 0.29) 0.15 (0.06 - 0.22) 0.15 (0.08 - 0.22)
RR2 0.05 (0.02 - 0.09) 0.04 (0.01 - 0.08) 0.05 (0.02 - 0.17)
CTPs 0.28 (0.20 - 0.32) 0.20 (0.14 - 0.33) 0.34 (0.17 - 0.47)
Indicated values are the median expression levels per group. Between parenthesis, the 25th-75th percentiles are given. * p<0.01 compared to 
FAB M1/2
In vitro deoxynucleoside analog cytotoxicity
Dose-response curves were obtained for all drugs and marked diff erences between 
individual patients were found. Th e median (25th-75th percentile) ara-C LC
50 
value was 
1.70 µM (0.59 - 3.38 µM; n=50). For the purine analogs 2-CdA and F-ara-A group 
median LC
50
 values were 0.073 µM (0.051 - 0.098 µM; n=46) and 1.19 µM (0.66 - 2.27 
µM; n=47), respectively. Th e group median for dFdC was 10.04 µM (2.05 - 20.86 µM; 
n=48), while DAC was only active in very high concentrations (median LC
50
 value = 
3426 µM (717 - 5700 µM; n=48)).
Correlations between mRNA expression levels and in vitro sensitivity to deoxynucleoside analogs
hENT1 mRNA expression inversely correlated with the LC
50
 values of ara-C (r
p
=-0.46; 
p=0.001; n=50) and also seemed to correlate inversely with the LC
50
 values of 2-CdA 
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(r
p
=-0.30; p=0.04, n=46), DAC (r
p
=-0.29; p=0.04, n=48) and dFdC (r
p
=-0.33; p=0.02, 
n=48). In other words, increased sensitivity to deoxynucleoside analogs was directly 
related to increased mRNA expression of the hENT1 nucleoside transporter. Further-
more, decreased dCK mRNA expression seemed to correlate with resistance to dFdC 
(r
p
=-0.31; p=0.03, n=48). Also, resistance to DAC seemed to correlate with increased 
CDA mRNA levels (r
p
=0.33; p=0.03, n=48). Th e accumulation of ara-CTP could depend 
on the ratio of the activation enzyme dCK and the inactivation enzymes PN-I and CDA. 
Th erefore, we also studied the relation between the dCK/PN-I and dCK/CDA ratios 
and in vitro drug sensitivity. Th e dCK/PN-I ratio correlated inversely with the LC
50 
values for dFdC (r
p
=-0.45, p=0.001, n=47) and the dCK/CDA ratio seemed to correlate 
with the LC
50 
values for DAC (r
p
=-0.29; 0.04, n=48). We did not observe correlations 
between these ratios and in vitro sensitivity to ara-C, 2-CdA and F-ara (Table 4). 
mRNA expression levels of hENT1, dCK, PN-I, CDA, dCMPD, RR1/2 and CTPs were 
entered into a stepwise multivariate regression model to identify the most important 
indicators with respect to in vitro sensitivity to deoxynucleoside analogs (dependent 
variables LC
50
 values ara-C, 2-CdA, DAC, F-ara-A or dFdC). In multivariate analysis, 
hENT1 mRNA expression predicted in vitro sensitivity to ara-C (p=0.002). Further-
more, CDA mRNA expression levels seemed to predict in vitro sensitivity to DAC 
(p=0.02), while other factors did not reach 
signifi cance. Also when we divided the AML samples in three subgroups based on 
their in vitro ara-C sensitivity, resistant patients expressed 3-fold lower hENT1 mRNA 
levels compared with sensitive patients (p=0.003; Figure 3).
Figure 2. Expression levels of genes that potentially are involved in ara-C resistance.
Relative mRNA expression of the human equilibrative nucleoside transporter 1 (hENT1), deoxycytidine kinase (dCK), pyrimidine nucleotidase 
I (PN-I), cytidine deaminase (CDA), ribonucleotide reductase subunit 1 and 2 (RR1 and RR2) and CTP synthetase (CTPs) were determined by 
quantitative real-time PCR (Taqman) analysis in 50 pediatric AML samples, obtained at diagnosis. Measurable amounts of all genes were found 
in all patients. Targets were expressed with great variability; group medians, 25th/75th percentiles and the ranges are given.
Figure 5.2 
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Table 4. Correlation between expression levels of potential resistance factors and in vitro deoxynucleoside analog sensitivity (LC50 values) in 
50 primary pediatric AML samples.
Resistance 
factor
Pearson
correlation
Ara-C 2-CdA DAC F-ara-A dFdC
hENT1 rp
p-value
-0.46**
0.001
-0.30*
0.04
-0.29*
0.04
-0.24
0.09
-0.38*
0.02
dCK rp
p-value
-0.11
0.43
-0.09
0.55
-0.04
0.79
0.004
0.98
-0.31*
0.03
CDA rp
p-value
0.13
0.38
-0.09
0.57
0.33*
0.02
0.06
0.69
0.001
0.99
dCK/PN-1 rp
p-value
-0.27
0.06
-0.09
0.55
-0.16
0.29
-0.26
0.08
-0.45**
0.001
dCK/CDA rp
p-value
-0.17
0.24
0.02
0.87
0.29*
0.04
-0.05
0.75
-0.18
0.23
*Pearson correlation (rp) signifi cant at the 0.05 level (2-tailed).
**Pearson correlation (rp) signifi cant at the 0.01 level (2-tailed).
Correlations between the mRNA expression levels of dCMPD, PN-I, RR1, RR2 and CTPS, and in vitro sensitivity to the diff erent deoxynucleoside 
analogs, were statistically not signifi cant.
DISCUSSION
For AML, ara-C is the essential drug during induction and consolidation therapy and is 
given both at intermediate and high-dose schedules.32,33 In the present study we analyzed 
possible resistance factors to ara-C, and other clinically important deoxynucleoside analogs, 
in AML by measuring the gene expression of the key players in transport and metabolism 
Figure 3. hENT1 mRNA expression in relation to in vitro ara-C sensitivity.
AML patient samples were divided into three subgroups based on in vitro ara-C sensitivity (sensitive = LC50 <0.98 µM), intermediate = 0.98< 
LC50 <5.18 µM) and resistant = LC50 >5.18 µM). Patients that are resistant to ara-C in vitro expressed 3.0-fold lower hENT1 mRNA levels 
compared with ara-C sensitive patients. P-value were determined by one-way Anova.
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of ara-C. Quantitative real-time PCR analysis revealed that AML FAB-M5 expressed lower 
levels of the ara-C degrading enzyme PN-I compared with FAB-M1/2. Although the analy-
sis included only a limited number of samples, this fi nding may provide an explanation for 
the relative sensitivity to ara-C of AML FAB-M5 that we reported previously.31
We studied the relation between the mRNA expression level of potential ara-C resis-
tance factors and in vitro sensitivity to deoxynucleoside analogs. Although in vitro drug 
resistance testing diff ers considerably from the in vivo situation, it does provide valuable 
indications as to which factors might be important in drug sensitivity in vivo.34 hENT1
mRNA expression correlated with sensitivity to ara-C and also seemed to correlate with 
sensitivity to 2-CdA, DAC and dFdC, indicating that transport across the cell membrane 
is an important step for deoxynucleoside analog induced cytotoxicity. In multivariate 
analysis hENT1 mRNA expression was the most important factor determining sensitivity 
to ara-C. Th is might be explained by the fact that entry of ara-C into the cell is mainly 
dependent on hENT1-mediated transport.5,6,35,36 In contrast, 2-CdA, DAC and dFdC 
diff er from ara-C with respect to their preferential nucleoside transporters and can be 
transported across the cell membrane by other members of the nucleoside transporter 
family as well.37 2-CdA can enter cells via hENT1, hENT2 and the human concentrative 
nucleoside transporter 3 (hCNT3)37,38, while hENT1, hENT2, hCNT1 and hCNT3 are 
able to mediate uptake of dFdC into cells.37 hENT1 mediated infl ux, however, seems to 
be a pivotal factor in ara-C cytotoxicity. Patients resistant to ara-C in vitro expressed 
3-fold lower hENT1 mRNA levels. Our results are supported by the fact that hENT1 has 
been implicated as a crucial factor in ara-C sensitivity in previous studies.39,40 Galmarini 
et al measured hENT1 mRNA expression in adult AML samples and demonstrated that 
hENT1 defi ciency was related to a shorter disease free survival.40 In addition, elevated 
hENT1 mRNA expression explained the remarkable ara-C sensitivity of infants with MLL
gene rearranged acute lymphoblastic leukemia (ALL).25 hENT1 may therefore be a valu-
able predictor of ara-C sensitivity at diagnosis. Unfortunately we were not able to asses 
the relation between hENT1 expression and in vivo response to treatment due to the het-
erogenity of the treatment and the limited follow-up time. Patients were treated accord-
ing to diff erent treatment protocols and several diff erent dosing schedules. AML patients 
may, however, benefi t from screening for hENT1 mRNA levels at diagnosis, because of 
its signifi cance for ara-C dosing. At intermediate dose ara-C (100-200 mg/m2) plasma 
levels are in the µM range and transport across the cell membrane is solely dependent 
on nucleoside transporters.41 At high dose ara-C (1-3 g/m2) however, hENT1 seems less 
crucial, although plasma concentrations might not exceed the Km of the transporter-me-
diated infl ux. At these high concentrations, Ara-C also enters the cell by passive diff usion, 
while dCK will be saturated.42,43 Patients with a low hENT1 mRNA level could potentially 
benefi t from up-front high dose ara-C treatment or an ara-C analog that is not dependent 
on transporter-mediated infl ux. A compound such as troxacitabine for example, which 
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passively diff uses across the cell membrane due to its unusual L-confi guration44,45, might 
be able to circumvent ara-C resistance caused by low hENT1 expression. 
Most studies on ara-C resistance have focused on the conversion of ara-C to ara-CTP 
and several studies have linked reduced dCK mRNA expression or functional activity 
to ara-C resistance.46-49 In acute leukemia, relapsed ALL and AML patients have been 
shown to express decreased dCK mRNA levels.50 In contrast, dCK was not rate-limit-
ing in the formation of ara-CTP in infants with MLL gene rearranged ALL.25 In this 
present study we did not observe a correlation between dCK mRNA expression and in 
vitro ara-C sensitivity in AML blasts. Although there was a considerable range in dCK
mRNA levels in AML blasts, the median expression was quite high, and it therefore 
seems unlikely that low dCK expression plays a role in ara-C resistance in childhood 
AML at diagnosis. We have previously reported on dCK mRNA levels in childhood 
AML blasts and most AML samples expressed mRNA levels that were in the range of 
cell lines that are sensitive to ara-C.51 Nevertheless, reduced dCK mRNA expression 
may be involved in resistance to gemcitabine. Both dCK mRNA and dCK protein levels 
have been shown to predict in vivo gemcitabine sensitivity.52 Our present study also 
indicated that reduced dCK mRNA expression could contribute to in vitro gemcitabine 
resistance in AML blasts. It should be mentioned however that the Pearson correlation 
coeffi  cient was low and was not signifi cant in multivariate analysis. 
Finally, multivariate analysis showed that DAC resistance seemed to correlate with 
increased mRNA levels of the inactivating enzyme CDA. DAC was initially developed 
as a cytotoxic agent and has activity in several hematological malignancies. Low-dose 
DAC is currently enjoying a revival as a specifi c inhibitor of DNA hypermethylation in 
cancer.20 DAC is an excellent substrate for CDA and elevated CDA mRNA levels may 
contribute to resistance to DAC.53
In conclusion, our fi ndings indicate that reduced drug infl ux into the cell caused 
by decreased hENT1 mRNA expression might be involved in resistance to ara-C, and 
other deoxynucleoside analogs, in childhood AML. 
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Chapter 6
Multidrug resistance genes in infant Acute 
Lymphoblastic Leukemia;
Ara-C is not a substrate for the Breast Cancer Resistance 
Protein (BCRP)
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ABSTRACT
Infants with acute lymphoblastic leukemia (ALL) are more resistant to chemothera-
peutic drugs than older children with ALL, except for Ara-C. Th e mechanisms under-
lying drug resistance in infant ALL, however, remain unknown. Possibly, multidrug 
resistance (MDR) proteins like P-glycoprotein, multidrug resistance associated protein 
(MRP1), lung resistance-related protein (LRP/MVP), and the breast cancer resistance 
protein (BCRP), play a role. Accordingly we determined the mRNA levels of the genes 
encoding these proteins in infants (n=13) and older children (non-infants) (n=13) 
with ALL, using quantitative real-time PCR. Infant ALL patients expressed 2.4-fold 
less BCRP mRNA (p=0.009) than non-infants with ALL. MDR1, MRP1 and LRP/MVP
expression did not diff er signifi cantly between both patient groups. Th e expression of 
the MDR genes did not correlate to prednisolone, vincristine, daunorubicin or Ara-C 
cytotoxicity, with the exception of BCRP expression, which signifi cantly correlated with 
resistance to Ara-C (r
s
=0.53, p=0.012), suggesting that Ara-C might be a substrate for 
BCRP. However, culturing patients ALL cells in the presence of the BCRP inhibitor 
Ko143 had no eff ect on Ara-C sensitivity. Moreover, inhibiting Bcrp1 in the Mdr1a, 
Mdr1b and Mrp1 defi cient and Bcrp1 over-expressing mouse cell line Mef3.8/T6400, 
also did not modulate Ara-C cytotoxicity. Th erefore we conclude that Ara-C is not 
a substrate for BCRP and that MDR proteins do not play a signifi cant role in drug 
resistance in infant ALL.
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INTRODUCTION
Nowadays, approximately 70% of the children diagnosed with acute lymphoblastic 
leukemia (ALL), treated using combination chemotherapy, achieve and remain in con-
tinuous complete remission. For a minority of patients with ALL, however, the prog-
nosis is far less promising. Infants (i.e. children <1 year of age) form the most striking 
example of a subgroup of ALL patients who have failed to benefi t from the greatly 
improved treatment regimens developed over the last few decades. Th e prognosis for 
infants with ALL still is very poor, with an event-free survival (EFS) of approximately 
35%.1 Treatment failure in infant ALL patients seems to be associated with cellular drug 
resistance. Pieters et al.2 demonstrated that leukemic cells from infants with ALL are in 
vitro signifi cantly more resistant to chemotherapeutic drugs, especially to prednisone 
and L-asparaginase, compared with cells from older children with ALL. One exception, 
however, is Ara-C to which infant ALL cells are highly sensitive.2
Multidrug resistance (MDR) is described as (cross)resistance to structurally unrelated 
cytotoxic drugs, which severely limits the eff ectiveness of the chemotherapeutic treat-
ment of the patient. Since leukemic cells from infants with ALL are in vitro resistant to 
multiple chemotherapeutic drugs, infant ALL patients can legitimately be classifi ed as 
multidrug resistant. MDR has been associated with decreased cellular drug retention as 
a result of increased drug effl  ux mediated by specialized ATP-dependent transmembrane 
transporter proteins. Several MDR related drug effl  ux proteins have been characterized, 
most of which appeared to be members of the ATP-binding cassette (ABC) transporter 
superfamily. Th e most extensively studied multidrug resistance protein is the Perme-
ability-glycoprotein (P-gp) encoded by the MDR1 gene. P-gp has been described to have 
broad substrate specifi city, decreasing the intracellular retention of, among others, anthra-
cyclins (e.g. daunorubicin, doxorubicin), anthracenes (e.g. mitoxantrone), vinca alkaloids 
(e.g. vincristine, vinblastine) and epipodophyllotoxins (etoposide and teniposide).3 Other 
identifi ed MDR proteins are the multidrug resistance related protein 1 (MRP1),4 lung 
resistance-related protein/major vault protein (LRP/MVP)5, and the recently discovered 
breast cancer resistance protein (BCRP).6,7 MRP1 is a member of the MRP family of ABC 
transporters, of which to date eight members have been identifi ed. So far, MRP1 is the only 
MRP family member that has been associated with clinical multidrug resistance. Although 
MRP1 shares only 15% homology with P-gp, the phenotype associated with MRP1 over-
expression results in a MDR phenotype comparable to that of P-gp over-expressing cells.8
Lying on a separate limb of the phylogenetic tree,9 BCRP is evolutionarily distinct from the 
other ABC transporters, and its gene encodes a so-called half-transporter that dimerizes 
to form an active transporter.10 Th is may suggest a separate role for BCRP in clinical drug 
resistance. To date, accepted substrates for BCRP include camptothecins, mitoxantrone 
and related molecules11, and methotrexate.12 LRP was identifi ed as the major vault pro-
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tein,13 an important component of well conserved cellular organelles called vaults, which 
are up-regulated in multidrug resistant cancer cell lines.14 Unlike P-gp, MRP1 and BCRP, 
LRP/MVP is not a member of the ABC transporter family. It is thought that LRP/MVP 
decreases the eff ectiveness of cytotoxic drugs, either by regulating nucleus-cytoplasmatic 
transport of cytotoxic drugs away from the nucleus and/or by involvement in sequestra-
tion of cytotoxic drugs in exocytotic vesicles.13 LRP/MVP has been reported to be involved 
in resistance to vincristine, doxorubicin and etoposide.15
Th e exact clinical value of the above described multidrug resistance proteins in 
childhood ALL is not clear and existing data are confl icting.16 Moreover, to date no 
data exists on the possible role these MDR effl  ux proteins might play in the observed 
drug resistance in infant ALL patients. Th erefore, we determined and compared the 
expression levels of MDR1, MRP1, LRP/MVP and BCRP using quantitative real-time 
PCR (Taqman) analysis, in leukemic samples form infants and non-infants diagnosed 
with ALL. In addition, the obtained mRNA expression levels of these MDR genes were 
correlated to the level of cytotoxicity induced in these samples by several important 
chemotherapeutic drugs used in the treatment of childhood ALL.
MATERIALS AND METHODS
Patient samples
Bone marrow and/or peripheral blood samples of 13 untreated infants (<1 year of age) 
initially diagnosed with ALL were collected at the Erasmus MC - Sophia Children’s 
Hospital, and other hospitals participating in the INTERFANT-99 treatment pro-
tocol. Samples of 13 initially diagnosed ALL patients older than 1 year of age were 
obtained from the German COALL study group (Prof. Dr. G. E. Janka-Schaub, Ham-
burg, Germany). Th e median age in the infant and non-infant group was 0.5 and 6.0 
years respectively. Th e immunophenotype of the infants predominantly was pro-B 
and pre-B, whereas most of the non-infant ALL patients had a common ALL (c-ALL) 
immunophenotype. In the infant group, 77% of the patients carried a rearrangement 
of the MLL gene on chromosome 11q23. In contrast, all the non-infant ALL patients 
harbored germ line MLL genes. 
Within 24 hours aft er sampling, mononuclear cells were isolated by density gradient 
centrifugation using Lymphoprep (density 1.077 g/ml; Nycomed Pharma, Oslo, Nor-
way), centrifuged at 480 g for 15 minutes at room temperature. Th e collected mono-
nuclear cells were washed twice and kept in culture medium consisting of RPMI 1640 
medium (Dutch modifi cation without L-glutamine; Gibco BRL, Life Technologies), 20% 
fetal calf serum (FCS ; Integro, Zaandam, Th e Netherlands), 2 mM L-glutamine (Gibco 
BRL, Life Technologies, Breda, Th e Netherlands) 5 μg/ml insulin, 5 μg/ml transferrin, 
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5 ng/ml sodium selenite (ITS media supplement; Sigma, St Louis MO, USA), 100 IU/
ml penicillin, 100 μg/ml streptomycin, 0.125 μg/ml fungizone (Gibco BRL, Life Tech-
nologies) and 0.2 mg/ml gentamycin (Gibco BRL, Life Technologies). Contaminating 
non-leukemic cells were removed using immunomagnetic beads (Dynal ASA, Oslo, 
Norway). All samples contained ≥90% leukemic cells, as determined morphologically 
on May-Grünwald-Giemsa (Merck, Darmstadt, Germany) stained cytospins. 
RNA extraction and cDNA synthesis
Total cellular RNA was extracted from a minimum of 5 x106 cells using TRIzol reagent 
(Gibco BRL, Life Technologies) according to the manufacturer’s protocol, except for 
minor modifi cations; An additional phenol-chloroform extraction was performed and 
the isopropanol precipitation at –20°C was facilitated by adding 1 μl (20 μg/ml) gly-
cogen (Roche, Almere, Th e Netherlands). Aft er precipitation with isopropanol, RNA 
pellets were dissolved in 20 μl RNAse-free TE-buff er (10 mM Tris-HCl, 1 mM EDTA, 
pH=8.0). Th e RNA was quantifi ed spectrophotometrically. Following a denaturation 
step of 5 minutes at 70°C, 1 μg of RNA was reverse transcribed to single stranded 
cDNA using a mix of random hexamers (2.5 μM) and oligo dT primers (20 nM). Th e 
RT reaction was performed in a total volume of 25 μl containing 0.2 mM of each dNTP 
(Amersham Pharmacia Biotech, Piscataway NJ, USA), 200 U Moloney murine leuke-
mia virus reverse transcriptase (M-MLV RT) (Promega, Madison Wisconsin, USA) and 
25 U RNAsin (Promega), at 37°C for 30 minutes, 42°C for 15 minutes and 94°C for 5 
minutes. Th e obtained cDNA was diluted to a fi nal concentration of 8 ng/μl. 
Quantitative real-time PCR (Taqman technology)
Th e mRNA expression levels of MDR1, MRP1, LRP/MVP and BCRP and the endogenous 
housekeeping gene GAPDH as a reference, were quantifi ed using real-time PCR analysis 
(Taqman) essentially as described recently.17 On an ABI Prism 7700 sequence detection 
system (PE Applied Biosystems), specifi c PCR products were amplifi ed and detected 
using dual-fl uorescent non-extendable probes labeled with 6-carboxyfl uorescein (FAM) 
and 6-carboxytetramethylrhodamine (TAMRA) at the 5’-end and 3’-end, respectively. 
Primers and probe combinations, reported previously,17 were designed using OLIGO 
6.0 primer analysis soft ware (Medprobe, Olso, Norway). All PCRs showed comparable 
effi  ciencies of E ≥ 95%, and were performed in duplicate in a reaction volume of 50 
μl containing 1x Taqman buff er A (PE Applied Biosystems), 4 mM MgCl
2
, 200 μM of 
each dNTP (Amersham Pharmacia Biotech), 300 nM forward and reverse primer, 200 
nM probe, 1.25 U AmpliTaq Gold DNA polymerase (Applied Biosystems) and 40 ng of 
cDNA from each patient as a template. Samples were heated for 10 minutes at 95 °C and 
amplifi ed for 40 cycles of 15 seconds at 95°C and 60 seconds at 60°C. A serial dilution 
of cDNA derived from a cell line RNA-pool (CEM, K562, and two EBV transformed 
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lymphoblastoid B-cell lines) was amplifi ed in parallel as a control to verify amplifi cation 
effi  ciency within each experiment. For each patient, the relative mRNA expression levels 
of MDR1, MRP1, LRP/MVP and BCRP were calculated using the comparative cycle time 
(C
t
) method.18 Briefl y, the target PCR C
t
 values, i.e. the cycle number at which emitted 
fl uorescence exceeds 10x the standard deviation of base-line emissions as measured from 
cycles 3 to 15, is normalized to the GAPDH PCR C
t
 value by subtracting the GAPDH C
t
value from the target PCR C
t
 value. Th e relative mRNA expression level to GAPDH for 
each target PCR can be calculated using the following equation : 
Relative mRNA expression = 2 –[Ct target – Ct GAPDH] x 100%.
In vitro drug cytotoxicity assay (MTT assay) 
In vitro drug cytotoxicity was determined using the MTT assay as described by Pieters 
et al.19 Briefl y, 100 μl aliquots of cell suspension (1.6 x105 cells) were cultured in round-
bottomed 96-well microtitre plates (Greiner bio-one) in the presence of six diff erent 
concentrations of each drug in duplicate. Th e drugs tested were: prednisone (PRED, 
Bufa, Uitgeest, Th e Netherlands), vincristine (VCR, Teva Pharma, Mijdrecht, Th e Neth-
erlands), daunorubicin (DNR, Rhône-Poulenc-Rorer, Amstelveen, Th e Netherlands), 
and Ara-C (Cytosar, Pharmacia & Upjohn BV, Woerden, Th e Netherlands). Th e range 
of end concentrations and the dilution factors were: PRED (0.0076-250 μg/ml, 8-fold), 
VCR (0.049-50 μg/ml, 4-fold), DNR (0.0019-2 μg/ml, 4-fold) and Ara-C (0097-10 μg/
ml, 4-fold). Control cells were cultured in eight wells in the absence of drugs. Four wells 
containing 100 μl culture medium were used as blanks. Aft er incubating the plates for 
four days at 37°C in humidifi ed air containing 5% CO
2
, 10 μl of 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyl tetrazoliumbromide (MTT, 5 mg/ml ; Sigma Aldrich, Zwijndrecht, 
Th e Netherlands) was added, and the plates were incubated for an additional six hours 
under the same conditions. During this fi nal 6-hour incubation, the yellow MTT tetra-
zolium salt is reduced to purple-blue formazan crystals by viable cells only. Th e formazan 
crystals were dissolved by adding 100 μl acidifi ed isopropanol (0.04 N HCl-isopropyl 
alcohol) and the optical density (OD), which is linearly related to the number of viable 
cells,20 was measured spectrophotometrically at 562 nm. Aft er subtraction of the blank 
values, the leukemic cell survival (LCS) was calculated by the equation : 
LCS = (OD
Day 4
 treated well / mean OD
 Day 4
 control wells) x 100%
Drug sensitivity was assessed by the LC
50
, the drug concentration lethal to 50% of the 
cells. Evaluable assay results were obtained when a minimum of 70% leukemic cells 
was present in the control wells aft er 4 days of incubation and when the control optical 
density (OD) was ≥ 0.050.19
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To determine Ara-C cytotoxicity in the absence and presence of the specifi c BCRP 
inhibitor Ko143,21 leukemic cells from patients were pre-incubated with 200 nM Ko143 
or with an equal volume of PBS for 1 hour at 37°C in humidifi ed air containing 5% CO
2
. 
Without washing the cells or removing the inhibitor from the culture medium, Ara-C 
cytotoxicity was determined using the MTT-assay as described above.
Cytotoxicity assays in the Mef3.8 and Mef3.8/T6400 cell lines 
Both the Mef3.8 and the Mef3.8/T6400 cell lines were maintained in DMEM supple-
mented with 10% FCS (HyClone), 10 mM HEPES, penicillin and streptomycin. Mef3.8 
cells are adherent mouse embryo fi broblasts which are nullizygous for P-gp and Mrp1.22
Th e Mef3.8/T6400 subline was obtained by selection for resistance to topotecan and 
expresses high levels of wild-type Bcrp1.22,23 Th e subline was routinely maintained un-
der continuous selection with 6.4 μM topotecan, but this concentration was reduced to 
0.64 μM for 2 days prior to use of these cells in the cytotoxicity assay. 
Sub-confl uent cells were seeded in 96-well pates at a density of 500 cells/well in a 
volume of 100 μl. Aft er allowing attachment of the cells for 4 hours, the cells were 
exposed to concentration series of Ara-C or mitoxantrone, in the presence or absence 
of 200 nM of the specifi c Bcrp1 inhibitor Ko143. Aft er 4-5 days, while cells were still 
sub-confl uent in the untreated wells, the wells were stained with 1:4000 Sybr Green I 
(Molecular Probes, Eugene, OR) nucleic acid stain, diluted in a hypotonic lysis buf-
fer (10 mM Tris, pH8.0, 2.5 mM EDTA, 0.1% Triton X-100) using 200 μl/well, and 
equilibration was allowed for 24 hours at 4°C in the dark. Relative cell proliferation 
was quantifi ed by measuring Sybr Green I fl uorescence using a plate reader (Cytofl uor 
4000 ; PerSpective Biosystems, Framingham, MA) with 485 nm excitation and 530 nm 
emission fi lters. Cytotoxicity of the drugs was expressed as the IC
50 
value, i.e. the con-
centrations of drugs which inhibits 50% of the growth of the cells. 
RESULTS
Using quantitative real-time PCR (Taqman technology), the mRNA expression levels 
of MDR1, MRP1, LRP/MVP and BCRP were determined in leukemic cells from infants 
(n=13) and older children (non-infants) (n=13) with newly diagnosed ALL. Infants 
expressed signifi cantly less BCRP mRNA (p=0.009) compared to older children with 
ALL. Th e diff erence in the median relative BCRP mRNA expression between the infant 
and non-infant group was 2.4-fold. No signifi cant diff erences in mRNA expression of 
MDR1, MRP1 and LRP/MVP were found, although a trend towards decreased MRP1
mRNA expression in infants was observed (Figure 1).
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Figure 6.1 
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Figure 1. Relative mRNA expression of MDR1, MRP1, LRP/MVP and BCRP in primary infant and non-
infant ALL samples.
Diff erences in MDR1, MRP1, LRP/MVP and BCRP mRNA expression between infants (n=13) and non-infants (n=13) with ALL were analyzed 
using the Mann-Whitney U test. The lines indicate the median values, circles (ο) represent individual patients. 
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Th e obtained mRNA levels of the MDR genes were correlated to the cytotoxicity of 
several important chemotherapeutic drugs used in the treatment of childhood ALL, 
like prednisone, vincristine, daunorubicin and Ara-C. No positive correlation was ob-
served between the mRNA expression of MDR1, MRP1, BCRP or LRP/MVP and the 
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Figure 2. Relation between Ara-C cytotoxicity and BCRP mRNA expression in pediatric ALL. 
The correlation between the Ara-C cytotoxicity (LC50 in μg/ml) and the relative expression of BCRP mRNA was calculated using the Spearman’s 
rank correlation test. Open circles (ο) indicate infants with ALL and closed circles (•) non-infant ALL patients. 
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Figure 3. Ara-C cytotoxicity in the absence and presence of Ko143 in pediatric ALL. 
Ara-C cytotoxicity determined in two Ara-C resistant and two Ara-C sensitive patients with ALL in the absence and presence of 200 nM of the 
specifi c BCRP inhibitor Ko143. 
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cytotoxicity of the drugs tested, except for BCRP and Ara-C. BCRP mRNA expression 
positively correlated with the LC
50
 values of Ara-C (R
s
=0.53, p=0.012) (Figure 2). Th ese 
fi ndings suggest that Ara-C might be a substrate for BCRP, and that Ara-C sensitivity 
in infant ALL may be explained by a decreased effl  ux of Ara-C out of these cells, medi-
ated by BCRP. To test this hypothesis, Ara-C cytotoxicity in the leukemic cells from 
two Ara-C resistant and two Ara-C sensitive ALL patients was determined both in the 
absence and presence of 200 nM of the specifi c BCRP inhibitor Ko143. Inhibition of 
BCRP by Ko143, however, had no eff ect on Ara-C cytotoxicity (Figure 3). 
Additionally, cytotoxicity to Ara-C and mitoxantrone was determined in cells from 
the Mdr1a/b-/-, Mrp1-/- mouse embryo fi broblast cell line Mef3.8 and the Bcrp1 (the 
mouse homologue of human BCRP) over-expressing subline Mef3.8/T6400, both in 
the presence and absence of 200 nM of Ko143 (Table 1). Although the Bcrp1 over-ex-
pressing subline Mef3.8/T6400, derived by selection for topotecan resistance, appeared 
to be signifi cantly more resistant to Ara-C compared to the parental Mef3.8 cell line 
(p<0.05), inhibition of Bcrp1 by Ko143 did not alter Ara-C cytotoxicity. Mitoxantrone, 
a known substrate for BCRP, served as a positive control in these experiments. Ko143 
markedly sensitized the Mef3.8/T6400 cell line 68-fold to mitoxantrone (p<0.001) 
(Table 1). 
Table 1. Bcrp1-mediated resistance to Ara-C in mouse Mef3.8/T6400 cells.
IC50 (nM)
Mef3.8 Mef3.8/T6400 Resistance Factor*
Ara-C 109 ± 50 184 ± 104 1.6 ± 0.3 (p<0.05)
Ara-C + 200 nM Ko143 117 ± 55 191 ± 106 1.6 ± 0.7 (ns)
Fold sensitisation by Ko143* 0.94 ± 0.11 0.98 ± 0.13
(ns) (ns)
Mitoxantrone 0.66 ± 0.33 31 ± 11 50 ± 8 (p<0.01)
Mitoxantrone + 200 nM Ko143 0.52 ± 0.30 0.48 ± 0.20 1.0 ± 0.2 (ns)
Fold sensitisation by Ko143* 1.3 ± 0.2 68 ± 11
(p<0.05) (p<0.01)
* Resistance and sensitization factors were calculated within each experiment. Means and standard deviations were derived from four 
independent assays. Results of two-tailed t-tests of the hypotheses that resistance factors and fold sensitization by Ko143 diff er from 1.0 are 
shown in parentheses; ns = not signifi cant.
DISCUSSION
Multidrug resistance is attributed to the over-expression of certain effl  ux proteins, that 
are capable of traffi  cking chemotherapeutic drugs out of the cell, like P-glycoprotein, 
MRP1 and BCRP, or away from the nucleus by LRP/MVP. Th e exact clinical value of 
these MDR proteins in childhood ALL, however, is not clear and existing data are 
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confl icting.16 Increased levels of P-glycoprotein expression, both at the protein24,25 and 
mRNA level26, as well as increased P-glycoprotein functioning27, 28 have been shown to be 
signifi cant unfavorable prognostic factors for clinical outcome in childhood ALL. Other 
studies, however, contradict this fi nding and show that P-glycoprotein expression has 
no clinical value.29,30,31 Data on the prognostic signifi cance of the other MDR proteins 
in childhood ALL are scarce. One study on a group of Indian ALL patients, most of 
whom were children, reported signifi cantly higher MRP1 mRNA expression at relapse 
than at presentation or remission.32 However, this fi nding has not been confi rmed by 
others,33,34 and MRP1 measured at the protein level appeared to have no prognostic 
importance30 in yet another study. LRP/MVP mRNA expression has been reported not 
to be of prognostic value in newly diagnosed childhood ALL.33 Furthermore, no diff er-
ences in LRP/MVP protein expression have been reported between initial and relapse 
ALL samples,30 only in multiple relapse samples, LRP/MVP expression was found to 
be signifi cantly increased.30 Even so, it has been suggested that children with initial 
ALL and no detectable LRP/MVP expression experience signifi cantly longer relapse-
free intervals compared to patients with LRP expression.35 Additional studies from our 
laboratory on a group of 146 uniformly treated children with ALL showed that neither 
P-gp, MRP1 nor LRP/MVP expression, measured at initial diagnosis, correlated with 
clinical outcome aft er combination chemotherapy (unpublished data). To date, only a 
single study on BCRP expression in childhood ALL has been reported, in which BCRP
mRNA was measured in 47 initial and 20 relapsed ALL samples. No diff erences between 
initial and relapsed ALL were observed and BCRP mRNA expression did not seem to 
have any prognostic signifi cance.36
Th ere is no published data either on the role the MDR proteins play in infant ALL or 
on possible diff erences in the expression of the MDR genes between infants and older 
children with ALL. However, since infants with ALL are more resistant to chemothera-
peutic drugs than older children,2 such data may well contribute to our understanding 
of the mechanisms underlying drug resistance in infant ALL, which to date remain un-
known. Hence, we measured the mRNA levels of MDR1, MRP1, LRP/MVP and BCRP 
in infant and non-infant ALL samples using quantitative real-time PCR. Th e only sig-
nifi cant diff erence observed between both groups was that infants expressed 2.4-fold 
less BCRP mRNA. Furthermore, the only signifi cant correlation found between the 
mRNA expression of the four MDR proteins and the cytotoxicity of several important 
chemotherapeutic drugs was between BCRP and Ara-C. Th e observed relationship 
indicated that patients with increased mRNA levels of BCRP are likely to be more 
resistant to Ara-C compared to children with lower BCRP mRNA levels, suggesting 
that Ara-C might be a substrate for BCRP. Nevertheless, culturing leukemic cells form 
ALL patients in the presence of Ko143, a specifi c BCRP inhibitor,21 did not sensitize 
the leukemic cells to Ara-C. Th e fi nding that Ara-C was not a substrate for BCRP was 
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confi rmed by additional cell line studies. Given the profound similarities between hu-
man BCRP and its mouse cognate Bcrp1,23 the P-gp and Mrp1 defi cient mouse embryo 
fi broblast cell line Mef3.8 and its Bcrp1 over-expressing sub line Mef3.8/T640022 con-
stitutes a sound model for studying BCRP. Inhibition of Bcrp1 in these cell lines did 
not modulate Ara-C cytotoxicity, whereas both cell lines were markedly sensitized to 
mitoxantrone, a known substrate for BCRP.11 In the Mef3.8/T6400 subline, 200 nM of 
Ko143 completely reversed the high level of resistance to mitoxantrone, demonstrating 
that culturing cells in the presence of this concentration of Ko143 indeed thoroughly 
inhibits Bcrp1. 
Taken together our data suggest that, despite of the observed correlation between 
BCRP mRNA expression and Ara-C resistance, Ara-C is not a substrate for BCRP. 
Moreover, since leukemic cells from infants with ALL are more resistant to chemo-
therapeutic drugs compared with cells from older children with ALL,2 but do not show 
increased expression of the MDR genes tested, we conclude that multidrug resistance 
proteins are unlikely to play a signifi cant role in clinical drug resistance in infants with 
ALL. 
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Chapter 7
Targeting FLT3 in primary MLL gene rearranged 
infant acute lymphoblastic leukemia
106
C
ha
pt
er
 7
ABSTRACT
Acute lymphoblastic leukemia (ALL) in infants is characterized by rearrangements of 
the MLL gene, drug resistance and a poor treatment outcome. Th erefore novel thera-
peutic strategies are needed to improve prognosis. Recently we showed that FLT3 is 
highly expressed in MLL rearranged ALL (MLL). Here we demonstrate FLT3 expres-
sion in infant MLL patients (n=41) to be signifi cantly higher compared to both infant 
(n=8) (p<0.001) and non-infant ALL patients (n=23) (p=0.001) carrying germ line MLL
genes. Furthermore, leukemic cells from infant MLL patients were signifi cantly more 
sensitive to the FLT3 inhibitor PKC412 than non-infant ALL cells, and at least as sensi-
tive as ITD positive AML cells (MTT-assay). Surprisingly, activation loop mutations 
only occurred in ~3% (1/36) of the cases, and no FLT3/ITDs were observed. However, 
measuring FLT3 phosphorylation in infant MLL patients expressing varying levels of 
wild-type FLT3 revealed that high-level FLT3 expression is associated with ligand-inde-
pendent FLT3 activation. Th is suggests that infant MLL cells displaying activated FLT3 
as a result of over-expression can be targeted by FLT3 inhibitors like PKC412. However, 
at concentrations of PKC412 minimally required to fully inhibit FLT3 phosphorylation, 
the cytotoxic eff ects were only fractional. Th us, PKC412 induced apoptosis in infant 
MLL cells is unlikely to be a consequence of FLT3 inhibition alone, but may involve 
inhibition of multiple other kinases by this drug.
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INTRODUCTION
Translocations involving the Mixed Lineage Leukemia (MLL, HRX, or ALL1) gene on 
chromosome band 11q23 are most frequently found in acute lymphoblastic leukemia 
(ALL) in infants (less than 1 year of age), with an incidence as high as ~80%.1,2 Th e pres-
ence of MLL gene rearrangements is an independent prognostic factor for an adverse 
outcome.2-5 Hence the prognosis for infant ALL is exceedingly poor with an event-free 
survival (EFS) of approximately 35%.6 Th is poor treatment outcome is largely due to 
cellular drug resistance. Leukemic cells from infants with ALL are signifi cantly more 
resistant to most chemotherapeutic drugs both in vitro and in vivo, as compared to 
cells from older children with ALL.7-9 Th is is especially true for prednisone and L-as-
paraginase. Since the clinical outcome for infant ALL patients bearing germ line MLL
genes appears to be much more favorable,9-11 novel therapeutic targets specifi c for MLL
rearranged infant ALL (infant MLL) are urgently needed.
In search for suitable targets, we recently compared gene expression profi les from 
MLL rearranged ALL patients with profi les from both ALL and acute myeloid leukemia 
(AML) patients carrying germ line MLL genes. Th is study demonstrated that MLL gene 
rearranged ALL is characterized by high-level expression of the gene encoding Fms-
like tyrosine kinase 3 (FLT3, STK-1, FLK-2, or CD135).12 FLT3 is a membrane-bound 
receptor for the hematopoietic growth factor FLT3 ligand (FLT3L or FL), and is impor-
tant in early hematopoietic development.13 Upon binding of FLT3L, wild-type FLT3 re-
ceptors dimerize and become activated by phosphorylation, positively aff ecting several 
signal transduction pathways all of which favor cell survival and proliferation.14 In the 
absence of ligand binding, FLT3 only has minimal kinase activity as a consequence of 
auto-inhibition by the juxtamembrane (JM) domain of the receptor.15
With an incidence of approximately 30%, FLT3 is the most frequently mutated gene 
in AML.16 Mutations in FLT3 appear to activate the receptor in a ligand-independent 
manner, constitutively promoting proliferation and survival, and thus providing the 
leukemic cell with a growth advantage and transforming capacity. Distinct types of such 
activating mutations within two separate regions of the FLT3 gene have been described. 
Th e fi rst are in-frame internal tandem duplications (ITDs) within the JM domain-cod-
ing sequence of FLT3.17 Th ese FLT3/ITDs disrupt the auto-inhibitory activity of the 
JM domain, leading to receptor dimerization and subsequent auto-phosphorylation in 
the absence of FLT3L.18 Th e second type of activating mutations aff ect either Asp835 
or Ile836 within the second tyrosine kinase domain of the FLT3 receptor. At fi rst point 
mutations were described that resulted in alternative amino acids at Asp835.19 Recently, 
insertions aft er Asp835, as well as deletions of the adjacent codon Ile836 (Δ836) have 
been reported.20,21 Analogous to point mutations at Asp816 within a corresponding 
domain of the receptor tyrosine kinase c-KIT,22 these mutations alter the conformation 
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of the activation loop from an inactive to an active state, allowing auto-phosphoryla-
tion, and thus activation of FLT3, again in the absence of its ligand.14
Th e identifi cation of activating mutations and their high incidence in AML patients 
have led to the development of several small molecule inhibitors in order to selectively 
target the constitutive FLT3 signal, inducing leukemic cells to undergo programmed 
cell death (apoptosis). Th e potential of several FLT3 inhibitors as therapeutic drugs 
has been, or is currently being tested in phase I/II clinical trials in adults with relapsed 
or refractory AML or myelodysplastic syndromes (MDS).23-27 Recently we found the 
staurosporine derivative PKC412, a known inhibitor of FLT3,28 to be cytotoxic to acute 
lymphoblastic leukemia cell lines carrying translocations involving MLL and activated 
FLT3 receptors as a consequence of either mutation or over-expression of wild-type 
FLT3.21 Moreover, PKC412 also appeared to be active in vivo, effi  ciently targeting human 
MLL rearranged ALL cells over-expressing wild-type FLT3 in mice.21 Th e present study 
was designed to explore FLT3 as a therapeutic target in primary patient samples from 
infants with MLL. Th erefore, we measured FLT3 as well as FLT3L mRNA expression 
levels in a large cohort of infant MLL patients and compared these to the expression 
levels of these genes in both infants and older children (non-infants) with ALL carrying 
germ line MLL genes. Additionally, the cytotoxic eff ects of PKC412 were determined in 
primary infant MLL and non-infant ALL samples. Finally we assessed the infant MLL 
samples for the presence of activating mutations in FLT3, and analyzed the level of 
FLT3 receptor phosphorylation in patients carrying either mutated or wild-type FLT3. 
PATIENTS, MATERIALS & METHODS
Patient samples
Primary bone marrow and/or peripheral blood samples from untreated infants (<1 
year of age) initially diagnosed with ALL were collected at the Erasmus MC - Sophia 
children’s hospital and other hospitals participating in the INTERFANT-99 treatment 
study. Samples from pediatric ALL patients older than 1 year of age (non-infants) were 
obtained either from the German Cooperative ALL (COALL) study group or the Eras-
mus MC - Sophia Children’s Hospital. Within 24 hours aft er sampling, mononuclear 
cells were isolated by density gradient centrifugation using Lymphoprep (density 1.077 
g/ml ; Nycomed Pharma, Oslo, Norway), centrifuged at 480 g for 15 minutes at room 
temperature. Isolated mononuclear cells were washed twice in PBS and resuspended 
in RPMI 1640 medium (Dutch modifi cation without L-glutamine ; Invitrogen life 
technologies, Breda Th e Netherlands) supplemented with 20% fetal calf serum (FCS ; 
Integro, Zaandam, Th e Netherlands), 2 mM L-glutamine (Invitrogen) 5 μg/ml insulin, 
5 μg/ml transferrin, 5 ng/ml sodium selenite (ITS media supplement ; Sigma, St Louis 
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MO, USA), 100 IU/ml penicillin, 100 μg/ml streptomycin, 0.125 μg/ml fungizone and 
0.2 mg/ml gentamycin (Invitrogen). Contaminating non-leukemic cells were removed 
using immunomagnetic beads as described by Kaspers et al.29 All samples used con-
tained >90% leukemic cells, as determined morphologically on May-Grünwald-Giemsa 
(Merck, Darmstadt, Germany) stained cytospins.
Patient characteristics were collected in reference labs of the INTERFANT-99 and 
the COALL study groups. As part of the INTERFANT-99 study, the infant ALL samples 
were screened for the presence of MLL rearrangements by FISH analysis, and the type 
of translocation determined using PCR. In the present study 35% of the infant ALL 
samples carried a t(4;11), 28.3% a t(11;19), 10% a t(9;11) and 13.3% had germ line MLL
genes. Th e remaining 13.3% of the samples either carried other less frequently found 
translocations involving the MLL gene, or PCR analysis could not be performed due to 
lack of material. 
RNA and DNA extraction
Total RNA and genomic DNA were extracted from a minimum of 5 x106 leukemic cells 
using TRIzol reagent (Invitrogen) according to the manufacturer’s instructions with 
minor modifi cations. Quantifi cation of both RNA and DNA was performed using a 
spectrophotometer and the integrity of the extracted RNA was assessed on 1% agarose 
gels.
Quantitative real-time PCR (TaqMan©)
Extracted RNA was reverse transcribed and the obtained cDNA was used to quantify 
FLT3 and FLT3L mRNA expression relative to the endogenous housekeeping gene glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH), using quantitative real-time PCR 
(TaqMan©) as described previously.30 Primer and probe combinations used to amplify 
and detect FLT3, FLT3L and GAPDH expression are listed in Table 1. 
Table 1. Primer and probe combinations used for quantitative real-time PCR (TaqMan©) analysis.
Target gene Primer/probe Sequence
FLT3 forward
 reverse
 probe
5’-AGC ATC CCA GTC AAT CAG-3’
5’-CTG GCT GGT GCT TAT GA-3’
5’-(FAM)-TTA AAG CCT ACC CAC AAA TCA GAT GT-(TAMRA)-3’
FLT3L  forward
 reverse
 probe
5’-GAG CCC AAC AAC CTA TCT C-3’
5’-GGA CGA AGC GAA GAC A-3’
5’-(FAM)-ATG GAG CGG CTC AAG ACT GT-(TAMRA)-3’
GAPDH forward
 reverse
 probe
5’-GTC GGA GTC AAC GGA TT-3’
5’-AAG CTT CCC GTT CTC AG-3’
5’-(FAM)-TCA ACT ACA TGG TTT ACA TGT TCC AA-(TAMRA)-3’
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Detection of FLT3/ITDs
Detection of internal tandem duplications (ITDs) of the JM domain of FLT3 was per-
formed as described by Kiyoi et al.31 PCRs were carried out in a total reaction volume 
of 50 μl containing TaqMan buff er II (Applied Biosystems), 2 mM MgCl
2
, 200 μM of 
each dNTP (Amersham Pharmacia Biotech), 300 nM forward and reverse primer,31
1.25 U AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, CA, USA) 
and 500 ng of genomic DNA as a template. Samples were heated for 10 minutes at 95°C 
to activate the AmpliTaq Gold polymerase and amplifi ed during 40 cycles of 15 seconds 
at 95°C and 60 seconds at 60°C. Genomic DNA extracted from the MV4-11 cell line, 
that has been shown to posses a FLT3/ITD,32 was used a as positive control. 
Detection of FLT3 activation loop mutations
Detection of the activating mutations aff ecting either Asp835 or Ile836 within the acti-
vation loop of the FLT3 gene was performed essentially as described by Yamamoto et al. 
(2001).19 However, to fi t our standard PCR procedure, a diff erent set of primers (forward: 
5’-TCA CCG GTA CCT CCT ACT G-3’; reverse: 5’-AAA TGC ACC ACA GTG AGT 
G-3’) was designed to amplify the region of interest. To detect mutations, PCR products 
amplifi ed as described above, were digested overnight at 37°C using the restriction 
enzyme EcoRV. Incomplete digested PCR products, visualized on 2% agarose gels, were 
extracted from the gel using the Wizard SV gel and Clean-up system (Promega, Leiden, 
Th e Netherlands). Clean undigested PCR fragments were cloned into pCR2.1 plasmids 
using a TA cloning kit (Invitrogen) and transformed into competent E. coli (DH5α) 
cells by heat shock. Individual clones were recovered from overnight cultures using 
the Wizard Plus SV Minipreps DNA purifi cation system (Promega) and sequenced on 
a 310 Genetic Analyzer (Applied Biosystems) using the BigDye Terminator v1.1 cycle 
sequencing protocol (Applied Biosystems), to confi rm the presence of a mutation. 
Detection of FLT3 gene amplifi cation using FISH analysis
Th e presence of FLT3 amplifi cation was determined with dual-color fl uorescence in 
situ hybridization (FISH) analysis on cytospin preparations. Two BAC clones, 153M24 
and 179F17 isolated from the human BAC library RPCI-11 (Children’s Hospital Oak-
land Research Institute - BACPAC resources, Oakland, CA, USA), containing FLT3 
sequences were used as probes. Probes were labeled by nick translation using digoxi-
genin-11-dUTP for 179F17 and biotin-16dUTP for 153M24 and were hybridized and 
detected as previously described.33 Th e hybridization mixture contained 50 ng of each 
labeled probe and 5 μg of human Cot-1 DNA. In all cases two independent observers 
examined 100 to 200 nuclei.
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In vitro PKC412 cytotoxicity (MTT assay) 
In vitro cytotoxicity to PKC412 was determined using the MTT assay as described pre-
viously.34 Briefl y, leukemic cells were cultured in round-bottomed 96-well microtitre 
plates (Greiner bio-one) in the presence of six concentrations of PKC412 (N-benzoyl 
staurosporine ; kindly provided by Th omas Meyer, Novartis Pharma AG, Basel, Swit-
zerland), with the highest concentration of 10 μM and a 3-fold dilution factor. Control 
cells were cultured in eight wells in the absence of PKC412. Four wells containing 100 
μl culture medium were used as blanks. Aft er incubating the plates for four days at 
37°C in humidifi ed air containing 5% CO
2
, 10 μl of 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazoliumbromide (MTT, 5 mg/ml ; Sigma) was added and the plates were 
incubated for an additional six hours under the same conditions. During this fi nal 6-
hour incubation, the yellow MTT tetrazolium salt is reduced to purple-blue formazan 
crystals by viable cells only. Formazan crystals were dissolved by adding 100 μl acidifi ed 
isopropanol (0.04 N HCl-isopropyl alcohol) and the optical density, which is linearly 
related to the number of viable cells,35 was measured at 562 nm on a spectrophotometer. 
Assay results were deemed successful when a minimum of 70% leukemic cells was pres-
ent in the control wells aft er 4 days of incubation and when the control optical density 
exceeds 0.050.34
Immunoprecipitation and Western Blot analysis of FLT3 phosphorylation 
Leukemic cells were cultured both in the absence and presence of 500 nM PKC412. 
Aft er four hours of exposure to PKC412, cells were washed twice in ice cold PBS and 
resuspended in 100 μl lysis buff er composed of 25 mM Tris buff er, 150 mM NaCl, 5 mM 
EDTA, 10% Glycerol, 1% Triton X-100, 10 mM Sodium Pyrophosphate, 1 mM Sodium 
Orthovanadate, 10 mM Glycerolphosphate, 1 mM dithiothreitol (DTT), 1 mM phenyl-
methylsulfonyl fl uoride (PMSF), 1% Aprotinine (Sigma), 10 mM Sodium Fluoride and 
20 μl freshly prepared Sodium Pervanadate. Accordingly, cell lysis was allowed for 30 
minutes on ice. Cell lysates were cleared by centrifugation for 15 minutes at 13000 rpm 
and 4ºC. Protein concentration was determined using the BCA protein assay (Pierce 
Biotechnology, Inc., Rockford, USA) with diff erent concentrations of bovine serum 
albumin (BSA) as standards. 
For immunoprecipitation (IP), aliquots of whole cellular lysates containing 500 μg 
of protein were pre-cleared with 10 μl of G-plus Agarose (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) and accordingly IP was performed with 10 μl of G-plus Agarose 
supplemented with 3 μg of rabbit polyclonal antibodies specifi c for the human FLT3 
(Santa Cruz Biotechnology). Following denaturation in Laemmli buff er, precipitates 
were separated on 4-12% polyacrylamide gradient gels and separated proteins were 
transferred to PVDF-membranes on which tyrosine-phosphorylation was detected 
using 4G10 mouse antibodies (Upstate Biotechnology, Lake Placid, NY, USA) and 
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visualized using peroxidase-labeled secondary rabbit anti-mouse antibodies and chemi-
luminescence (ECL kit, Amersham, Little Chalfont, UK). To confi rm FLT3 receptor 
expression, blots were stripped and re-probed with anti rabbit polyclonal antibodies 
against FLT3 (Santa Cruz). 
Statistical analysis
Differences in FLT3 and FLT3L expression between patient groups were statisti-
cally evaluated using the Mann-Whitney U test. Differences in mean cytotoxicity 
responses between patient groups were statistically analyzed using the Student t-test. 
All analyses were two-tailed, and differences were considered statistically significant 
at P<0.05.
RESULTS
Using quantitative real-time PCR we confi rmed our earlier gene expression profi ling 
data12 : elevated FLT3 mRNA expression levels were detected in MLL gene rearranged 
infant ALL (infant MLL) as compared to both infants and older children (non-infants) 
carrying germ line MLL genes (Figure 1a). Infant MLL patients (n=41) expressed sig-
nifi cantly (p<0.001) ~16-fold higher levels of FLT3 mRNA as compared to infant ALL 
patients (n=8) and ~2-fold higher than non-infant ALL patients (n=22) (p=0.001). No 
diff erences in FLT3L expression were observed between infant MLL (n=33), infant ALL 
(n=4) and non-infant ALL (n=10) patients (Figure 1b).
PKC412 has been shown to be cytotoxic to lymphoblastic leukemia cell lines car-
rying MLL gene rearrangements. In the present study we investigated the eff ects of 
PKC412 on primary infant MLL cells. In vitro PKC412 cytotoxicity was determined in 
29 infant MLL and 19 non-infant ALL patients, as well as in fi ve AML patients carrying 
FLT3/ITDs. Figure 2a shows the mean cytotoxic response at four increasing concen-
trations of PKC412. At PKC412 concentrations ranging from 40 nM to 375 nM, no 
response is observed in the non-infant ALL samples, whereas these concentrations of 
PKC412 increasingly induced leukemic cell death in the infant MLL samples (Figure
2a). Th e diff erences in cytotoxic response to PKC412 between infant MLL and non-
infant ALL samples were statistically signifi cant at PKC412 concentrations of 125 nM 
and higher (p≤0.01). Moreover, the cytotoxic response to PKC412 in infant MLL was 
comparable to the response observed in FLT3/ITD positive AML samples (Figure 2a). 
Using the median FLT3 expression from Figure 1 as the cut-off  value, the infant MLL 
samples for which both FLT3 expression and PKC412 cytotoxicity data was obtained 
were divided into two groups expressing either low or high levels of FLT3 transcripts. 
As shown in Figure 2B, the cytotoxic response to PKC412 is more pronounced in infant 
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MLL samples expressing high FLT3 mRNA levels as compared to infant MLL samples 
expressing lower levels of FLT3, although these diff erences did not reach statistical 
signifi cance.
To investigate whether activating mutations in FLT3 could explain the observed 
sensitivity to PKC412, we next assessed the infant MLL samples for the presence of 
both internal tandem duplications (ITDs) within the JM domain and activation loop 
mutations aff ecting either Asp835 or Ile836. None of the 39 infant MLL samples tested 
appeared to exhibit a FLT3/ITD. Figure 3a shows the amplifi ed region surrounding 
the FLT3/ITD in MV4;11 cells as a positive control and four examples of FLT3/ITD 
negative infant MLL patients. Out of 36 infant MLL samples tested only one patient 
(~3%) turned out to harbor a mutation within the activation loop FLT3. Figure 3b 
shows incomplete EcoRV digestion of the amplifi ed region harboring codons Asp835 
and Ile836 (encompassing the EcoRV recognition sequence) within the FLT3 activation 
loop from this patient. Complete digestion of this PCR product from a patient sample 
negative for this type of mutation is also shown. Sequence analysis of the mutation 
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Figure 1. Relative FLT3 and FLT3L expression in childhood ALL with and without MLL gene 
rearrangements
A. Relative mRNA expression of the Fms-like tyrosine kinase 3 (FLT3) as determined by quantitative real-time PCR (TaqMan) in infants with MLL 
(n=41) and both infants (n=8) and non-infants (n=22) with ALL harboring germ line MLL genes. B. Relative FLT3 ligand (FLT3L) expression in 
primary infant MLL (n= 33), infant ALL (n=4) and non-infant ALL (n=10) samples. Open circles (Ο) indicate individual patients and lines (—) 
median expression values. Diff erences in FLT3 and FLT3L expression between two patient groups were statistically analyzed using the Mann-
Whitney U test. N.S. means that the p-value was higher than the 0.05 in all comparisons. 
114
C
ha
pt
er
 7
revealed that this patient carried a three-nucleotide (CAT) deletion that results in a 
deletion of isoleucine 836 (Δ836) (Figure 3c).
 Since the frequency of known activating FLT3 mutations in our cohort of infant 
MLL patients appeared to be very low, whereas the infant MLL cells are more sensitive 
to the FLT3 inhibitor PKC412 as compared to leukemic cells from non-infant ALL pa-
tients (Figure 2), we asked whether high-level expression of FLT3 is suffi  cient to auto-
phosphorylate and thus activate FLT3 in the absence of activating mutations. To study 
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Figure 2. In vitro PKC412 cytotoxicity in childhood ALL with and without MLL gene rearrangements
A. MTT dose-response curves showing the mean cytotoxic response to PKC412 in primary leukemic cells from infants with MLL (n=29), 
non-infants with ALL (n=19) and FLT3/ITD positive AML patients (n=5). B. MTT dose-response curves showing the mean cytotoxic response to 
PKC412 in infant MLL samples expressing high levels of FLT3 (n=9) compared to infant MLL samples expressing lower FLT3 levels (n=8). Error 
bars represent standard error of the mean (SEM).
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this, FLT3 phosphorylation was assessed in several infant MLL patients displaying 
varying levels of FLT3 expression as well as in a non-infant ALL patient (Figure 4). Th e 
fi rst three patients express high levels of wild-type FLT3 (as determined by sequence 
analysis of the entire FLT3 gene) and exhibit signifi cant levels of FLT3 posphorylation 
and thus activation, which was completely reversed upon exposure of the leukemic cells 
Figure 7.3 
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Figure 3. FLT3 activating mutations in infant MLL
A. Internal tandem duplication (ITD) of the juxtamembrane domain of FLT3 in the MV4-11 cell line (C; positive control) and four examples of 
infant MLL patients negative for FLT3/ITDs as determined by PCR. B. Amplifi ed PCR-product covering the EcoRV site within the activation loop 
of FLT3, undigested (U) and digested in both a patient positive (+) and negative (–) for this type of mutation. C. Sequence analysis of the 
activation loop mutation found in one out of 36 patients tested. 
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Figure 7.4 
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Figure 4. Relation between high-level FLT3 expression, FLT3 activation and in vitro sensitivity to 
PKC412
A. Immunoprecipitation analysis of FLT3 in primary infant MLL cells carrying wild-type (patients #1-3 and #5) or mutated (patient #4) FLT3, 
cultured for 4 hours in the absence and presence of 500 nM of PCK412. Patient #6 represents a non-infant ALL patient. To determine the 
phosphotyrosine content of FLT3, immunoblots were probed with anti-phosphotyrosine (4G10) and with anti-FLT3 to assess FLT3 loading. B. 
MTT dose-response curves showing the mean cytotoxic response to PKC412 for the individual patients. Error bars represent standard error of the 
mean (SEM) of duplicate wells. C. Representation of the FLT3 expression levels for the individual patients.
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to 500 nM of PKC412 for four hours (Figure 4a). Patient #4 represents the one infant 
MLL patient in which the Δ836 activation loop mutation was identifi ed. As expected, 
reversible FLT3 phosphorylation was also detected in this sample (Figure 4a). Patient 
#5 and #6 are samples from an infant MLL and a non-infant ALL patient respectively, 
expressing low levels of FLT3 (Figure 4c). No FLT3 phosphorylation could be observed 
in these samples (Figure 4a). Figure 4b clearly demonstrates that the patients express-
ing high levels of wild-type FLT3 are sensitive to PKC412, whereas the samples from 
patients expressing low FLT3 levels that lack FLT3 phosphorylation do not respond to 
this drug. Patient #4, carrying the Δ836 activation loop mutation seems to respond only 
at concentrations of PKC412 above 300 nM (Figure 4b).
In the MLL rearranged ALL cell line SEMK2-M1, over-expression of FLT3 has been 
shown to be due to amplifi cation of the FLT3 gene on chromosome 13q12.21 To inves-
tigate whether gene amplifi cations of FLT3 also explained high-level FLT3 expression 
as observed in primary MLL rearranged ALL cells, we screened infant MLL (n=39) 
samples for FLT3 amplifi cations using FISH analysis. However, none of the 39 samples 
tested showed amplifi ed FLT3.
DISCUSSION
Th e class III receptor tyrosine kinase Fms-like tyrosine kinase 3 (FLT3) is one of the 
most frequently mutated genes in hematological malignancies, including both AML 
and ALL.14 Internal tandem duplications (ITDs) of the juxtamembrane (JM) domain 
and mutations within the activation loop of the receptor appeared to constitutively 
activate the receptor in a ligand-independent manner, consequently promoting pro-
liferation and survival.19,31 It was recently shown by microarray analysis that FLT3 is 
over-expressed in patients with MLL gene rearranged ALL (designated MLL), when 
compared to patients with both conventional ALL and AML lacking chromosomal ab-
normalities involving the MLL gene.12 Furthermore, human leukemia cell lines carrying 
chromosomal translocations involving MLL and activated FLT3 are sensitive to FLT3 
inhibition in vitro and in a mouse model of MLL.21 In the present study we show that 
over-expression of wild-type FLT3 is associated with sensitivity to PKC412 in primary 
infant MLL cells.
 Using quantitative real-time PCR analysis we confi rmed high-level FLT3 expression 
in leukemic cells from patients carrying MLL gene rearrangements as previously shown 
by gene expression profi ling.12 Infant MLL patients signifi cantly expressed higher levels 
of FLT3 mRNA as compared to both infant ALL and non-infant ALL samples harbor-
ing germ line MLL genes. Screening the cohort of infant MLL patients for the presence 
of described activating mutations in FLT3, however, showed these mutations to be 
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extremely rare in this group of patients. Nevertheless, comparing the mean cytotoxic 
response of the FLT3 inhibitor PKC412 in leukemic cells from infant MLL and non-
infant ALL patients, we observed that infant MLL patients are markedly more sensitive 
to this drug. To evaluate the relative sensitivity of infant MLL samples to PKC412 in re-
spect to patient samples harboring activating mutations, we also assessed the cytotoxic 
response of PKC412 to several FLT3/ITD positive AML samples. Infant MLL patients 
appeared at least equally as sensitive to PKC412 as AML patients carrying FLT3/ITDs. 
Interestingly, infant MLL patients displaying high-level FLT3 expression tended to be 
more sensitive to PKC412 as compared to infant MLL patient expressing lower levels 
of FLT3, suggesting a relation between the level of FLT3 expression and sensitivity to 
PKC412. In addition we observed that high-level FLT3 expression is associated with 
FLT3 phosphorylation, which is in concordance with previous data.36 Th is suggests that 
high-level expression of wild-type FLT3 may indeed be suffi  cient to activate the recep-
tor in the absence of ligand binding, thereby sensitizing these leukemic cells to FLT3 
inhibition. 
Th e most frequent type of activating mutations found in acute myeloid leukemia 
(AML) are FLT3/ITDs, which occur in approximately 24% of the adult cases and in 
about 10-15% of the childhood cases.14 In adult ALL, tandem duplications of the JM do-
main are rarely observed.14 Recently Armstrong et al. described novel deletions within 
a 7-amino acid region of the JM domain of FLT3 in 3 out of 25 (12%) children with hy-
perdiploid ALL.37 In the present study, no FLT3/ITDs were observed in primary infant 
MLL samples, which is in concordance with data reported by Xu et al.38 In contrast to 
MLL rearranged ALL, FLT3/ITD is rather frequently observed in AML patients carry-
ing intragenic abnormalities within the MLL gene like partial tandem duplications.39,40
In comparison to previously reported frequencies, the incidence of activation loop 
mutations in this cohort of infant MLL samples (~3%) seems rather low. We have previ-
ously reported the incidence of activation loop mutations in another group of MLL 
samples to be approximately 17% (5/30).21 Taketani et al. reported 8 out of 44 (~18%) 
infant MLL cases (less than one year of age) to harbor mutations within the activation 
loop.41 Despite this discrepancy it can be concluded that the incidence of activating 
mutations in infant MLL is <20% (3-18%); therefore, activating mutations do not fully 
explain the relative sensitivity of primary leukemic cells from infant MLL patients to the 
FLT3 inhibitor PKC412. Recently Zheng et al. reported evidence that in primary AML 
samples expressing both wild-type FLT3 and FLT3L, constitutively activated FLT3 can 
be detected as a consequence of autocrine signaling.42 Th eoretically this could sensitize 
these cells to FLT3 inhibition, creating the possibility that the sensitivity to PKC412 as 
observed in primary infant MLL samples might be explained by elevated FLT3L expres-
sion resulting in increased ligand-dependent receptor activation. However, we show 
that FLT3L expression does not statistically diff ers between primary infant MLL, infant 
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ALL and non-infant ALL samples, suggesting that it is unlikely that infant MLL cells are 
more sensitive to PKC412 than non-infant ALL cells due to elevated autocrine receptor 
activation. Th erefore, the fact that infant MLL patients expressing high amounts of 
wild-type FLT3 mRNA exhibit pronounced levels of phosphorylated FLT3 that was 
completely inhibited by 500 nM of PKC412 within a four hour exposure period, sug-
gests that indeed over-expression of wild-type FLT3 is suffi  cient to activate FLT3 in a 
ligand-independent manner. 
Th us, over-expression of FLT3 identifi es groups of patients sensitive to FLT3 inhibi-
tion as is shown in the present study in infant MLL, as well as in AML patients as 
previously reported.43 Th e reason for FLT3 over-expression in MLL patients, however, 
remains unclear. One explanation might be that the immunophenotype of infant ALL 
cells usually is that of a very immature early B-lineage progenitor in which FLT3 ex-
pression has been shown to be the highest.14 Leukemic cells from infant ALL patients 
carrying germ line MLL genes most oft en show common or pre-B phenotypes, ex-
pressing lower levels of FLT3. Th e consistently high expression of FLT3 specifi cally in 
MLL, may also suggest that MLL translocations infl uence the expression of this gene. 
In search for a mechanism by which FLT3 expression is elevated in infant MLL, we 
screened 39 infant MLL samples for the presence of FLT3 gene amplifi cation like found 
in the MLL rearranged ALL cell line SEMK2 which expresses exceedingly high levels of 
wild-type FLT3.21 However none of the patient samples appeared to harbor amplifi ed 
FLT3, excluding gene amplifi cation as the etiology for FLT3 over-expression. 
Aft er the discovery of the high incidence of activating FLT3 mutations in AML, 
several small molecule tyrosine kinase inhibitors were developed to target the con-
stitutive FLT3 signal as potentially novel therapeutic drug. Th e effi  cacy of several of 
the most promising FLT3 inhibitors including PKC412,28 CEP-701,32 and SU541644 is 
currently being tested in phase II clinical trials in adult AML, and preliminary results 
are encouraging.23,24,26,27 Interestingly, sensitivity towards these inhibitors seems to vary 
between the diff erent types of activating mutations.45 PKC412, a staurosporine deriva-
tive originally identifi ed as a inhibitor of protein kinase C (PKC),46 has been shown 
to be eff ective against activated FLT3 resulting from both ITD and mutations in the 
activation loop of the receptor.45 Moreover, PKC412 has also been shown to display 
inhibiting activity against several other class III receptor tyrosine kinases like KDR, 
c-KIT and PDGFR.46 In the present study we demonstrate PKC412 to exhibit anti-
leukemic activity against primary infant MLL cells with activated FLT3 receptors, 
whereas these eff ects were not observed in infant MLL cells lacking activated FLT3. 
Th ese observations imply that leukemic cell death induced upon exposure to PKC412 
in these cells specifi cally seems due to inhibition of FLT3. However, PKC412 has been 
shown almost completely inhibit FLT3 phosphorylation at a concentration of 100 nM.21
While the present study does show a statistically signifi cant diff erence in mean PKC412 
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cytotoxicity between infant MLL (~10% leukemic cell death) and non-infant ALL (no 
response) patients at this dose level, the absolute diff erence is rather small. At higher 
dosages of PKC412 the diff erences are more pronounced, and substantial percentages 
of leukemic cell death are observed within the infant MLL patient group. Given that 
FLT3 activation should fully be inhibited at PKC412 concentrations of approximately 
100 nM, the increasing amounts cell death as observed at higher PKLC412 concentra-
tions may not specifi cally be a consequence of FLT3 inhibition, but may rather be due 
to non-specifi c inhibition of any of the multiple other kinases inhibited by PKC412. 
Th erefore these data suggest that infant MLL samples are signifi cantly more sensitive 
to multi-target kinase inhibition that includes the inhibition of FLT3. Moreover our 
data indicates that FLT3 inhibition alone may not be suffi  cient to induce substantial 
degrees of leukemic cell death in primary leukemia samples, including ITD positive 
AML samples. Th is latter may suggest that the greater degree of cytotoxicity that has 
been reported in similar primary MLL samples using the FLT3 inhibitor CEP-70136
may be due to inhibition of additional targets by this agent at concentrations similar 
to those required to inhibit FLT3. Nevertheless, initial results from phase I/II clinical 
trials using PKC412 or CEP-701 as single agents in refractory adult AML (and MDS) 
patients show that both inhibitors exhibit potential clinical activity. PKC412, admin-
istered orally at a dose of 75 mg three times daily, decreased peripheral blood counts 
by 50% in 14/20 (70%) of the patients.23 CEP-701, given orally at a dose of 60 mg twice 
daily, signifi cantly reduced bone marrow and peripheral blood blasts in 5/14 (36%).24
Th us, receptor tyrosine kinase inhibition using small molecule FLT3 inhibitors may be 
a potential therapeutic approach for innovative treatments for MLL gene rearranged 
infant ALL. Based upon these fi ndings, a phase I/II study using FLT3 inhibitors in 
childhood leukemia is currently in preparation. Possible strategies are to use FLT3 in-
hibitors in relapsed MLL or selected MLL rearranged cases at very high risk of relapse, 
either as single agents or in combination with conventional chemotherapeutic drugs, as 
preclinical studies demonstrating synergistic eff ects of FLT3 inhibitors with cytarabine 
(Ara-C) and daunorubicin have been reported.47
In conclusion, the present study shows that FLT3 expression is high in leukemic 
cells from infants diagnosed with MLL rearranged ALL, and that high FLT3 expres-
sion likely is associated with auto-phosphorylation (activation) of FLT3. Infant MLL 
samples were more sensitive to PKC412 than non-infant ALL samples. However, the 
concentration of PKC412 required to induce substantial levels of leukemic cell death 
in these samples is higher than the concentration needed to completely inhibit FLT3 
phosphorylation. Th us, PKC412 induced cell death in infant MLL samples likely is a 
consequence of multi-target kinase inhibition, including inhibition of FLT3. Th erefore, 
inclusion of multi-target tyrosine kinase inhibitors in current treatment regimens may 
be a potential novel therapeutic strategy to improve outcome for infant MLL patients. 
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Chapter 8
D-HPLC analysis of the entire FLT3 gene for 
mutations and splice variants in MLL rearranged 
and hyperdiploid Acute Lymphoblastic Leukemia
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ABSTRACT
Both MLL rearranged acute lymphoblastic leukemia (MLL) and childhood hyperdiploid 
(HD) ALL are characterized by high-level FLT3 expression, which has been associated 
with ligand-independent FLT3 activation. Lacking known activating FLT3 mutations, 
these samples oft en are assumed to harbor wild-type FLT3 genes. However, data on 
possible yet unidentifi ed activating genetic abnormalities in other regions of FLT3 is 
missing. Using D-HPLC analysis, we screened the entire FLT3 coding sequence for the 
presence of mutations in infant MLL (n=45) and pediatric HD ALL (n=30) samples, 
as well as in mononuclear cell samples from healthy individuals (n=23). Seven small 
genetic abnormalities (mostly point mutations) were found in ≤10% of the infant MLL 
and HD ALL cases. Additionally, we observed fi ve splice variants that (except for one) 
were detectable both in leukemic and non-leukemic samples. Th e level of expression 
of these isoforms (on average ~6% of total FLT3 expression) generally was very low, 
suggesting that these alternative transcripts are naturally generated as by-products of 
normal FLT3 transcription. Th us, evidence of prominent additional genetic alterations 
contributing to ligand-independent FLT3 activation as observed in infant MLL and HD 
ALL is lacking, suggesting that FLT3 activation in these types of ALL mainly results 
from high-level expression of wild-type FLT3. 
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INTRODUCTION
As a member of the class III receptor tyrosine kinase (RTK) family, Fms-like tyrosine 
kinase 3 (FLT3) consists of an extracellular portion comprising fi ve conserved immu-
noglobulin-like (Ig-like) domains, a transmembrane domain and an intracellular re-
gion composed of a juxtamembrane (JM) domain and a protein tyrosine kinase domain 
(TKD) that is interrupted by a kinase insertion domain (KID) (Figure 1). Regulating 
the development of hematopoietic progenitors as well as the activity of mature blood 
cells, class III RTKs play crucial roles in hematopoiesis.1 FLT3 is particularly important 
in early B-lineage development,2 and as such is most abundantly expressed in immature 
B-cells.3
Occurring in approximately 30%4 of the cases, constitutively activated FLT3 as a 
consequence of mutation, has become a hallmark of acute myeloid leukemia (AML). 
Two well described types of activating FLT3 mutations are in-frame internal tandem 
duplications (ITDs) within the JM domain,5 and point mutations or small deletions/
insertions either aff ecting codon Asp835 or Ile836 within the TKD.6-8 Both types of 
mutation result in loss of the auto-inhibitory activity of the receptor,9,10 which gives 
rise to ligand-independent FLT3 signaling, providing leukemic cells with a growth 
advantage and transforming capacity.4,11 Th ese fi ndings prompted the development 
of small molecule tyrosine kinase inhibitors to specifi cally target leukemic cells that 
are dependent on abnormal FLT3 activity. Several of these FLT3 inhibitors (includ-
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Figure 1. Schematic representation of the FLT3 receptor and its exon structure.
The FLT3 receptor consists of an extracellular domain containing fi ve immunoglobulin-like (Ig-like) domains, a transmembrane (TM) domain 
and an intracellular portion consisting of the juxtamembrane (JM) domain and a protein tyrosine kinase (PTK) domain, interrupted by a kinase 
insertion domain (KID). The gene encoding FLT3 comprises 24 exons. Dashed lines connect functional FLT3 domains to their corresponding exons 
encoding them. The position of the fi ve Ig-like domains is based on the corresponding domains within the murine Flt3 receptor as determined 
by Rosnet et al38. Filled (gray) exons represent the deleted exons within the diff erent splice variants, and black arrows indicate the location of 
each genetic abnormality. 
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ing PKC412, CEP-701, SU5416) have been shown to induce apoptosis in vitro in cells 
expressing diff erent types of activating FLT3 mutations. Th e therapeutic potential of 
these inhibitors is currently being explored in phase I/II clinical trials and the initial 
results seem promising.12-14
In childhood acute lymphoblastic leukemia (ALL) the occurrence of activating FLT3
mutations seems restricted to MLL gene rearranged and hyperdiploid (HD; more than 
50 chromosomes) cases. In both of these subtypes of ALL, mutations within the activa-
tion loop of FLT3 occur in 3 to 18% of the cases,14,15 whereas FLT3/ITDs are rarely 
found.16 However, in both MLL rearranged and hyperdiploid ALL a mechanism other 
than mutation appears to result in ligand-independent FLT3 activation. We and others 
have demonstrated that high-level FLT3 expression, which is characteristic for MLL
rearranged17 and hyperdiploid ALL,18 in the absence of ITDs and known TKD mu-
tations, is associated with FLT3 phosphorylation (activation) and sensitivity towards 
FLT3 inhibitors.19,20
As yet, most studies mainly focused on activating ITDs and TKD mutations in FLT3, 
and leukemic samples tested negative for the presence of these mutations oft en are 
regarded as being wild-type. However, reports on novel FLT3 mutations also resulting 
in ligand-independent FLT3 signaling are slowly emerging.21,22 Th erefore, the occur-
rence of possible unidentifi ed activating FLT3 mutations may challenge the proposed 
hypothesis that FLT3 receptor activation as observed in primary MLL and HD ALL 
merely is a consequence of wild-type FLT3 overexpression.7 Th erefore, in the present 
study we screened the entire FLT3 coding sequence for genetic abnormalities using De-
naturing High Performance Liquid Chromatography (D-HPLC) and sequence analysis 
in a large cohort of primary infant MLL and childhood HD ALL samples. 
MATERIALS & METHODS
Patient samples
Bone marrow and/or peripheral blood samples from untreated infants with ALL were 
collected at diagnosis at the Erasmus MC – Sophia Children’s Hospital (Rotterdam, 
Th e Netherlands) and other hospitals participating in the INTERFANT-99 collabora-
tive treatment protocol. Childhood HD ALL samples were collected at the Erasmus 
MC – Sophia Children’s Hospital. Within 24 hours aft er sampling, mononuclear cells 
were isolated applying density gradient centrifugation using Lymphoprep (Nycomed 
Pharma, Oslo, Norway). All samples contained at least 90% leukemic cells, as deter-
mined morphologically on May-Grünwald-Giemase (Merck, Darmstadt, Germany) 
stained cytospins. When necessary, contaminating non-malignant cells were removed 
using immunomagnetic beads as described elsewhere.23 Non-leukemic mononuclear 
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cells were isolated from peripheral blood samples obtained from volunteering healthy 
adult individuals. 
RNA extraction and cDNA synthesis
Total cellular RNA was extracted from a minimum of 5x106 leukemic cells using TRIzol 
reagent (Gibco BRL, Life Technologies) according to the manufacturer’s protocol. Th e 
integrity of the extracted RNA was assessed on 1% agarose gels and quantifi ed spectro-
photometrically at 260 and 280 nm. One μg of RNA was reverse transcribed into single 
stranded cDNA in a total reaction volume of 25 μL containing a mixture of random 
hexamers (2.5 μM) and oligo dT primers (20 nM), 0.2 nM of each dNTP (Amersham 
Pharmacia Biotech, Piscataway, NJ), 200 U Moloney murine leukemia virus reverse 
transcriptase (M-MLV RT) (Promega, Madison, WI), and 25 U RNAsin (Promega) 
at 37ºC for 30 minutes, 42ºC for 15 minutes. Finally, to inactivate enzyme activity, 
samples were incubated at 94ºC for 5 minutes. Th e obtained cDNA was diluted to a 
fi nal concentration of 8 ng/μL and stored at -80ºC.
PCR amplifi cation
With the exception of the fi rst 34 nucleotides the entire FLT3 coding sequence (NCBI 
accession number: U02687) was amplifi ed as nine partially overlapping PCR products 
using primer combinations as listed in Table 1. All PCRs were performed in a total 
reaction volume of 50 μL containing 1x TaqGold buff er II (Applied Biosystems, Foster 
City, CA, USA), 2 mM MgCl
2
, 200 μM of each dNTP (Amersham Pharmacia Biotech.), 
300 nM forward and reverse primer, 1.25 U AmpliTaq Gold DNA polymerase (Applied 
Biosystems) and 40 ng of cDNA (synthesized as described above) as a template. PCRs 
were initiated by a denaturation step at 95°C for 10 minutes, following 40 cycles of 15 
seconds at 95°C and 1 minute at 60°C. 
Denaturing High performance Liquid Chromatography (D-HPLC) analysis
PCR products were denatured at 95°C for 5 minutes and slowly cooled down to 4°C 
to allow heteroduplex formation. Subsequently, 10 μL aliquots of PCR product were 
injected under temperature and acetonnitrile gradient conditions as listed in Table 1, 
and analyzed for the presence of mutations by Denaturing High performance Liquid 
Chromatography (D-HPLC) using the WAVETM-system 3500HT (Transgenomic Inc., 
Omaha, NE, USA). Abnormal PCR products were identifi ed by examination of the 
WAVE patterns using Navigator soft ware (Transgenomic). PCR products suspected to 
harbor genetic abnormalities were sequenced. Sequence analysis was performed on a 
3100 Genetic Analyser (Applied Biosystems) using the BigDye Terminator v1.1 cycle 
sequencing protocol (Applied Biosystems). 
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Table 1. Primer combinations and D-HPLC analysis conditions. 
PCR Sequences† First nt§ Temp (ºC)# Acetonitrile 
gradient (%)*
PCR 1
 Forward
 Reverse
5’-CGC TGC TCG TTG TTT TT-3’
5’-TTG GGT TTC TGT CAT TTT CA-3’
92
468
57 56.7 – 65.7
PCR 2
 Forward
 Reverse
5’-GCC CCA GGG AAC ATT T-3’
5’-AAG GGT TCC CCT ACT TTA AGA-3’
346
860
57 58.8 – 67.8
PCR 3
 Forward
 Reverse
5’-CAG GGG GAA AGC TGT AAA-3’
5’-GAA GGT CCA CGT ACA TCT GA-3’
661
1212
56 59.2 – 68.2
PCR 4
 Forward
 Reverse
5’-AAA GCA TCC CAG TCA ATC A-3’
5’-TGG GAG ACT TGT CTG AAC AC-3’
1056
1474
56 57.4 – 66.4
PCR 5
 Forward
 Reverse
5’-AAG CAT CGG CAA GTC AG-3’
5’-TCC CAT TTG AGA TCA TAT TCA-3’
1388
1868
58 58.3 – 67.3
PCR 6
 Forward
 Reverse
5’-ATG AAA GCC AGC TAC AGA TG-3’
5’-GGG GTA AAA ACT GAA ATT GTG-3’
1772
2238
56 58.1 – 67.1
PCR 7
 Forward
 Reverse
5’-GGG CGT GCA CAC TGT-3’
5’-AGC CAA TCC AAA GTC ACA TA-3’
2093
2555
57 58.1 – 67.1
PCR 8
 Forward
 Reverse
5’-AAG TCG TGT GTT CAC AGA GAC-3’
5’-GGC CGT TTC CTT GAG TC-3’
2470
2858
58 56.8 – 65.8
PCR 9
 Forward
 Reverse
5’-TTC CGG TTG ATG CTA ACT T-3’
5’-TGA AGC AGC AGT TGA TAA TAG AT-3’
2732
3155
57 57.5 – 66.5
†All oligonucleotides were designed using the OLIGO 6.22 software (Molecular Biology Insights, Cascade, CA). §The position of the fi rst 
nucleotide (nt) given for each primer is based on the complete coding sequence for FLT3 with NCBI accession number U02687. #Temperatures 
used for D-HPLC analysis for indicated PCRs. *% WAVE Optimised TEAA buff er B (Transgenomic) from time 0.5 – 5 minutes.
Quantitative real-time PCR 
Quantitative real-time PCR (TaqMan©) analysis was performed on an ABI Prism 7700 
sequence detection system (Applied Biosystems). Using primer combinations as listed 
in Table 2, specifi c amplifi cation of either the wild-type or the alternatively spliced 
FLT3 transcript (lacking exon 7 and exon 8 partially) as well as of the housekeeping 
gene encoding for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was achieved 
and detected using the DyNAmo SYBR Green qPCR kit (Finnzymes, Espoo, Finland). 
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PCRs were carried out in total reaction volumes of 50 μL containing 25 μL SYBR Green 
Master mix (Finnzymes) supplemented with 3 μL MgCl
2
 (25 mM), 300 nM forward 
and reverse primer, 1x ROX reference dye (Finnzymes) and 40 ng cDNA (synthesized 
as described above) as template. Relative mRNA expression of both the wild-type and 
alternatively spliced FLT3 transcripts was calculated using the comparative cycle time 
(C
t
) method.24 Briefl y, target PCR C
t
 values, i.e. the PCR cycle number at which emit-
ted fl uorescence exceeds 10x the standard deviation (SD) of base-line emission, was 
normalized to the GAPDH PCR C
t
 value by subtracting the GAPDH C
t
 value from the 
target PCR C
t
 value, which yields the ΔC
t
 value. From this ΔC
t
 value, mRNA expression 
relative to GAPDH for each target PCR was calculated using the following equation : 
Relative mRNA expression (%) = 2 –ΔCt x 100%. 
Table 2. Primer sequences used for quantitative real-time PCR (TaqMan©) analysis.
Target gene Sequence
FLT3
Wild-type transcript
Forward 
Reverse 
5’-GGC TGT TCA CAA TAG ATC TAA A-3’
5’-AGA ATC CGT ATC ATA GTT CTG TT-3’
FLT3
Alternatively spliced transcript
Forward 
Reverse
5’-GCC CTG GTC TGC ATA TC-3’
5’-CTT GCC ACT ATT GTG AAC AG-3’
GAPDH
Forward
Reverse 
5’-GTC GGA GTC AAC GGA TT-3’
5’-AAG CTT CCC GTT CTC AG-3’
RESULTS
Identifi cation of (novel) FLT3 mutations and the detection of a described SNP 
Using nine partially overlapping PCRs we amplifi ed the coding sequence of the FLT3
gene in leukemic cells obtained from 45 infant MLL and 30 childhood HD ALL patients, 
as well as in mononuclear cell samples from 23 healthy adult individuals. All PCR prod-
ucts were screened for the presence of mutations using Denaturing High Performance 
Liquid Chromatography (D-HPLC). A total of eight diff erent abnormal D-HPLC pat-
terns were observed, all of which corresponded to genetic alterations as determined by 
sequence analysis. Seven of these abnormal D-HPLC patterns corresponded to actual 
mutations, including fi ve diff erent point mutations, a known activating TKD mutation, 
and a seven amino acid insert in the vicinity of described FLT3/ITDs (Tables 3 and 
4). Th e remaining abnormal D-HPLC pattern appeared to correspond to a described 
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single nucleotide polymorphism (SNP) (NCBI: rs1933437). With the exception of this 
SNP, none of these genetic abnormalities were observed in mononuclear cell samples 
from healthy individuals.
One of the fi ve observed point-mutations, i.e. the A‡G at codon L561 which resides 
within the transmembrane (TM) domain, was a synonymous mutation which had been 
described before.25 Th is silent mutation was found in 3 of 45 (7%) infant MLL and 2 of 
30 (7%) HD ALL samples. Th e remaining four point-mutations all resulted in amino 
acid substitutions. Within the infant MLL patient group (n=45) one patient (2%) car-
ried an A‡T mutation that resulted in the substitution of the basic amino acid arginine 
(R) for a polar (uncharged) serine (S) at codon 391 within the fourth Ig-like domain 
(Table 3). Another infant MLL patient (2%) had a G‡A mutation, replacing valine (V) 
for isoleucine (I), both of which are non-polar, hydrophobic amino acids, at codon 557 
within the TM domain (Table 3). Within the childhood HD ALL patient group (n=30), 
two point-mutations were found, both located within the JM domain of FLT3. One 
patient (3%) carried an A‡T mutation resulting in the substitution of basic amino 
acid lysine (K) for a non-polar (hydrophobic) isoleucine (I) at codon 567 (Table 4). In 
another HD ALL sample (3%) a T‡A mutation was detected changing the non-polar 
(hydrophobic) amino acid valine (V) into a polar (uncharged) glutamine (Q) at codon 
579 (Table 4).
Table 3. Novel and described FLT3 mutations identifi ed in primary infant MLL samples.
Mutation Frequency§ Exon Amino acid change Location Described before
A ‡ T 2% (1/45) 9 R391S Ig-like domain 4 No
G ‡ A 2% (1/45) 13 V557I TM domain No
A ‡ G 7% (3/45) 13 Synonymous (L561) TM domain Yes, in AML25
CAT del 2% (1/45) 20 Δ836 JM domain Yes, in MLL7
§6/45 (~13%) infant MLL patients carried a mutation. In 3/45 (~7%) cases the mutation resulted in an amino acid change. 
Table 4. Novel and described FLT3 mutations identifi ed in primary childhood HD ALL samples.
Mutation Frequency§ Exon Amino acid change Location Described before
A ‡ G 7% (2/30) 13 Synonymous (L561) TM domain Yes, in AML25
A ‡ T 3% (1/30) 14 K567I JM domain No
T ‡ A 3% (1/30) 14 V579Q JM domain No
Insertion 3% (1/30) 14 7 aa insert at D586 JM domain No
§5/30 (~17%) childhood HD ALL patients carried a mutation. In 3/30 (~10%) cases the mutation resulted in an amino acid change.
One infant MLL patient (2%) was found to harbor the known FLT3 activating Δ836 
mutation, which is a three base pair (CAT) deletion aff ecting codon I836 within the 
activation loop of the TKD.7 In one childhood HD ALL sample (3%) a seven amino acid 
insertion was identifi ed at codon 586 within the JM domain, which is closely near the 
insertion site at which most FLT3/ ITDs have been identifi ed (Figure 2). Th us, leukemia 
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specifi c mutations leading to amino acid changes occurred in 3/45 (~7%) of the infant 
MLL and 3/30 (10%) of the HD ALL cases. 
Th e D-HPLC pattern associated with the SNP (alleles C/T) in exon 6 identifi ed het-
erozygous patients only. Based on the D-HPLC patterns, no discernment could be made 
between patients homozygous for either the C or the T allele. Th e average estimated 
heterozygosity for this SNP is 0.487 (NCBI: rs1933437). Th e frequency of heterozygous 
samples within the infant MLL and the childhood HD ALL patient groups were 44% 
and 33% respectively. Among the samples from the healthy controls, 38% appeared to 
be heterozygous for this SNP. 
Identifi cation of FLT3 splice variants 
In addition to the above mentioned genetic abnormalities, we found that fi ve of the 
nine PCRs covering the FTL3 gene, generated additional transcripts that were substan-
tially shorter than the wild-type products (Figure 3a en 3b). Sequence analysis showed 
that these shorter products correspond to specifi c FLT3 transcripts lacking entire exons 
(Table 5). Amplifi cation of these regions on genomic DNA from corresponding pa-
tients only detected undeleted (wild-type) sequences, suggesting that these truncated 
transcripts are splice variants. 
Interestingly, with the exception of the deletion of exon 15, which was observed in 
only one out of 45 (~2%) infant MLL samples, the other four splice variants were pres-
ent in all samples (leukemic and non-leukemic) tested. Out of these fi ve splice variants, 
two remained in frame i.e. the deletion of exon 15 aff ecting the tyrosine kinase domain, 
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Figure 2. Internal tandem duplication found in a childhood HD ALL patient.
A. D-HPLC patterns characteristic for the internal tandem duplication (ITD) within the FLT3 juxtamembrane domain, as observed in a HD ALL 
sample compared to the wild-type pattern of the same region. B. Sequence analysis of the FLT3 juxtamembrane (JM) domain, showing a seven 
amino acid (21 bp) insert in this patient. 
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and the deletion of exon 7 plus part of exon 8 aff ecting the third Ig-like domain (Figure
1 + Table 5). Th e other three splice variants were not in-frame and thus are likely to 
generate truncated FLT3 receptors. 
Th e intensity of PCR products on agarose gels as well as the height of D-HPLC pat-
terns corresponding to these PCR products are poor estimates for the actual quantity 
of template sequences originally present within each sample. Th erefore, using primer 
combinations specifi cally amplifying either the deleted or wild-type form (Figure 3c), 
we performed quantitative real-time PCR analysis on one of the splice variants that 
seemed to be present most abundantly in several leukemic samples, i.e. the isoform 
devoid of exon 7 and exon 8 partially. Th is demonstrated that the percentage of splice 
variant present as part of the total amount of PCR product (both deleted and wild-type) 
ranged from ~2% to 4.5% (average ~3%) in non-malignant samples, and in leukemic 
samples ranged from ~2% to 12% (average ~6%) (Figure 3d).
Figure 3. Detection and quantifi cation of one of the FLT3 splice variants
Detection of the FLT3 splice variant devoid of exon 7 and part of exon 8 by A. agarose gel electrophoresis and B. D-HPLC analysis. C. Primer 
combinations for quantitative real-time PCR specifi cally amplifying either the wild-type (FLT3 Fwt and FLT3 Rwt) or the alternatively spliced 
transcript (FLT3 Fsv and FLT3 Rsv). D. Quantifi cation of the splice variant was performed by applying quantitative real-time PCR analysis on 
four mononuclear cell samples from healthy individuals and leukemic cell samples from fi ve infant MLL patients that ostensibly expressed the 
highest levels of this isoform. 
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DISCUSSION
Once identifi ed as being one of the genes most frequently mutated in acute myeloid 
leukemia (AML), FLT3 attracted a lot of attention, especially when the signifi cance of 
these mutations became apparent. Constitutively activating FLT3 in a ligand-indepen-
dent manner, these mutations appeared to be involved in the malignant transformation 
of leukemic cells.4,11 As such, activated FLT3 became a promising therapeutic target 
in AML for which several small molecule inhibitors have been developed. Recently, 
several phase I/II clinical trials showed promising fi rst results with these inhibitors 
against leukemic cells from adult patients with refractory AML.12-14 Both MLL and HD 
ALL are characterized by high-level expression of FLT3,17,18 which is associated with 
activated FLT3 and sensitivity to FLT3 inhibitors.19,20,26 However, these samples oft en 
lack known activating ITD or TKD mutations in the JM domain or tyrosine kinase 
activation loop respectively, suggesting that wild-type FLT3 overexpression may be suf-
fi cient for ligand-independent receptor activation. To study whether other yet uniden-
tifi ed abnormalities in FLT3 contribute to ligand-independent FLT3 signaling in ALL 
or whether indeed high-level expression of wild-type FLT3 is suffi  cient, we screened the 
entire FLT3 coding region for the presence of genetic abnormalities in a large cohort of 
primary infant MLL and childhood HD ALL samples.
Several genetic abnormalities other than described TDK mutations and ITDs were 
found, some of which may potentially be involved in ligand-independent FLT3 activa-
tion. One of the genetic abnormalities was a known C‡T single nucleotide polymor-
phism (SNP) (NCBI: rs1933437). Another point-mutation turned out to be a silent 
A‡G alteration which was reported earlier in 3 out of 34 (9%) primary AML samples,25
but has not been reported in ALL before. Both in infant MLL and childhood HD ALL 
~7% of the patients carried this synonymous mutation. To the best of our knowledge, 
the remaining point mutations have not been reported previously. Th e T‡A (V579Q) 
mutation found within the JM domain of one childhood HD ALL sample, however, 
does resemble a recently described T‡C mutation that results in an alternative alanine 
(A) at the same codon.27 Both of these mutations, as well as the A‡T (L567I) mutation 
found within the JM domain in another HD ALL sample, may lead to constitutive FLT3 
activation. Th e JM domain is believed to play an important role in the auto-inhibitory 
activity of the receptor and disruption of this domain for example by ITDs releases its 
repressive conformation, allowing ligand-independent activation.9 However, whether 
point mutations, like more severe genetic abnormalities such as FLT3/ITDs, are suf-
fi cient to signifi cantly disrupt the JM domain remains to be examined. 
Th e impact of the remaining novel point mutations identifi ed in the present study 
seems less obvious. Th e G‡A (V557I) mutation found in an infant MLL samples re-
sults in an amino acid change within the TM domain, but the class of amino acid at 
137FLT3 D-HPLC analysis in pediatric ALL 
that codon remains similar, as both valine and isloleucine are non-polar (hydrophobic) 
amino acids. Furthermore, the fact that this mutation resides within the TM domain, 
suggests that it may not aff ect domains that appeared critical in the regulation of the 
receptor. However, Akin et al. (2004) recently described a patient diagnosed with mast 
cell disease to carry a germ line F522C mutation within the TM region of the Kit recep-
tor protein, a class III RTK family member of FLT3. Interestingly, introducing c-kit 
carrying this mutation in Cos-7 cells unexpectedly revealed this mutation to induce 
ligand-independent activation of Kit, which could be inhibited by imatinib mesylate.28
Similarly, although extremely rare, an activating mutation within the TM region of the 
non-tyrosine kinase granulocyte colony-stimulating factor (G-CSF) receptor has been 
shown to occur in patients with AML.29 Both of these examples suggest a signifi cant 
role for the TM domain in receptor activation. In contrast, however, three described 
point mutations occurring in the TM region of the fi broblast growth factor receptor 3 
(FGF3), another RTK, do not seem to infl uence receptor activation directly but rather 
induced increased sensitivity of FGF3 to its natural ligand.30
Finally we found a R391S mutation aff ecting the fourth Ig-like domain in one of 
the infant MLL samples. Th e extracellular Ig-like domains of RTKs are responsible for 
ligand binding, and hence a conformational change as a result of this amino acid sub-
stitution may aff ect binding of FLT3 ligand (FLT3L) to its receptor. In correspondence, 
point mutations within the Ig-like region of the fi broblast growth factor receptor 2 
have been reported to aff ect ligand binding specifi city.31 Th us, point mutations within 
the extracellular region may also infl uence ligand binding of FLT3, provided that these 
mutations occur at critical amino acids. However, as will be discussed below, we more 
oft en found abnormalities within the ligand binding domain of FLT3 due to deletions 
of entire exons. 
In addition to point mutations we also identifi ed fi ve splice variants of the FLT3
gene. Th e splice variant that lacks exon 15, deleting part of the tyrosine kinase domain 
(TKD), was found in only one infant MLL sample. Th is in-frame deletion presumably 
results in a major defect in tyrosine kinase activity, either constitutively activating the 
receptor or keeping it permanently inactive. Th e four remaining splice variants found 
in this study were present in all samples tested, both malignant and non-malignant. 
Most leukemic samples displayed small percentages of alternatively spliced transcripts 
comparable to that of mononuclear cell samples from healthy individuals, not exceed-
ing 5%. Th e maximum percentage of splice variant observed in leukemic samples was 
~12%, suggesting that the infl uence of these alternative transcripts on FLT3 activity 
probably is limited. 
Th ese alternatively spliced isoforms can roughly be divided in those that are deleted 
in- frame and those that are not (Table 5). In-frame exon deletions will result in intact 
FLT3 receptors lacking the deleted sequence. Th ose deletions that are not in-frame 
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probably give rise to truncated receptors, as the amino acid sequence following the 
deletion most likely form nonsense messages. As such, the alternatively spliced iso-
form devoid of exon 19, which partially encodes the kinase insertion domain (KID), 
presumably results in a truncated FLT3 receptor lacking the far C-terminal portion of 
the tyrosine kinase domain. Subsequently, this truncated receptor presumably loses 
its auto-phosphorylating abilities, hence can be expected to be inactive. Moreover, the 
KID domain has been shown to be essential for tyrosine kinase activity of the Kit recep-
tor as the lack of this domain abolishes STAT activation,32 supporting that deletions 
aff ecting the KID domain are likely to result in receptor inactivation. 
Th e other three splice variants aff ect diff erent Ig-like domains within the extracellular 
region of FLT3 (Figure 1). Two of these, partially deleting the second and the fourth Ig-
like domain respectively, are not in-frame. Th ese isoforms probably generate transcripts 
that encode truncated FLT3 receptors devoid of intracellular domains. When translated 
these truncated receptors may be secreted as soluble proteins which, when their ligand-
binding ability remained intact, may act as competitive inhibitors of ligand-dependent 
FLT3 signaling. For several class III RTKs, such a mechanism has been described. For 
example, a soluble truncated form of the vascular endothelial growth factor (VEGF) 
receptor (known as sFLT-1) also generated by alternative splicing33 has been shown to 
be expressed both by leukemia and lymphoma cells.34 Co-expression of VEGF, a posi-
tive regulator of angiogenesis, and its receptor has been observed in a variety of solid 
tumors and is believed to promote neo-vascularization and consequently tumor expan-
sion via both paracrine and autocrine signaling. Soluble truncated forms of the VEGF 
receptor appeared to inhibit tumor angiogenesis and growth by actively competing 
for ligand with wild-type membrane-bound VEGF receptors.35 Similarly, a truncated 
soluble form of the fi broblast growth factor receptor 4 (FGFR4) has been described that 
results from alternative splicing in human epithelial breast cancer cell lines MCF-7.36
Again competitive inhibition with the wild-type receptor was observed, as the presence 
of soluble FGFR4 receptor neutralized the FGF-1 induced MAPK phosphorylation 
in these cells.36 Th us theoretically, soluble truncated forms of FLT3 generated by the 
observed splice variants may intercept FLT3 ligand and thereby competitively inhibit 
ligand-dependent FLT3 activation in leukemic cells.
Finally, the last splice variant gives rise to a deletion of exon 7 and part of exon 8. 
Because this deletion is in-frame, translation of this transcript presumably generates 
an intact receptor lacking the third Ig-like domain almost entirely. Since the presence 
of fi ve extracellular Ig-like domains, which harbor the specifi c ligand-binding site, is 
characteristic for class III RTKs, this may have drastic implications for ligand binding 
and specifi city. For example for the class III RTK Fms it has been shown that the three 
N-terminal Ig-like domains constitute the high-affi  nity M-CSF binding region whereas 
the fourth and fi ft h Ig-like domains do not seem to be involved in ligand binding.37 Th us 
139FLT3 D-HPLC analysis in pediatric ALL 
leukemic samples in which this specifi c isoform occurs next to the wild-type receptor 
may display decreased levels of ligand induced FLT3 activation.
To conclude, the observed splice variants of FLT3 presumably translate into recep-
tors that either lack the ability to become activated or inhibit ligand-dependent activa-
tion. Th erefore these splice variants rather strengthen the idea that FLT3 activation in 
FLT3 over-expressing infant MLL and HD ALL samples is ligand independent as ligand 
dependent activation is thwarted. However, given the low expression levels and the fact 
that these splice variants also generally occur in healthy mononuclear cells suggests 
that the presence of these alternative transcripts merely is a concomitant of normal 
FLT3 transcription. In contrast, the leukemia-specifi c mutations giving rise to actual 
amino acid changes may potentially result in ligand-independent receptor activation 
or altered ligand-binding specifi city. However, these mutations only occurred in ~7% 
(3/45) and ~10% (3/30) of the infant MLL and childhood HD ALL patients respec-
tively. Taking into account that FLT3 is consistently highly expressed17 in the majority 
of infant MLL and HD ALL cases, and that high-level FLT3 expression is associated 
with FLT3 phosphorylation,20,26 these mutations do not explain FLT3 phosphorylation 
in the majority of these patients. Th erefore we conclude that the newly described muta-
tions may contribute to ligand-independent FLT3 activation in a minority of infant 
MLL and childhood HD ALL patients, but that in the majority of these ALL patients 
the constitutively activated FLT3 signal is a consequence solely of high-level expression 
of wild-type FLT3.
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Chapter 9
Silencing of the tumor suppressor gene FHIT is 
highly characteristic for MLL gene rearranged 
infant acute lymphoblastic leukemia
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ABSTRACT
MLL rearranged acute lymphoblastic leukemia (MLL) is an aggressive type of acute lym-
phoblastic leukemia (ALL), diagnosed predominantly in infants (<1 years of age). Since 
current chemotherapy fails in >50% of patients with MLL, new therapeutic strategies 
are desperately needed. For this, understanding the biological features characterizing 
MLL is necessary. Analysis of gene expression profi les revealed that the expression of 
the tumor suppressor gene FHIT is reduced in children with MLL rearranged ALL as 
compared to ALL patients carrying germ line MLL. In the present study this fi nding 
was confi rmed by quantitative real-time PCR. In 100% of the infant MLL cases tested, 
methylation of the FHIT 5’CpG region was observed, resulting in strongly reduced 
mRNA and protein expression. In contrast, FHIT methylation in infant and non-infant 
ALL patients carrying germ line MLL was found in only ~60% (p≤0.004). FHIT expres-
sion was restored upon exposing leukemic cells to the demethylating agent decitabine, 
which induced apoptosis. Likewise and more specifi cally, leukemic cell death was in-
duced by transfecting MLL rearranged leukemic cells with expression vectors encoding 
wild-type FHIT, confi rming tumor suppressor activity of this gene. Th ese observations 
imply that suppression of FHIT may be required for the development of MLL, and 
provide new insights in leukemogenesis and therapeutic possibilities for MLL.
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INTRODUCTION
In contrast to acute lymphoblastic leukemia (ALL) diagnosed in children ranging from 
1 to 9 years of age, ALL in infants (<1 year of age) is associated with an exceedingly 
poor treatment outcome,1,2 mainly due to cellular drug resistance.3-5 Furthermore, ALL 
at infancy is characterized by a high incidence of balanced chromosomal translocations 
involving the Mixed Lineage Leukemia (MLL, ALL-1, or HRX) gene, which occur in 
approximately 75% of the cases.2,4 Th e most commonly found translocations involv-
ing MLL in infant ALL include t(4;11)(p21;q23) (~60%), t(11;19)(q23;p13.3) (~20%) 
and, t(9;11)(p22;q23) (~5%). Infants diagnosed with MLL rearranged ALL have a poor 
prognosis (with an event free survival of ~35%),1,2 whereas infant ALL patients car-
rying germ line MLL seem to have a far better outcome.6,7 Recently we demonstrated 
that MLL gene rearranged ALL (designated MLL) displays a gene expression profi le 
that is clearly distinguishable from both ALL and acute myeloid leukemia (AML) bear-
ing germ line MLL genes.8 Taken together these characteristics indicate that MLL is a 
distinct biological entity that responds poorly to conventional ALL-directed therapy. 
Th erefore, in order to improve the prognosis of this disease, new therapeutic strate-
gies are urgently needed. For this, understanding both the biology and etiology of this 
disease is crucial. Important aspects of the biology of MLL like high-level expression 
of certain HOX genes8,9 and of Fms-like tyrosine kinase 3 (FLT3),8-10 are now emerging 
and, as shown here, continue to emerge from gene expression analysis.
Gene expression profi ling revealed that numerous genes are diff erentially expressed 
between ALL patients with and without MLL gene rearrangements, including FHIT
of which the expression appears to be reduced in MLL (Figure 1a). Th e FHIT gene is 
located on chromosome 3p14.2 encompassing the most active common fragile site in 
the human genome i.e. the FRA3B locus.11 Th e encoded protein FHIT is a member of 
the histidine triad protein (HIT) family and appears to be the human orthologue of the 
yeast Scizosaccharomyces pombe protein Aph1 as it exhibits diadenosine triphosphate 
hydrolase activity.11,12 Restoring FHIT expression in cancer cells that lack FHIT expres-
sion has been shown to induce apoptosis and suppresses tumourigenicity.13,14 Likewise, 
exogenous FHIT expression in FHIT negative human breast cancer cell lines enforces 
cells to undergo apoptosis.15 Furthermore, treating heterozygous Fhit knockout mice 
with adenoviral constructs encoding human FHIT, inhibits tumor development in the 
fore stomach upon exposure to the carcinogen N-nitrosomethylbenzylamine.16 Based 
on these and other studies, FHIT is hypothesized to be a tumor suppressor gene. Inter-
estingly, FHIT is aberrantly expressed in a wide variety of human cancers,17 but data on 
FHIT expression specifi cally in childhood acute leukemias is limited. In both cervical18,19 
and gastric cancer,20 abnormal FHIT expression appeared to be a prognostic factor for an 
adverse outcome. However, this has not been confi rmed in human adult leukemias.21,22
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In solid tumors, aberrant or absent expression of FHIT most oft en is due to loss of 
heterozygosity (LOH) or homozygous deletions, and less frequently to 5’CpG island 
methylation. Recently however, Zheng et al. (2004) demonstrated that inactivated 
FHIT as a consequence of 5’CpG island hypermethylation can be found in childhood 
ALL, especially in hyperdiploid and translocation-negative subtypes.23 Here we report 
that in a large cohort of MLL rearranged infant ALL cases silencing of FHIT by 5’CpG 
island hypermethylation was observed in 100% of the cases. Furthermore we show 
that FHIT silencing could be reversed by exposing cells to the demethylating agent 
decitabine, which was accompanied by the induction of leukemic cell death. Finally, 
we demonstrate that transfecting MLL cells lacking endogenous FHIT expression with 
expression vectors encoding wild-type FHIT induced apoptosis and restored the tumor 
suppressor activity of this gene. 
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Figure 1. FHIT expression in childhood ALL with and without MLL rearrangements
Expression of the fragile histidine triad (FHIT) gene as determined by A. micro-array analysis comparing gene expression profi les from patients 
with MLL (n=20) and ALL (n=25) (also see Armstrong et al., (2002)), and B. quantitative real-time PCR relative to the housekeeping gene 
GAPDH (%) in infants with MLL (n=35) and both infants (n=8) and non-infants (n=22) with ALL harboring germ line MLL genes. Boxes (�) 
indicate median expression values, the dashed lines the 25th and 75th percentile respectively. Diff erences in FHIT expression between two patient 
groups was statistically analyzed using the Mann-Whitney U test.
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PATIENTS, MATERIALS & METHODS
Patient samples
Primary bone marrow and/or peripheral blood samples from untreated infants (<1 
year of age) diagnosed with ALL were collected at the Erasmus MC - Sophia Children’s 
Hospital and other hospitals participating in the INTERFANT-99 treatment protocol. 
Samples from ALL patients older than 1 year of age were obtained from the German 
COALL study. Th e presence of MLL gene rearrangements was assessed by RT-PCR and 
FISH analysis. Th is and other patient characteristics were collected by the involved 
study centers. Within 24 hours aft er sampling, mononuclear cells were isolated by 
density gradient centrifugation using Lymphoprep (density 1.077 g/ml ; Nycomed 
Pharma, Oslo, Norway), centrifuged at 480 g for 15 minutes at room temperature. Th e 
collected mononuclear cells were washed twice and kept in culture medium consisting 
of RPMI 1640 medium (Dutch modifi cation without L-glutamine ; Invitrogen life tech-
nologies, Breda, Th e Netherlands), 20% fetal calf serum (FCS ; Integro, Zaandam, he 
Netherlands), 2 mM L-glutamine (Invitrogen) 5 μg/ml insulin, 5 μg/ml transferrin, 5 
ng/ml sodium selenite (ITS media supplement ; Sigma, St Louis MO, USA), 100 IU/ml 
penicillin, 100 μg/ml streptomycin, 0.125 μg/ml fungizone and 0.2 mg/ml gentamycin 
(Invitrogen). Contaminating non-leukemic cells were removed by immunomagnetic 
beads as described by Kaspers et al. (1994).24 All samples contained >90% leukemic 
cells, determined morphologically on May-Grünwald-Giemsa (Merck, Darmstadt, 
Germany) stained cytospins. For RNA and DNA isolation, a minimum of 5 x106 cells 
were lysed in TRIzol reagent (Invitrogen) and stored at -80ºC until extraction.
Cell lines
All human leukemia cell lines used in this study were maintained in RPMI 1640 with 
L-Alanyl-L-Glutamine (Invitrogen) supplemented with 10% FCS (Integro), 100 IU/ml 
penicillin, 100 μg/ml streptomycin and 0.125 μg/ml fungizone (Invitrogen) and grown 
as suspension cultures at 37°C in humidifi ed air containing 5% CO
2
. Both RS4;11 and 
SEMK2-M1 are B lineage acute lymphoblastic leukemia cell lines carrying transloca-
tion t(4;11). MV4-11 is a myelomonocytic leukemia cell line also bearing translocation 
t(4;11). Jurkat, Molt-4 and CCRF-CEM all are T-ALL cell lines, and HL60 is an acute 
promyelocytic leukemia line. Th e cell lines REH and TOM-1 are TEL-AML1 and Phila-
delphia chromosome positive acute lymphocytic leukemias respectively and K563 is a 
chronic myelogenous leukemia (CML) cell line. 
RNA and DNA extraction
Both total RNA and genomic DNA were extracted from a minimum of 5 x106 leukemic 
cells using TRIzol reagent (Invitrogen) according to the manufacturer’s instructions, 
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with minor modifi cations.25 Th e integrity of the extracted RNA was assessed on 1% 
agarose gels. 
Quantitative real-time PCR (TaqMan©)
Extracted RNA was reverse transcribed and the obtained cDNA was used to quantify 
FHIT mRNA expression relative to the endogenous housekeeping gene glyceraldehyde-
3-phosphate dehydrogenase (GAPDH), using quantitative real-time PCR (TaqMan©) 
as described previously25. Primer and probe sequences used to amplify and detect FHIT
and GAPDH expression are listed in Table 1. 
Table 1. Primer and probe combinations used for quantitative real-time PCR (TaqMan©) analysis.
Target gene Primer/probe Sequence
FHIT  forward
 reverse
 probe
5’-TGG CCA ACA TCT CAT CA-3’
5’-ACG TGC TTC ACA GTC TGT C-3’
5’-(FAM)-TGA TGA AGT GGC CGA TTT GTT-(TAMRA)-3’
GAPDH  forward
 reverse
 probe
5’-GTC GGA GTC AAC GGA TT-3’
5’-AAG CTT CCC GTT CTC AG-3’
5’-(FAM)-TCA ACT ACA TGG TTT ACA TGT TCC AA-(TAMRA)-3’
FHIT 5’CpG methylation analysis by MSP
Exposing DNA to bisulfi te converts unmethylated cytosine into uracil bases. Meth-
ylated cytosine bases, however are protected from this modifi cation. Th erefore, aft er 
bisulfi te modifi cation the nucleotide sequence of methylated DNA diff ers from that 
of unmethylated DNA. Using primers specifi c for the predicted sequence of bisulfi te 
treated methylated DNA, allows the amplifi cation of PCR products only when methyl-
ated DNA was present before bisulfi te exposure. Similarly, primers specifi c for bisulfi te 
treated unmethylated DNA can be designed. 
For bisulfi te modifi cation, 5 μg of genomic DNA was denatured in 0.2 M NaOH 
for 15 minutes at 37 °C. Accordingly, 200 μl of a 100 mM hydroquinone, 5 M sodium 
bisulfi te (Sigma) and 0.35 M NaOH (Merck) solution (pH 5) was added per μg of DNA, 
following a 4 hour incubation at 50°C in the dark. Bisulfi te treated DNA was subse-
quently purifi ed using Wizard DNA purifi cation resin (Promega) followed by ethanol 
precipitation.
Methylation specifi c PCR (MSP) using primer sequences specifi c for either meth-
ylated or unmethylated FHIT aft er bisulfi te treatment, was performed essentially as 
described by Zöchbauer-Müller et al. (2001).26 Briefl y, MSP was performed in a total 
reaction volume of 50 μl containing PCR buff er (Qiagen Inc., Valencia, CA, USA), 10 
μl Q-solution (Qiagen), 0.4 mM of each dNTP (Amersham Pharmacia Biotech), 3 mM 
and 5 mM MgCl
2
 for the methylated FHIT and unmethylated FHIT PCR respectively, 
0.6 μM forward and reverse primer,33 1 Unit of HotStarTaq (Qiagen) and ~100 ng bi-
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sulfi te treated DNA as a template. Amplifi cation was performed using a touchdown 
PCR with the annealing temperature decreasing from 71ºC to 64ºC over 14 cycles of 
annealing for 1 minutes and denaturation for 15 seconds at 95ºC, followed by 30 cycles 
of 95ºC for 15 sec and 64ºC for 1 min. Amplifi ed PCR products were analyzed on 3% 
agarose gels. 
Methylation of HL60 DNA
Since the human AML cell line HL60 shows signifi cant FHIT protein expression, bisul-
fi te treated HL60 DNA was used as positive control for the unmethylated FHIT MSP. To 
generate a positive control for the methylated FHIT MSP, HL60 DNA was enzymatically 
methylated using the CpG methylase M.Sss I. Th e methylation reaction was performed 
in a total volume of 100 μl containing NEBuff er 2, 0.16 mM S-adenosylmethionine, 10 
Units of M. Sss I methylase (New England BioLabs, Beverly, MA, USA) and 10 μg HL60 
DNA, incubated at 37ºC for 3 hours, followed by a 20 minute incubation at 65ºC to 
inactivate the enzyme. Accordingly, the methylated HL60 DNA was bisulfi te modifi ed 
as described above. 
5-aza-2’-deoxycytidine (decitabine) treatment of SEMK2 cells 
To study the eff ects of demethylation on FHIT protein expression, SEMK2 cells were 
maintained in culture medium both in the absence and presence of 1 μM of the demeth-
ylating drug 5-aza-2’-deoxycytidine (decitabine) (Sigma) for 7 days. Th e decitabine cul-
ture medium was refreshed daily. Every 24 hours, cell viability was assessed by Annexin 
V staining determined by fl ow cytometry using a FACSCalibur (Becton Dickinson). 
Sampled cells were washed twice in phosphate buff ered saline (PBS), and spun down 
cell pellets were stored at -80ºC until protein extraction.
Ectopic FHIT expression in RS4;11 cells
Th e entire wild-type FHIT coding sequence was amplifi ed using primers containing 5’ 
extensions encoding a BamHI (forward primer) or a BglII (reverse primer) restriction 
sites (Table 2). Accordingly, this wild-type FHIT transcript was cloned into the BamHI/
BglII site of the eukaryotic expression vector pSG5 (Stratagene, La Jolla, CA, USA).
RS4;11 cells (1 x107) were transfected by electroporation in 400 µL RPMI 1640 with 
L-Alanyl-L-Glutamine (Invitrogen) containing 4 µg of either the pSG5-FHIT con-
struct or empty vector (mock transfection), in 4 mm electroporation cuvettes (BioRad, 
Hercules, CA, USA). To compensate for the amount of cell death induced merely as 
a consequence of the electroporation procedure, control cells were electroporated in 
the absence of vector. Electroporation was performed using an EPI 2500 gene pulser 
(Fischer, Heidelberg, Germany) applying a rectangle pulse of 600 V for 2 msec. Aft er 
incubating for 15 minutes at room temperature, the cells were diluted 10-fold with 
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RPMI 1640 (Invitrogen) supplemented with 10% FCS (Integro), 100 IU/ml penicillin, 
100 μg/ml streptomycin and 0.125 μg/ml fungizone (Invitrogen) and incubated at 37°C 
and 5% CO
2
. Cell viability was assessed by Annexin V staining determined by fl ow 
cytometry using a FACSCalibur (Becton Dickinson). Flow cytometry was also used to 
determine transfection effi  ciency of pEGFP-C1 (Invitrogen).
Table 2. Primer sequences used to amplify the entire FHIT coding sequence for FHIT cloning.
Primers Sequence§
FHIT
forward
reverse
                BamHI
5’-CGG GAT CCC GCC ACC ATG TCG TTC AGA TTT GGC-3’
5’-GAA GAT CTT CGG GCG GTC TTC AAA CT-3’
                BglII
§Primer extensions encoding the indicated restriction sites are depicted in italic font. The actual 
primer sequences corresponding to the FHIT gene (NCBI: NM_002012) are depicted in plain font. 
Protein extraction and Western Blot analysis
Cell pellets stored at -80ºC were briefl y thawed and resuspended in 50 μl lysis buff er 
composed of 50 mM Tris buff er, 150 mM NaCl, 100 mM EDTA, 1% Triton X-100, 2 
mM PMSF, 3% aprotinine (Sigma), 4 μg/ml pepstatin (Sigma) and 4 μg/ml leupeptin 
(Sigma). Accordingly, cells were lysed for 15 minutes on ice. Th e supernatant of the 
lysed cells was cleared by centrifugation for 15 minutes at 13000 rpm and 4ºC. Th e 
protein content of the cleared lysates was determined using the BCA protein assay 
(Pierce Biotechnology, Inc., Rockford, USA) with diff erent concentrations of bovine 
serum albumin as standards. 
Cell lysates containing 25 μg of protein were separated on 10% polyacrylamide gels 
topped with 4% stacking gels, and transferred to nitrocellulose membranes (Schleichler 
& Schuell, Dassel, Germany). Western blots were probed with anti-FHIT rabbit poly-
clonal antibodies (Upstate Biotechnology, Lake Placid, NY, USA) or with anti-Actin 
mouse monoclonal antibodies (Sigma). Accordingly, the blots were labeled with either 
peroxidase-conjugated anti-rabbit or anti-mouse IgG antibodies (DAKO, Glostrup, 
Denmark) and visualized using SuperSignal® West Femto chemiluminescent substrate 
(Pierce Biotechnology).
RESULTS
FHIT expression in childhood ALL with and without MLL gene rearrangements
More detailed analysis of our recently published micro-array study comparing gene 
expression profi les from MLL rearranged ALL (MLL) patients (n=20) with those from 
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patients diagnosed with conventional ALL bearing germ line MLL genes (n=24),8
revealed that FHIT expression was signifi cantly (p<0.001) reduced in MLL (Figure
1a). Using quantitative real-time PCR (Taqman) analysis we confi rmed FHIT mRNA 
expression to be low in MLL gene rearranged infant ALL (infant MLL) as compared to 
both infants and older children (non-infants) not carrying chromosomal abnormali-
ties involving the MLL gene (Figure 1b). Infant MLL patients (n=35) express ~15-fold 
less (p<0.001) FHIT mRNA compared to infant ALL patients (n=8) and 11-fold less 
(p<0.001) than non-infant ALL patients (n=22) both carrying germ line MLL genes. 
FHIT 5’CpG island methylation analysis by MSP
Biallelic deletions in FHIT preferentially seem to occur in exon 5, which is the fi rst 
coding exon of the FHIT gene.11,27 Deletions in exon 5 usually result in reduced or aber-
rant expression of FHIT. Th e probe sets for FHIT on the Aff ymetrix micro-array chip 
HG-U95A used in the above described gene expression profi ling study, do not cover 
exon 5 but are located in more downstream exons. In contrast, the forward primer used 
in the present quantitative real-time PCR analysis, is located within exon 5. Since FHIT
mRNA could be detected using this primer, and results similar to the results from the 
micro-array study were obtained, we reasoned that a mechanism other that deletions in 
exon 5 may underlie reduced FHIT expression in patients with MLL. 
Interestingly, all leukemia cell lines with germ line MLL genes tested (HL60, REH, 
K562, Tom-1, Jurkat, Molt-4 and CCRF-CEM) showed varying levels of FHIT protein 
expression (although K562 very weakly). In contrast, RS4;11, SEMK2-M1 and MV4-
11, all of which harbor translocation t(4;11) involving the MLL gene did not express 
the FHIT protein (Figure 2). However, a smaller protein was detected in the RS4;11 
line which may suggest the presence of truncated (aberrant) FHIT transcripts (Figure
2). Nevertheless, no detectable levels of FHIT mRNA were found in these cells. Lack 
of FHIT protein expression in the t(4;11) positive cell lines may be caused by 5’CpG 
island hypermethylation of the FHIT gene. To test this hypothesis we determined the 
methylation status of FHIT using a methylation specifi c PCR (MSP). Th e HL60 cell line 
shows pronounced levels of FHIT protein expression (Figure 2), and does not display 
FHIT 5’CpG methylation. As a positive control for methylated FHIT, enzymatically 
methylated HL60 DNA was used. As shown in Figure 3a, unmethylated FHIT is de-
tected by in bisulfi te treated HL60 DNA and weakly in enzymatically methylated HL60 
DNA. Methylated FHIT is detected in enzymatically methylated DNA only, providing 
sound controls for both methlated and unmethylated FHIT promoters. 
 Th e frequency of FHIT 5’CpG island methylation in bisulfi te modifi ed DNA 
from a group of 87 childhood ALL patients consisting of 44 infants and 43 non-infants 
diagnosed with ALL (Figure 4). In 56% (24/43) of the non-infant ALL patients and 93% 
(41/44) of the infant ALL patients methylated FHIT was observed. Th e non-infant group 
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was further subdivided into a B-lineage (n=32) and a T-lineage (n=11) ALL group, of 
which 56% (18/32) and 55% (6/11) were positive for methylated FHIT respectively. 
Th e infant ALL group consisted of both of MLL germ line (n=8) and MLL rearranged 
(n=36) patients. Th e frequency of FHIT methylation in the 8 infant MLL germ line 
cases (63%) resembled that of the non-infant ALL cases, whereas all 36 MLL rearranged 
cases showed methylated FHIT (p≤0.004). Figure 3b shows FHIT 5’CpG methylation 
in three infant MLL patients bearing the three most common translocations involving 
MLL, and an infant ALL sample exhibiting germ line MLL, negative for FHIT 5’CpG 
island methylation. 
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Figure 2. FHIT protein expression in human leukemia cell lines
FHIT protein expression in human leukemia cell lines as detected on Western blots probed with anti-FHIT polyclonal antibodies. The same blots 
were re-probed with anti-actin monoclonal antibodies to assure equal loading in each lane. 
Figure 3. Methylation analysis of the FHIT 5’CpG region by MSP
A. Positive and negative controls for the methylation specifi c polymerase chain reaction. FHIT methylation specifi c PCR (MSP) and FHIT
unmethylated specifi c PCR (USP) optimized on unmethylated (U) and artifi cially methylated (M) DNA derived from HL60 cells. B. FHIT MSP in 
infant ALL. Examples of FHIT MSP products amplifi ed in DNA samples from infant ALL patients harboring translocation t(4;11), t(11;19), t(9;11) 
involving MLL and from a patient carrying germ line MLL.
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Figure 4. Frequency of FHIT 5’CpG hypermethylation in childhood ALL
Overview of the frequency of FHIT 5’CpG island methylation as determined by methylation specifi c PCR (MSP) in childhood acute lymphoblastic 
leukemia (ALL). The non-infant ALL group is further divided in to a B-lineage and T-lineage ALL group. Infants with ALL were categorized by 
the presence or absence of chromosomal translocations involving the MLL gene. Statistically signifi cant diff erences in the frequency of FHIT
methylation were observed between infant and non-infant ALL patients (p<0.0001) and between MLL rearranged and MLL germ line infant ALL 
cases (p=0.004) (Fisher exact test). 
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Figure 5. FHIT expression in methylated and unmethylated non-infant ALL
Comparison of the relative FHIT mRNA expression between primary non-infant ALL samples displaying either unmethylated (U) (n=8) and 
methylated (M) (n=8) FHIT 5’CpG regions. The diff erence in FHIT expression between both patient groups was statistically analyzed using the 
Mann-Whitney U test.  
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Relation between FHIT 5’CpG methylation, FHIT mRNA and FHIT protein expression
Th e MSP approach only allows the samples to be scored either positive or negative for 
the presence of methylated 5’CpG island sequences. No discrimination can be made 
in the degree of 5’CpG island methylation per sample. Th erefore, to establish a rela-
tion between positive MSP results and reduced FHIT mRNA expression, we compared 
FHIT expression levels between non-infant ALL samples displaying methylated and un-
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Figure 6. Relation between FHIT methylation, FHIT protein and FHIT mRNA expression.
FHIT protein expression assessed by Western blot analysis in samples from both A. infant and B. non-infant ALL patients exhibiting both 
methylated and unmethylated FHIT promoters (as determined by MSP). Patient samples were orderly arranged with increasing levels FHIT
mRNA expression. 
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methylated FHIT genes, for those patients for which both expression and MSP data was 
available. Figure 5 shows that unmethylated samples express signifi cantly higher levels 
of FHIT mRNA as compared to methylated non-infant ALL samples (p=0.003). Figure 6 
demonstrates that methylation of 5’CpG islands within the FHIT gene indeed suppresses 
FHIT mRNA and FHIT protein expression in both infant and non-infant ALL patients. 
In infants (Figure 6a) as well as non-infants (Figure 6b) with ALL, patients with methyl-
ated 5’CpG regions only show weak expression of FHIT protein, whereas patients with 
unmethylated promoters express pronounced FHIT protein levels. Also, a clear relation 
between FHIT mRNA and FHIT protein expression was observed (Figure 6).
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Figure 7. Re-expression of FHIT upon exposure to 5-aza-2’-deoxycytidine (decitabine).
A. Western blot analysis of FHIT protein re-expression in cells from the human leukemia cell line SEMK2-M1 continuously exposed to 10 μM of 
the demethylating agent 5-aza-2’-deoxycytidine (decitabine). FHIT protein expression in HL60 cells (exhibiting unmethylated FHIT promoters) 
served as a positive control. B. Apoptosis induction in SEMK2 cells upon exposure to indicated concentrations of decitabine.
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Re-expression of FHIT upon exposure to 5-aza-2’-deoxycytidine (decitabine)
When FHIT is methylated, treatment of the cells with demethylating drugs like e.g. 
5-aza-2’-deoxycytidine (decitabine), should reverse the silencing and result in the 
re-expression of methylated genes. Figure 7a shows that FHIT protein expression re-
emerges in SEMK2-M1 cells aft er 6 days of exposure to 1 μM of decitabine treatment 
and successively becomes stronger in the following period of time. Treatment of SEMK2 
cells with 1 or 0.5 μM decitabine markedly induced apoptosis (Figure 7b).
Ectopic FHIT expression in RS4;11 cells
Finally, we studied whether ectopic FHIT expression would confi rm tumor suppressor 
activity in MLL rearranged ALL cells lacking endogenous FHIT expression as a conse-
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Figure 8. Eff ects of ectopic FHIT expression in RS4;11 cells. 
A. Western blot analysis of FHIT protein expression in RS4;11 cells transfected with pSG5 vectors encoding wild-type FHIT. B. Relative 
percentage of Annexin V positive RS4;11 cells after transfection with pSG5-FHIT or pSG5 (empty vector) at indicated time points as determined 
by fl ow cytometry. Error bars are from two independent experiments. 
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quence of 5’CpG methylation. For this, RS4;11 cells were transfected with the eukary-
otic expression vector pSG5 encoding wild-type FHIT or empty vector. Accordingly, 
the amount of cell death induced in RS4;11 cells transfected with either pSG5-FHIT or 
empty vector was expressed as a relative measure to control cells subjected to electro-
poration only. Interestingly, re-introduction of FHIT expression (Figure 8a) in RS4;11 
cells clearly induced cell death as compared to cells transfected with empty vector only 
(Figure 8b). Th e transfection effi  ciency in RS4;11 cells (viable aft er electroporation) 
typically ranges between 40-45%. Th us, when corrected for the fact that approximately 
half of the cells actually were transfected with the pSG5-FHIT vector, the eff ects of 
FHIT re-expression in these cells may even be more pronounced. 
DISCUSSION
MLL gene rearranged ALL (MLL) represents a unique leukemia predominantly oc-
curring in children less than one year of age (i.e. infants). Infant MLL is an aggressive 
type of leukemia characterized by exceptionally high white blood cell (WBC) counts 
at presentation, resistance to multiple chemotherapeutic drugs3,5 and a poor treatment 
outcome.1,2 Because these patients oft en relapse on current therapies, a better under-
standing of this disease is warranted in order to develop more specifi c and successful 
treatment strategies. Here we report that infant MLL is characterized by silencing of the 
putative tumor suppressor gene FHIT as a consequence of 5’CpG island hypermethyl-
ation in 100% of the cases. 
Analysis of our gene expression profi ling data revealed FHIT expression to be re-
duced in patients with MLL when compared to other ALL patients.8 Recently a similar 
observation has been reported28. In the present study we confi rmed by quantitative 
real-time PCR that FHIT mRNA expression in infants with MLL is 11 to 15-fold 
lower as compared to both infant and non-infant ALL patients carrying germ line MLL
genes, respectively. We found that the 5’CpG island region of FHIT is methylated in 
all 36 (100%) infant MLL cases tested, whereas in infant and non-infant ALL carry-
ing germ line MLL genes this frequency was approximately 60%. Recently, Zheng et 
al23 reported hypermethylation of the 5’CpG islands region of FHIT to be associated 
with hyperdiploid and translocation-negative subtypes of pediatric leukemia. In their 
study, the frequency of methylated FHIT was determined in childhood ALL patients 
positive for translocations t(12;21)/TEL-AML1, or other chromosomal rearrangements 
(not further specifi ed) as well as in hyperdiploid positive and negative childhood ALL 
patients. Th e highest frequencies of methylated FHIT were observed in hyperdiploid 
positive (~22%) and in B-lineage ALL (~8%) and T-ALL (~38%) patients negative for 
TEL-AML1 or other translocations. Th e frequency of FHIT methylation in TEL-AML1 
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positive patients or patients positive for other translocations both appeared to be <1%.23
Since translocations involving the MLL gene predominantly occur in infant ALL pa-
tients (less than 1 year of age), and these patients are under-represented in the study of 
Zheng and co-workers23, the remarkably high frequency of FHIT 5’CpG methylation 
in patients harboring MLL rearrangements might therefore have been missed in that 
study.
Th e present study further demonstrates that FHIT methylation correlates with 
strongly reduced FHIT mRNA and FHIT protein expression. Moreover, reduced FHIT
expression was confi rmed to be a consequence of 5’CpG island methylation, as expos-
ing leukemia cells carrying MLL gene rearrangements and methylated (silenced) FHIT
to the demethylating drug 5’-aza-2’-deoxycytidine (decitabine) restores FHIT protein 
expression. Finally we demonstrate tumor suppressor activity of FHIT, as restoring the 
expression of this gene in RS4;11 cells in which FHIT is silenced by hypermethylation 
led to FHIT expression and induced leukemic cell death. Th is latter fi nding supports 
that the induced cell death as observed in SEMK2 cells upon exposure to decitabine, 
may at least in part be due to restored tumor suppressor activity of FHIT. Obviously, 
additional genes that become re-expressed upon demethylation may contribute to the 
observed toxicity to decitabine, especially since it was shown that MLL rearranged ALL 
cases display a high incidence of silenced genes that are known to be frequently methyl-
ated in hematological malignancies.29 Th erefore, treatment with demethylating agents 
such as decitabine, may particularly be eff ective in MLL rearranged leukemias. Sup-
porting this hypothesis is our fi nding that decitabine (like other cytosine analogues) 
depend on the human equilibrative nucleoside transporter 1 (hENT1) to cross the 
cell membrane,30 which is highly expressed in infant MLL cells.25 Th us, compared to 
other ALL subtypes, demethylating drugs are likely to up-regulate higher numbers of 
silenced genes and may be transported more eff ectively into the leukemic cells from 
(infant) MLL patients. 
For childhood leukemia a two-step mutation model has been proposed in which the 
fi rst mutation occurs in utero, followed by a second, post-natal mutation giving rise to 
a clinically overt leukaemia.31 Th is is, among other evidence, supported by the fact that 
fusion products generated by balanced translocations involving MLL can be identifi ed 
on neonatal bloodspots of children developing leukemia within the fi rst years of age.32
Assuming that rearranged MLL is one of the initial events in the development of infant 
MLL, the relatively short latency period between this event and the emergence of overt 
leukemia suggests that possibly all genetic hits necessary for infant MLL to develop oc-
cur in utero. FLT3 mutations may be secondary events,9 however the incidence of these 
mutations in infant MLL is limited.10,33,34 Our fi nding that the FHIT gene is silenced 
in all infant MLL cases tested, raises important questions; is loss of FHIT expression a 
secondary genetic hit additionally required for clonal expansion of (pre)neoplastic cells 
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that have acquired translocations involving MLL, or is 5’CpG island hypermethylation 
of FHIT rather a consequence of MLL gene rearrangements? Another possibility might 
be that methylated FHIT is an epigenetic phenomenon that fi ts the immunophenotype 
of highly immature B-cells characteristic for (infant) MLL. 
Encompassing a common fragile site, FHIT is highly susceptible to genomic altera-
tions like translocations and deletions upon exposure to environmental carcinogens 
(e.g. cigarette smoke and alcohol).35 Interestingly, exposure to cigarette smoke has re-
cently been associated with FHIT methylation in non-malignant lung tissue from heavy 
smokers.26 However, parental smoking during pregnancy does not seem to directly 
contribute to the risk of childhood ALL.36,37 Th erefore the fi nding that the frequency of 
FHIT 5’CpG methylation is considerably higher in infant ALL patients carrying trans-
locations involving MLL as compared to MLL germ line infant ALL patients rather 
implies that FHIT methylation may be driven by the MLL fusion protein itself. Th is 
hypothesis is supported by a recent study showing that the leukemia promoting PML-
RAR fusion protein in t(15:17) positive acute promyelocytic leukaemia (APL) binds to 
the promoter region of the putative tumor suppressor gene RARβ2 and subsequently 
recruits either DNMT1 or DNMT3 to hypermethylate the promoter.38 Our fi nding that 
100% of the infant MLL cases tested were positive for FHIT methylation may point to 
a similar mechanism. Especially since all MLL fusion proteins that arise from fusions 
between MLL and one of >30 diff erent partner genes,39 have in common that the MLL
gene donates its N-terminal region containing the transcription repression domain. 
Part of this domain is highly homologues to the eukaryotic DNA methyltransferase 1 
(DMNT1) and is able to specifi cally bind to unmethylated CpG sequences,40 which may 
be critical in MLL-associated oncogenesis.41 However, further studies are required to 
determine whether MLL fusion proteins are indeed responsible for gene silencing.
To conclude, the present study shows that (infant) MLL is uniformly characterized 
by silencing of the tumor suppressor gene FHIT as a consequence of 5’CpG hypermeth-
ylation and that restoration of the expression of this gene induces cell death in MLL
rearranged ALL cells in vitro. Th is suggests that silencing of FHIT may be involved in 
leukemogenesis of this aggressive type of leukemia and may eventually be used as a 
novel therapeutic target.
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SUMMARY,
GENERAL DISCUSSION,
AND PERSPECTIVES
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Acute lymphoblastic leukemia (ALL) in infants is characterized by a high incidence 
(~80%) of rearrangements of the MLL gene, resistance to several important chemother-
apeutic drugs, and a poor treatment outcome. Th e current literature and knowledge on 
infant ALL is extensively reviewed in chapter 2. 
With overall survival rates for infant ALL not exceeding 50%, combination che-
motherapy including glucocorticoids (prednisone and dexamethasone), vincristine, 
L-asparaginase, 6-mercaptopurine, methotrexate, and anthracyclines (daunorubicin 
and doxorubicin) as successfully used for the treatment of childhood ALL, obviously 
is not suffi  cient to treat ALL in infants. In 1998 we observed that, compared to cells 
from older children, leukemic cells from infant ALL patients are signifi cantly more 
sensitive to the cytidine analogue Ara-C (cytosine arabinoside or cytarabine),1 which 
is a drug typically used in the treatment of acute myeloid leukemia (AML). In 1999 
this knowledge was implemented in an international collaborative treatment protocol 
for infant ALL, i.e. INTERFANT-99, in which the use of Ara-C is markedly intensifi ed 
throughout the protocol. 
As shown in chapter 3, Ara-C sensitivity in infant ALL cells appeared to be a result 
of elevated expression of the human equilibrative nucleoside transporter 1 (hENT1), 
on which Ara-C is mainly dependent to permeate the cell membrane.2 Interestingly, 
sensitivity to Ara-C in infant ALL appeared not to be associated with rearrangements of 
the MLL gene, as both MLL rearranged and MLL germ line infant ALL cases appeared 
equally sensitive to this drug in vitro, and comparable ENT1 expression levels were ob-
served between both patient groups (chapter 4). Th us, both MLL rearranged and MLL
germ line infant ALL patients may benefi t from treatment regimens that include Ara-C. 
However, high-dose Ara-C regimens generate high extracellular drug concentrations in 
vivo, causing Ara-C also to enter the cell by passive diff usion. In other words, high-dose 
Ara-C circumvents membrane transport via ENT1. Th erefore, elevated ENT1 expres-
sion in leukemic cells from infants with ALL may only be benefi cial when these patients 
are treated with low to moderate dosages of Ara-C. Nevertheless, improved outcomes 
have been reported for infant ALL patients treated with protocols in which high-dose 
Ara-C had been implemented during the consolidation phase.3,4 Moreover, improved 
outcome for adult pro-B ALL cases (both MLL rearranged and MLL germ line) was 
noted with intensifi ed post-remission therapy including high-dose Ara-C.5 Th e IN-
TERFANT-99 treatment protocol includes both low and high-dose Ara-C throughout 
the duration of the treatment, and therefore may well improve prognosis for infant ALL 
patients treated according to this protocol. 
In addition to sensitivity to Ara-C, infant ALL cells also appeared to be highly sen-
sitivity to the adenosine analogue 2-CdA (2-chlorodeoxyadenosine or cladribine).6
Whether 2-CdA sensitivity in infant ALL can also be attributed to increased ENT1 
expression remains uncertain. Wright, et al (2002) showed that 2-CdA does not seem 
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to enter pediatric ALL cells via the same membrane nucleoside transport system re-
sponsible for cellular Ara-C infl ux.7 However, the number of ALL samples used in that 
study was rather small. In contrast, in chapter 5 we demonstrate a signifi cant correla-
tion between ENT1 expression and sensitivity to 2-CdA in a large cohort of childhood 
AML patients. Interestingly, in several studies synergistic eff ects between Ara-C and 
2-CdA have been observed in vitro,8-10 and the addition of 2-CdA to Ara-C containing 
regimens have been shown to increase complete remission rates in AML.11,12 Taken 
together these observations support that regimens combining the use of Ara-C and 2-
CdA may potentially be benefi cial for infant ALL patients. Moreover, given the appar-
ent sensitivity of infant ALL cells to nucleoside analogues, the use of newly developed 
nucleoside analogous like for example clofarabine13,14 and troxacitabine (troxatyl),15,16
may be interesting candidate drugs for further testing in infant ALL. 
Another specifi c class of nucleoside analogue drugs that may additionally be ef-
fective specifi cally against MLL rearranged infant ALL (infant MLL) cells are DNA 
demethylating cytidine analogues such as 5-azacytidine, 5-aza-2’-deoxycytidine 
(decitabine), or the recently identifi ed agent zebularine.17 Determining the extent of 
concurrent hypermethylation of E-cadherin, Dap-kinase, O6MGMT, p73, p16, p15 and 
p14, Gutierrez, et al18 showed that among several pediatric ALL subtypes, MLL rear-
ranged cases had the highest methylation index (i.e. number methylated genes divided 
by the number of genes studied). Th us, MLL seems to be characterized by aberrant 
DNA hypermethylation. In concordance with this, we observed that the tumor sup-
pressor gene FHIT is silenced by 5’CpG island methylation in 100% of the infant MLL 
cases tested, whereas silencing of this gene in older children with ALL carrying germ 
line MLL genes was observed in only ~50% of the cases (chapter 9). Furthermore we 
demonstrated that ectopic expression of FHIT in MLL rearranged RS4;11 cells that lack 
endogenous FHIT expression, induced leukemic cell death. Likewise, exposing MLL 
cells to the demethylating agent decitabine resulted in re-expression of FHIT protein 
and also induced apoptosis. Th erefore, inhibition of DNA methylation may be an ef-
fective novel therapeutic strategy in the treatment of infant MLL, especially since we 
found that decitabine (like other cytosine analogues) depends on ENT1 to cross the cell 
membrane (chapter 5), which is highly expressed in infant ALL cells (chapter 3). 
Nevertheless, since combinations of multiple chemotherapeutic drugs rather than 
single (types of) agents are required to cure acute leukemias, extending the drug reper-
toire against infant MLL with several nucleoside analogues probably is not suffi  cient to 
signifi cantly improve the survival rate. Th us, in addition to exploring the use of eff ective 
nucleoside analogue drugs, additional innovative treatment strategies are needed that 
either overcome resistance to conventional drugs (like prednisone and L-asparaginase) 
or that involve novel agents that more eff ectively target infant MLL cells in alternative 
ways.
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Overcoming drug resistance inevitably requires understanding of the mechanisms 
involved. Th e fact that infant MLL cells literally are resistant to multiple drugs, may 
suggest the involvement of multidrug resistance (MDR) proteins, which are special-
ized membrane pumps capable of traffi  cking multiple drugs out of the cell. However, 
as shown in chapter 6, drug resistance in infant ALL is not likely a consequence of 
increased drug effl  ux mediated by MDR pumps. 
Although highly informative, studies like this exclude only limited numbers of 
possible explanations for drug resistance at a time. Fortunately, the completion of the 
Human Genome (HUGO) project and the rapidly advanced gene expression profi ling 
technologies, nowadays allows comparisons of multiple patient groups for the expres-
sion of vast numbers of genes Recently, we demonstrated how such a gene expression 
profi ling study can be a suitable approach in understanding drug resistance at a genetic 
level. Comparing gene expression patterns in childhood ALL patients either resistant 
or sensitive to prednisone, vincristine, L-asparaginase, and daunorubicin in vitro, we 
found 124 diff erentially expressed genes to be related to resistance to these drugs.19
Moreover, this gene expression signature associated with drug resistance appeared to be 
highly predictive for clinical outcome. Interestingly, only three of the 124 diff erentially 
expressed genes had been associated with drug resistance before, indicating that the 
mechanisms underlying resistance to these drugs are complex and largely unknown. 
Validation studies now need to further reveal the exact causal mechanisms that are 
involved. Some of these genes may represent universal determinants of drug resistance 
that apply to all types of leukemia, including infant MLL. For example, one of the genes 
that appeared to be over-expressed in prednisone-resistant ALL cells was MCL-1,19 an 
anti-apoptotic member of the BCL-2 family. Since infant MLL cells are highly resistant 
to prednisone1,6 we determined MCL-1 expression in a group of infant MLL samples 
using real-time quantitative PCR. Interestingly, we observed increased MCL-1 expres-
sion in infant MLL samples as compared to samples from older children with ALL, and 
found the expression of this gene to correlate with resistance to prednisone both in 
infant and non-infant ALL (Stam, et al unpublished data). MCL-1 plays an important 
role in the survival of multiple myeloma (MM) cells, in which MCL-1 is abundantly ex-
pressed. Recently, two MCL-1 inhibitors, i.e. Seliciclib (CYC202 or R-roscovitine) and 
R-etodolac (SDX-101) were shown to induce apoptosis in MM cells by down-regulating 
MCL-1.20,21 Moreover, sub-cytotoxic doses of R-etodolac sensitized MM cells to dexa-
methasone induced cell death. Th erefore, prednisone resistance in infant MLL cells 
may possibly be overcome by compounds like Seliciclib and R-etodolac, or may directly 
induce leukemic cell death. Hence, inhibition of MCL-1 may be another therapeutic 
possibility to improve prognosis for infant MLL.
In addition to identifying genes possibly related to resistance to certain drugs, gene 
expression profi ling techniques also are particularly suitable for the identifi cation of 
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novel molecular therapeutic targets. As the comparison of gene expression profi les 
from drug sensitive and resistant patients may lead to the identifi cation of genes in-
volved in drug resistance, comparison of leukemia subtypes may identify genes that 
are uniquely expressed within certain types of leukemia, allowing the development of 
subtype specifi c therapy (i.e. targeted therapy). Several gene expression profi ling stud-
ies have demonstrated that acute lymphoblastic leukemias carrying characteristic chro-
mosomal abnormalities cluster together, clearly distinguishing themselves from other 
ALL subtypes.22-24 Likewise, Armstrong, et al 25 demonstrated that MLL rearranged ALL 
specifi es a unique type of leukemia displaying a gene expression pattern that is clearly 
distinguishable from both ALL and AML without MLL rearrangements. Soon aft er this 
fi nding, this MLL specifi c gene expression signature proved to be of great value for the 
discovery of novel therapeutic targets. 
For example, FLT3, the gene encoding Fms-like tyrosine kinase 3, appeared to be 
one of the genes most consistently highly expressed in patients with MLL.25 FLT3 is 
important in early B-lineage development26 and as such is most abundantly expressed 
in immature B-cells,27 which may explain the high expression of this gene in MLL cells, 
that typically display immature pro-B phenotypes. Normally FLT3 becomes activated 
upon binding of the hematopoietic growth factor FLT3 ligand (FLT3L). However, in 
AML the FLT3 gene appeared to frequently carry mutations that constitutively activate 
this receptor in a ligand-independent manner, providing leukemic cells with a growth 
advantage and transforming capacity (reviewed by Gilliland and Griffi  n).28 As such, 
constitutively activated FLT3 became a promising therapeutic target in AML. Several 
small molecule inhibitors have been shown to effi  ciently inactivate FLT3, accompa-
nied by induced leukemic cell death in vitro. Th ese fi ndings prompted the initiation 
of several phase I/II clinical trials to determine the effi  cacy of these inhibitors against 
leukemic cells from refractory AML patients, and so far the results are promising.29-31
Interestingly, we frequently observed constitutively activated FLT3 in primary samples 
from infants with MLL. However, screening these patients for the presence of known 
activating mutations revealed that such mutations rarely occur. Moreover, in an ad-
ditional study in which we screened the entire FLT3 gene for the presence of possible 
yet unidentifi ed genetic abnormalities that may induce ligand-independent FLT3 ac-
tivation, we found that it is unlikely that activated FLT3 in infant MLL is a result of 
activating mutations. In contrast, we observed that constitutively activated FLT3 in 
MLL patients frequently occurs in patients merely displaying high-level expression of 
wild-type FLT3 (chapter 7 and chapter 8). We (chapter 7) and others32 have recently 
demonstrated that high-level FLT3 expression in primary infant MLL samples is as-
sociated with activated FLT3 and cytotoxic responsiveness to FLT3 inhibitors. Th ese 
data therefore show that FLT3 inhibition may represent a novel therapeutic strategy for 
infant MLL that urgently demands clinical testing. 
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Interestingly, in combination with Ara-C, some FLT3 inhibitors display synergistic 
cytotoxic eff ects in leukemic cells that are dependent on FLT3 activation.33,34 Th is, to-
gether with the in vitro responsiveness of MLL cells to FLT3 inhibition, suggests that 
the addition of FLT3 inhibitors to Ara-C containing regimens may possibly further 
improve treatment response for patients with infant MLL.
In conclusion, infant MLL urgently requires innovative therapeutic strategies in 
order to improve prognosis. For this it is of utmost importance to understand this 
malignancy by accurately studying its unique molecular biological and properties. As 
shown in this thesis, this may provide insights into what type(s) of drugs may actu-
ally be eff ective against infant MLL, and may provide a sense for why other classes of 
drugs are highly ineff ective. Moreover, this may lead to identifying genes specifi cally 
expressed in infant MLL that may be worth testing as therapeutic targets. Th erefore, 
continued molecular studies designed to further gain insight in the biology of infant 
MLL, should ultimately lead to the development of eff ective treatment regimens, turn-
ing this aggressive type of leukemia into a curable disease, as has been reached for older 
children with ALL over the last decades. 
172
C
ha
pt
er
 1
0
REFERENCES
 1. Pieters R, den Boer ML, Durian M, et al. Relation between age, immunophenotype and in 
vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for 
treatment of infants. Leukemia. 1998;12:1344-1348.
 2. Gati WP, Paterson AR, Larratt LM, Turner AR, Belch AR. Sensitivity of acute leukemia cells 
to cytarabine is a correlate of cellular es nucleoside transporter site content measured by 
fl ow cytometry with SAENTA-fl uorescein. Blood. 1997;90:346-353.
 3. Silverman LB, McLean TW, Gelber RD, et al. Intensifi ed therapy for infants with acute lym-
phoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer. 
1997;80:2285-2295.
 4. Reaman GH, Sposto R, Sensel MG, et al. Treatment outcome and prognostic factors for 
infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children’s 
Cancer Group. J Clin Oncol. 1999;17:445-455.
 5. Ludwig WD, Rieder H, Bartram CR, et al. Immunophenotypic and genotypic features, clini-
cal characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: 
results of the German multicenter trials GMALL 03/87 and 04/89. Blood. 1998;92:1898-
1909.
 6. Ramakers-van Woerden NL, Beverloo HB, Veerman AJ, et al. In vitro drug-resistance 
profi le in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and 
immunophenotype. Leukemia. 2004;18:521-529.
 7. Wright AM, Paterson AR, Sowa B, Akabutu JJ, Grundy PE, Gati WP. Cytotoxicity of 2-chlo-
rodeoxyadenosine and arabinosylcytosine in leukaemic lymphoblasts from paediatric pa-
tients: signifi cance of cellular nucleoside transporter content. Br J Haematol. 2002;116:528-
537.
 8. Kristensen J, Nygren P, Liliemark J, et al. Interactions between cladribine (2-chlorodeoxy-
adenosine) and standard antileukemic drugs in primary cultures of human tumor cells from 
patients with acute myelocytic leukemia. Leukemia. 1994;8:1712-1717.
 9. Hubeek I, Peters GJ, Broekhuizen AJ, Kaspers GJ. Modulation of cytarabine induced cyto-
toxicity using novel deoxynucleoside analogs in the HL60 cell line. Nucleosides Nucleotides 
Nucleic Acids. 2004;23:1513-1516.
 10. Chow KU, Boehrer S, Napieralski S, et al. In AML cell lines Ara-C combined with purine 
analogues is able to exert synergistic as well as antagonistic eff ects on proliferation, apoptosis 
and disruption of mitochondrial membrane potential. Leuk Lymphoma. 2003;44:165-173.
 11. Juliusson G, Hoglund M, Karlsson K, et al. Increased remissions from one course for inter-
mediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when 
combined with cladribine. A randomized population-based phase II study. Br J Haematol. 
2003;123:810-818.
 12. Holowiecki J, Grosicki S, Robak T, et al. Addition of cladribine to daunorubicin and cytara-
bine increases complete remission rate aft er a single course of induction treatment in acute 
myeloid leukemia. Multicenter, phase III study. Leukemia. 2004;18:989-997.
 13. Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pedi-
atric patients with advanced leukemia. Blood. 2004;103:784-789.
 14. Faderl S, Gandhi V, Keating MJ, Jeha S, Plunkett W, Kantarjian HM. Th e role of clofarabine 
in hematologic and solid malignancies-Development of a next-generation nucleoside ana-
log. Cancer. 2005.
General Discussion 173
 15. Giles FJ, Garcia-Manero G, Cortes JE, et al. Phase II study of troxacitabine, a novel dioxolane 
nucleoside analog, in patients with refractory leukemia. J Clin Oncol. 2002;20:656-664.
 16. Bouff ard DY, Jolivet J, Leblond L, et al. Complementary antineoplastic activity of the cyto-
sine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells. 
Cancer Chemother Pharmacol. 2003;52:497-506.
 17. Cheng JC, Matsen CB, Gonzales FA, et al. Inhibition of DNA methylation and reactivation 
of silenced genes by zebularine. J Natl Cancer Inst. 2003;95:399-409.
 18. Gutierrez MI, Siraj AK, Bhargava M, et al. Concurrent methylation of multiple genes in child-
hood ALL: Correlation with phenotype and molecular subgroup. Leukemia. 2003;17:1845-
1850.
 19. Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant 
acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004;351:533-
542.
 20. Raje N, Kumar S, Hideshima T, et al. Seliciclib (CYC202 or R-roscovitine), a small-molecule 
cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in mul-
tiple myeloma. Blood. 2005;106:1042-1047.
 21. Yasui H, Hideshima T, Hamasaki M, et al. SDX-101, the R-enantiomer of etodolac, induces 
cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in 
multiple myeloma. Blood. 2005;106:706-712.
 22. Ross ME, Zhou X, Song G, et al. Classifi cation of pediatric acute lymphoblastic leukemia by 
gene expression profi ling. Blood. 2003;102:2951-2959.
 23. Fine BM, Stanulla M, Schrappe M, et al. Gene expression patterns associated with recurrent 
chromosomal translocations in acute lymphoblastic leukemia. Blood. 2004;103:1043-1049.
 24. Yeoh EJ, Ross ME, Shurtleff  SA, et al. Classifi cation, subtype discovery, and prediction of 
outcome in pediatric acute lymphoblastic leukemia by gene expression profi ling. Cancer 
Cell. 2002;1:133-143.
 25. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene 
expression profi le that distinguishes a unique leukemia. Nat Genet. 2002;30:41-47.
 26. Mackarehtschian K, Hardin JD, Moore KA, Boast S, Goff  SP, Lemischka IR. Targeted dis-
ruption of the fl k2/fl t3 gene leads to defi ciencies in primitive hematopoietic progenitors. 
Immunity. 1995;3:147-161.
 27. Stirewalt DL, Radich JP. Th e role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 
2003;3:650-665.
 28. Gilliland DG, Griffi  n JD. Th e roles of FLT3 in hematopoiesis and leukemia. Blood. 
2002;100:1532-1542.
 29. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an 
activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, 
PKC412. Blood. 2005;105:54-60.
 30. Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows 
biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. 
Blood. 2004;103:3669-3676.
 31. O’Farrell AM, Yuen HA, Smolich B, et al. Eff ects of SU5416, a small molecule tyrosine ki-
nase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory 
acute myeloid leukemia. Leuk Res. 2004;28:679-689.
174
C
ha
pt
er
 1
0
 32. Brown P, Levis M, Shurtleff  S, Campana D, Downing J, Small D. FLT3 inhibition selectively 
kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. 
Blood. 2005;105:812-820.
 33. Levis M, Pham R, Smith BD, Small D. In vitro studies of a FLT3 inhibitor combined with 
chemotherapy: sequence of administration is important to achieve synergistic cytotoxic ef-
fects. Blood. 2004;104:1145-1150.
 34. Yee KW, Schittenhelm M, O’Farrell AM, et al. Synergistic eff ect of SU11248 with cytarabine 
or daunorubicin on FLT3 ITD-positive leukemic cells. Blood. 2004;104:4202-4209.
Chapter 11
NEDERLANDSE SAMENVATTING
VOOR NIET-INGEWIJDEN

Nederlandse Samenvatting 177
BLOED
Ons bloed bestaat voor ongeveer de helft  uit een gelige vloeistof (het bloedplasma), 
met daarin de verschillende soorten bloedcellen, waarvan de rode bloedcellen (welke 
het bloed de rode kleur geven) in aantal veruit het sterkst vertegenwoordigd zijn. 
Bloedcellen worden gevormd in een sponsachtig weefsel (het beenmerg) dat zich be-
vindt in de holten van onze botten, waarna ze worden afgegeven aan het bloed. Om 
een gezonde balans tussen de verschillende soorten bloedcellen te handhaven, maakt 
het beenmerg dagelijks ongeveer 1.000.000.000.000 (één biljoen) nieuwe bloedcellen 
aan. Al onze verschillende bloedcellen hebben met elkaar gemeen dat ze ontstaan uit 
dezelfde voorloper cel, de zogenaamde hematopoetische stamcel. Onder invloed van 
complexe mechanismen in het beenmerg ontwikkelen deze onrijpe, nog niet-functio-
nele stamcellen zich tot functionele witte bloedcellen (belangrijk voor de afweer tegen 
ziektekiemen), rode bloedcellen (nodig voor het transport van zuurstof door het gehele 
lichaam) of bloedplaatjes (betrokken bij de stolling van het bloed). Wat betreft  de witte 
bloedcellen maken we onderscheid tussen lymfatische cellen (de B- en T-lymfocyten) 
en niet-lymfatische cellen (zoals monocyten en granulocyten). 
WAT IS LEUKEMIE?
Bij leukemie (Grieks voor “wit bloed”), ofwel kanker van witte bloedcellen, is er sprake 
van een witte bloedcel welke tijdens zijn uitrijping in het beenmerg “ontspoort” en 
zich voortdurend ongecontroleerd begint te vermenigvuldigen. Als gevolg hiervan zal 
er in het beenmerg een opeenhoping plaatsvinden van talloze nog niet-functionele 
witte bloedcellen (de leukemiecellen), allen afk omstig van de onrijpe witte bloedcel die 
initieel “ontspoorde”. Deze opeenhoping van niet-functionele bloedcellen belemmert 
vervolgens de aanmaak van gezonde bloedcellen, hetgeen leidt tot bloedarmoede (door 
een tekort aan rode bloedcellen), bloedingen (door een tekort aan bloedplaatjes) en 
verhoogde gevoeligheid voor infecties (door een tekort aan gezonde witte bloedcellen). 
Uiteindelijk zullen de leukemiecellen ook terecht komen in de bloedsomloop, en van 
daaruit verschillende organen, zoals de milt, de lever en de nieren binnen dringen. 
Wanneer leukemie niet wordt behandeld is het een dodelijke ziekte.
VERSCHILLENDE TYPEN LEUKEMIE
Afh ankelijk van het type witte bloedcel dat “ontspoorde” kan er onderscheid gemaakt 
worden tussen lymfatische en niet-lymfatische (of myeloïde) leukemie. Lymfatische 
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leukemie kan vervolgens weer worden onderverdeeld in B- en T-cel leukemie. Volgens 
hetzelfde principe wordt ook niet-lymfatische leukemie onderverdeeld in verschillende 
typen, afh ankelijk van het type bloedcel dat is ontspoord. Lymfatische en niet-lymfa-
tische leukemie worden vervolgens weer verder onderverdeeld in chronische of acute
leukemie. Acute leukemie ontwikkelt zich zeer snel en agressief, terwijl chronische 
leukemie zich veel langzamer ontwikkelt. 
LEUKEMIE BIJ KINDEREN
In Nederland wordt er jaarlijks bij ±150 kinderen leukemie geconstateerd. Daarmee 
is leukemie de meest voorkomende vorm van kanker op de kinderleeft ijd, en tevens 
de belangrijkste doodsoorzaak van ziekte bij kinderen. Veruit het meest voorkomende 
type leukemie bij kinderen is acute lymfatische leukemie (ALL), welke wordt vastge-
steld bij ongeveer 80% van alle kinderen met leukemie. Dankzij intensief onderzoek in 
de afgelopen decennia is de prognose voor kinderen met ALL heden ten dage relatief 
gunstig. Met behulp van combinatie chemotherapie geneest ongeveer 80% van alle 
kinderen met ALL. Echter, er zijn nog steeds kinderen met ALL waarvoor de prognose 
veel minder gunstig is. 
LEUKEMIE BIJ ZUIGELINGEN 
Ongeveer 4% van alle kinderen waarbij ALL wordt geconstateerd zijn jonger dan 1 jaar 
(zuigelingen). Met overlevingskansen variërend van ongeveer 40-50% is de prognose 
voor zuigelingen met ALL ongunstig te noemen. Naast een slechte prognose, laat ALL 
bij zuigelingen zich karakteriseren door het zeer frequent voorkomen (~80% van de 
gevallen) van chromosomale afwijkingen waarbij het zogenaamde MLL gen betrokken 
is. Bij oudere kinderen met ALL komen dit soort afwijkingen slechts zeer sporadisch 
voor. Deze afwijkingen in het MLL gen komen overigens alleen voor in de leukemiecel-
len, en niet in de gezonde cellen in het lichaam van de patiënt. Dit betekent dat deze gen 
afwijkingen dus niet erfelijk zijn, maar tijdens de ontwikkeling van het kind worden 
verworven. Verscheidene studies hebben aangetoond dat deze MLL afwijkingen tijdens 
de zwangerschap ontstaan in de witte bloedcellen van het nog ongeboren kind, en dat 
het tot stand komen van deze afwijkingen de eerste stap vormen van de transformatie 
van een gezonde witte bloedcel in een leukemiecel. Zuigelingen met ALL worden dan 
ook veelal geboren met leukemie, hoewel dat bij de geboorte nog niet echt merkbaar 
is. Verder is aangetoond dat de aanwezigheid van afwijkingen in het MLL gen in de 
leukemiecellen sterk geassocieerd is met een slechte prognose. Zuigelingen met ALL 
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waarbij deze afwijking niet gevonden wordt, hebben veel betere overlevingskansen. Het 
onderzoek beschreven in dit proefschrift  richt zich dan ook specifi ek op zuigelingen 
met ALL welke worden gekenmerkt door MLL afwijkingen, en dus een slechte prog-
nose. Hoofdstuk 2 bevat een gedetailleerde beschrijving van deze vorm van leukemie 
bij zuigelingen, en hoe de bevindingen uit het in dit proefschrift  beschreven onderzoek 
mogelijk bij kunnen dragen aan een betere behandeling voor deze kinderen.
CELLULAIRE DRUG RESISTENTIE
Hoewel de huidige chemotherapeutische behandelingen zeer eff ectief zijn tegen ALL 
bij kinderen ouder dan 1 jaar, falen deze behandelingen in ongeveer 50% van de zuige-
lingen met ALL. Een belangrijke reden hiervoor is cellulaire chemotherapie resistentie. 
Leukemiecellen van zuigelingen met ALL zijn beduidend meer resistent voor enkele 
belangrijke medicijnen die deel uitmaken van de huidige behandeling van ALL, dan de 
leukemiecellen van oudere kinderen. Er is echter een uitzondering. Leukemiecellen van 
zuigelingen met ALL zijn zeer gevoelig voor het middel Ara-C, dat gewoonlijk gebruikt 
wordt voor de behandeling van acute myeloïde leukemie (AML). 
GEVOELIGHEID VOOR ARA-C EN DE ENT1 TRANSPORTER
Ara-C is een medicijn dat als zodanig nog niet actief is, maar in de cel nog enige veran-
deringen moet ondergaan om uiteindelijk actief te worden. Eenmaal geactiveerd komt 
Ara-C in het DNA terecht, hetgeen resulteert in de vernietiging van de leukemiecel. 
Echter, alvorens het inactieve Ara-C in de cel omgezet kan worden in zijn actieve vorm, 
moet het eerst de cel binnen zien te komen. Als gevolg van de moleculaire structuur 
van Ara-C, kan dit geneesmiddel niet zomaar de leukemie cellen binnendringen, maar 
is hiervoor afh ankelijk van gespecialiseerde eiwitten in de celmembraan (zogenaamde 
nucleoside transporters. Voor het transport van Ara-C over de cel membraan is hoofd-
zakelijk de nucleoside transporter ENT1 van belang. Hoofdstuk 3 van dit proefschrift  
laat zien dat de leukemiecellen van zuigelingen met ALL (welke zeer gevoelig zijn voor 
Ara-C) beduidend meer ENT1 tot expressie brengen dan de leukemiecellen van oudere 
kinderen met ALL. Tevens blijkt de hoogte van de ENT1 expressie te correleren aan 
de gevoeligheid voor Ara-C. Met andere woorden, hoe meer ENT1 transporters er op 
een ALL cel zitten, hoe meer Ara-C de cel binnen kan dringen, en hoe meer leukemie-
cellen van deze patiënt door Ara-C vernietigd zullen worden. Hoofdstuk 4 laat zien 
dat niet alleen zuigelingen met ALL en een MLL afwijking een hoge ENT1 expressie 
vertonen, en dus gevoelig zijn voor Ara-C, maar dat dit ook geldt voor zuigelingen 
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met ALL waarbij MLL afwijkingen ontbreken. In Hoofdstuk 5 is aangetoond dat een 
verhoogde ENT1 expressie niet alleen gerelateerd is aan gevoeligheid voor Ara-C bij 
ALL patiënten, maar dat dit ook het geval is bij kinderen met AML. Dit laatste doet 
sterk vermoeden dat de snelheid waarmee Ara-C de leukemiecel binnen kan dringen 
via ENT1 (ofwel de hoogte van de ENT1 expressie) een algemene factor is die bijdraagt 
aan de gevoeligheid (bij hoge ENT1 expressie), of resistentie (bij lage ENT1 expressie) 
voor dit geneesmiddel. Echter, er is gebleken dat zeer hoge doseringen van Ara-C de 
leukemiecel binnen kunnen dringen zonder gebruik te maken van de ENT1 transpor-
ter. Nadeel hiervan is wel dat dit de kans op bijwerkingen van dit middel verhoogt. De 
bevindingen zoals beschreven in de boven genoemde hoofdstukken van dit proefschrift  
zouden er daarom toe kunnen leiden dat, wat Ara-C betreft , er in de toekomst “therapie 
op maat” ge geven kan worden. Kinderen met acute leukemie waarvan de leukemie-
cellen een hoge ENT1 expressie vertonen, kunnen bij voorkeur behandeld worden 
met lagere Ara-C doseringen. Gezien de gevoeligheid van deze patiënten voor Ara-C 
zullen afgepaste doseringen van dit middel afdoende moeten zijn voor het gewenste 
anti-leukemische eff ect, waarbij de kans op negatieve bijwerkingen beperkt blijft . Aan 
de andere kant zou ervoor gekozen kunnen worden om kinderen met acute leukemie 
waarvan de leukemiecellen een lage ENT1 expressie vertonen, te behandelen met an-
dere medicijnen of, wanneer noodzakelijk, met hoge Ara-C doseringen. 
MULITDRUG RESISTENTIE IN ALL BIJ ZUIGELINGEN 
Naast het voorkomen van eiwitten in de celmembraan die bepaalde medicijnen helpen 
de leukemiecel binnen te dringen (zoals ENT1 dit doet met Ara-C), zijn er ook eiwitten 
in de cel membraan die precies het tegenovergestelde doen. Veel middelen die gebruikt 
worden in de behandeling van ALL bij kinderen vinden vrij eenvoudig hun weg de 
leukemiecel in. Vervolgens dienen deze middelen lang genoeg in de leukemiecel te 
verblijven om de leukemiecel te elimineren. In sommige gevallen bezitten leukemiecel-
len eiwitten op hun celmembraan die heel eff ectief allerlei medicijnen de cel weer uit 
kunnen pompen, nog voordat deze middelen hun dodelijke functie uit kunnen voeren. 
Omdat dit soort membraan transporters niet slechts één, maar vaak meerdere typen 
medicijnen (drugs) tegelijkertijd de cel uit kunnen pompen, worden deze transporters 
“multidrug resistentie eiwitten” genoemd. Het zou dus kunnen dat leukemie patiënten 
waarvan de leukemiecellen multidrug resistentie eiwitten bezitten veel moeilijker te 
behandelen zijn dan patiënten waarvan de leukemiecellen dit soort eiwitten niet bezit-
ten. In Hoofdstuk 6 van dit proefschrift  is onderzocht of de expressie van een aantal 
bekende multidrug resistentie eiwitten bij zuigelingen met ALL (die resistent zijn 
voor veel medicijnen gebruikt in de behandeling van ALL) verhoogd zijn t.o.v. oudere 
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kinderen met ALL (welke over het algemeen gevoelig zijn voor medicijnen gebruikt 
in de behandeling van ALL). De resultaten van deze studie wijzen echter uit dat het 
onwaarschijnlijk is dat multidrug resistentie eiwitten een rol spelen bij de resistentie 
tegen chemotherapeutische middelen bij zuigelingen met ALL. 
FLT3 REMMING ALS NIEUWE THERAPEUTISCHE BENADERING 
Naast eiwitten in de cel membraan die allerlei medicijnen de cel in of uit transporteren, 
zijn er ook membraan eiwitten die fungeren als receptoren. Deze receptoren ontvangen 
signalen (in de vorm van moleculen) afgegeven door bijvoorbeeld omringende (vaak 
andere typen) cellen. Deze signaalmoleculen binden zich vervolgens aan hun recepto-
ren, waarna de receptor het signaal weer doorgeeft  aan de binnenzijde van de cel. De 
verwerking van zulke signalen heeft  meestal tot gevolg dat de cel enige veranderingen 
ondergaat. FLT3 is zo’n membraan receptor. FLT3 speelt een belangrijke rol bij de 
uitrijping van B-lymfocyten. FLT3 komt dan ook met name tot expressie op de mem-
branen van zeer onrijpe B-lymfocyten, en wordt geactiveerd door signaalmoleculen 
afk omstig van het beenmerg. Geactiveerd FLT3 spoort jonge, onrijpe B-lymfocyten aan 
om zich snel te vermenigvuldigen en beschermt ze tegen signalen die tot doel hebben 
de cel te vernietigen. Normaliter is de activering van FLT3 tijdelijk van aard en zal 
alleen plaatsvinden wanneer het nodig is, bijvoorbeeld als het lichaam behoeft e heeft  
aan nieuwe, rijpe (en dus functionele) B-lymfocyten. Hoofdstuk 7 en Hoofdstuk 8
van dit proefschrift  laten zien dat de leukemiecellen van zuigelingen met ALL welke 
MLL afwijkingen bezitten een zeer hoge expressie van FLT3 vertonen, en dat als ge-
volg hiervan de FLT3 receptor onafgebroken geactiveerd is, zelfs in de afwezigheid van 
geschikte signaalmoleculen. Hierdoor worden deze leukemiecellen voortdurend aan-
gespoord om zich te vermenigvuldigen (één van de kenmerken van kankercellen) en 
worden ze beschermd tegen signalen die tot doel hebben de leukemiecel te vernietigen 
(zoals geïnduceerd door allerlei chemotherapeutische middelen). Dit zou dus heel goed 
kunnen bijdragen aan de verklaring waarom deze vorm van leukemie zo agressief is en 
moeilijk te behandelen. In Hoofdstuk 7 is onderzocht of het middel PKC412, dat in 
staat is FLT3 te remmen, van therapeutisch belang kan zijn voor zuigelingen met ALL. 
Uit dit onderzoek bleek dat PKC412 inderdaad in staat is geactiveerd FLT3 op ALL 
cellen van zuigelingen met MLL afwijkingen te inactiveren, hetgeen gepaard gaat met 
de vernietiging van de leukemiecel. Het remmen van FLT3 zou daarom een eff ectieve 
nieuwe therapeutische benadering kunnen zijn voor zuigelingen met ALL. 
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INACTIVERING VAN FHIT IN ALL BIJ ZUIGELINGEN
In het algemeen wordt kanker veroorzaakt door de foutieve activering van genen 
die ongecontroleerde celdeling (vermeerdering) stimuleren (de zogenaamde proto-
oncogenen) en/of de inactivering van genen die normaal gesproken helpen voorkomen 
dat een gezonde cel een kankercel wordt (de zogenaamde tumor suppressor genen). 
Hoofdstuk 9 van dit proefschrift  laat zien dat ALL bij zuigelingen gekarakteriseerd 
wordt door de inactivering van het tumor suppressor gen FHIT. Bij oudere kinderen 
met ALL komt de inactivering van FHIT veel minder frequent voor. Verder laat Hoofd-
stuk 9 zien dat het re-activeren van FHIT in leukemiecellen van zuigelingen met ALL 
tot gevolg heeft  dat de leukemiecel wordt vernietigd. Dit suggereert dat het inactief 
zijn van FHIT mogelijk betrokken is geweest bij het tot stand komen van de leukemie. 
Met andere woorden, om leukemiecel te kunnen worden heeft  deze cel het FHIT gen 
uit moeten zetten; immers de activering van FHIT in deze cellen resulteert in celdood. 
Nu bestaan er verscheidene nieuwe medicijnen die in staat zijn geïnactiveerde genen 
te activeren. Zoals beschreven in Hoofdstuk 9 re-activeren dit soort medicijnen ook 
geïnactiveerd FHIT. Een gunstige bijkomstigheid is dat dit soort middelen sterk lijken 
op het middel Ara-C, en daarom ook gebruik maken van de ENT1 transporter om de 
leukemiecel binnen te dringen (Hoofdstuk 5). Zoals beschreven in Hoofdstuk 3 bezit-
ten de leukemiecellen van zuigelingen met ALL zeer veel ENT1 transporters op hun 
membraan, waardoor dit soort middelen heel makkelijk de leukemiecel binnen kunnen 
komen. Het zou daarom heel goed kunnen dat deze medicijnen zeer eff ectief zijn voor 
de behandeling van ALL bij zuigelingen, hetgeen dan ook nader onderzocht zal worden 
in toekomstig onderzoek. 
CONCLUSIES EN PERSPECTIEVEN
Om de prognose voor zuigelingen met ALL te verbeteren zijn er dringend nieuwe in-
novatieve behandel strategieën nodig. Teneinde dit te bereiken is het van groot belang 
dat we doorgaan met het bestuderen van de unieke moleculair biologische eigenschap-
pen van deze agressieve vorm van leukemie. Zoals dit proefschrift  laat zien, kunnen dit 
soort studies inzichten verschaff en in waarom sommige medicijnen niet werken, en 
welke (soort) medicijnen nu juist wel erg eff ectief zouden kunnen zijn. Het beschreven 
laboratorium onderzoek kan uiteindelijk leiden tot de identifi catie van medicijnen 
die het waard zijn om daadwerkelijk bij patiënten te gaan testen, zoals bijvoorbeeld 
medicijnen die fungeren als FLT3 remmers. Nu is het onwaarschijnlijk dat een enkel 
medicijn op zichzelf voldoende is om de prognose voor zuigelingen met ALL drastisch 
te verbeteren. Echter, wanneer op deze manier meerdere medicijnen gevonden kunnen 
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worden die heel specifi ek ingrijpen op verschillende biologische kenmerken van dit 
type leukemie, worden de mogelijkheden om tot een meer adequate behandeling te 
komen aanzienlijk vergroot. Resultaten voortvloeiend uit voortdurend laboratorium 
onderzoek zullen er dan ook toe moeten leiden dat ALL bij zuigelingen uiteindelijk een 
beter te genezen ziekte wordt, zoals dit in de afgelopen decennia bereikt is voor oudere 
kinderen met ALL.
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draait. Namelijk, kinderen met leukemie. Ik wil alle kinderen met leukemie, en hun 
ouders, die ertoe besloten hebben hun bloed en beenmerg te doneren als bijdrage aan 
het onderzoek naar deze afschuwelijke ziekte, vanuit de grond van mijn hart bedanken. 
Zonder jullie enorme bijdrage is het onderzoek naar leukemie eenvoudigweg niet mo-
gelijk. Ik wil jullie bedanken dat ik onderzoek heb mogen doen op jullie leukemiecellen, 
en hoop dat ik daarmee mijn spreekwoordelijke steentje bij heb kunnen dragen, en nog 
lang bij zal mogen dragen, aan de bestrijding van deze uiterst oneerlijke, levensbedrei-
gende ziekte bij kinderen. 
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gen aan het in dit proefschrift  beschreven onderzoek, en het tot stand komen van dit 
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Zoals de mensen die mij de kans hebben gegeven onderzoek te doen naar leukemie 
bij zuigelingen. Te beginnen bij mijn promotor Prof.dr. R. Pieters. Beste Rob, enorm 
bedankt voor je prettige, ongecompliceerde en vaak gestroomlijnde (mt. vr. gr. r.) ma-
nier van begeleiden. Dank ook voor je ongeëvenaarde relativeringsvermogen en kristal 
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de kans hebt gegeven m´n eigen onderzoeksgroep te vormen binnen het lab. Een kans 
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te zetten op de afdeling kinderoncologie aan het Radboud ziekenhuis te Nijmegen. Ik 
hoop (en weet dat ook eigenlijk wel) dat je beseft  dat je een belangrijk aandeel hebt 
gehad in mijn besluit in Rotterdam te blijven. 
Tevens wil ik mijn copromotor Dr. M.L. den Boer bedanken. Beste Monique, ontzettend 
bedankt voor de enorme vrijheid de je me altijd hebt geboden, waardoor ik zoveel van 
mezelf en mijn ideeën in het project heb kwijt gekund. Bedankt ook voor je precieze 
nauwkeurigheid, waardoor ik met een gerust hart zo af en toe eens een typfoutje (of 
twee) kon laten liggen in de talloze teksten die je in de afgelopen jaren voor me hebt 
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mezelf te zijn), waar je me dan een kwartiertje van tevoren nog even aan herinnerde, 
zodat ik bij veel van de door mij (bijna) vergeten afspraken keurig op tijd aanwezig was. 
Trots kan ik je melden dat ik inmiddels een agenda heb (en (soms) gebruik)).
I’d like to thank Scott Armstrong and Steve Sallan from the Dana Farber Cancer Insti-
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KG). Een warm nest waar ik een kleine zes jaar geleden als verlegen knaapje door Ka-
rin werd voorgesteld als Arnold en/of Roland, of zoiets. Inmiddels niet meer zo heel 
erg verlegen durf ik hardop te schrijven dat het lab KG de leukste afdeling binnen het 
Erasmus MC is. Een afdeling, overigens, waarvan ik sterk vermoed dat er in het geheim 
gigantische subsidies worden ontvangen voor het van de straat houden van ondergete-
kende. Het liefst zou ik jullie allemaal op persoonlijke wijze willen bedanken, maar ik 
zou niet weten bij wie te beginnen en waar te eindigen. Tevens zou het m’n proefschrift  
wel heel erg dik maken, waarbij de verhouding onderzoek : dankwoord wel heel onge-
bruikelijk proporties aan zou nemen. Daarbij mag ik toch hopen dat jullie stuk voor 
stuk wel weten hoe zeer ik jullie waardeer. Dus, doe ik het als volgt; allemaal bedankt 
voor alle gezellige borrels, wijn proeverijen (die doorgaands weer naadloos overgingen 
in gezellige borrels), de fi jne werksfeer, de leuke kerstvieringen, de lachwekkende fi lm 
avonden, het oplossen van mijn eenzaamheid, de spannende dart avonden, de leuke 
labuitjes, het reanimeren van mijn computer, het luisteren naar mijn oeverloos gezwam, 
het voorschieten van geld voor een TAXI!!!, het uithouden met mij en mijn gezang, de 
leuke conversaties, de boeiende discussies, de zinloze gesprekken, jullie uiteenlopende 
soorten humor, alle AXE “click” momenten, en het feit dat jullie na al die jaren nog altijd 
even aardig voor me zijn. Lieve collega’s, en Th eo (buiten categorietje), bedankt! 
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Pauline en Susan, zonder jullie toewijding en inzet wat betreft  de verwerking van het 
bloed en het beenmerg van de talloze leukemie patiënten dat wekelijks (de weeken-
den inbegrepen) ons lab bereikt, zou ons lab eenvoudigweg niet het lab zijn dat het is. 
Meestal worden jullie zo essentiële werkzaamheden in wetenschappelijke publicaties 
beschreven in slechts één alinea. Maar neem van mij aan, jullie zijn een volledige ency-
clopedie in goud waard! Bedankt!
Marli, dank je dat je me de eerste jaren van mijn leven als AIO, leek die ik was, wegwijs 
maakte (en vooral bijstond) in het kweken van leukemiecellen. Sinds je ons lab verlaten 
hebt, is er daar nooit meer een directe duplo telling (DDT) uitgevoerd, en de geruchten 
doen de ronde dat het een techniek is die eigenlijk niet bestaat... Maar wij weten wel 
beter, toch? 
Pauline (a.k.a. Plien, a.k.a. Mini-me, a.k.a. Hoofdzuster Oost-nederland, a.k.a. Die 
kleine, a.k.a. Hoofdzuster Amsterdam & omstreken), wat moet ik in vredesnaam zonder 
je? Onvermoeibaar en altijd even vrolijk pipetteer je al mijn hersenspinsels aan elkaar. 
Toen ik benaderd werd met het aanbod om m´n eigen lab op te zetten in Nijmegen, 
was je onvoorwaardelijk bereidt je met mij in dat grote avontuur te storten. Toen ik op 
het laatste moment besloot toch in Rotterdam te blijven, bleef je even onvoorwaardelijk 
achter me staan. Dat is me niet in de koude kleren gaan zitten. I owe you one! Niet 
alleen ben je een fi jne collega en een prima analist, maar hebben Saskia en ik jou en 
Marien tevens mogen leren kennen als goede vrienden. 
Ook wil ik graag mijn dank betuigen aan de analisten van het specieel laboratorium, 
waar de deur altijd open staat voor een cappuccino en een gezellig praatje. Henk, 
Rolinda, Mieke, Carla, Emmy, Eline, Mirjam, ook jullie ontzettend bedankt!
En dan natuurlijk de AIO´s van het eerste uur: Amy, Wendy en Barbara. Zo groen als gras 
betrokken we in 2000 als startende AIO’s onze “AIO kamer”... toen nog gewoon als mede 
AIO’s. In de periode die volgde zijn jullie voor mij veel meer geworden dan slechts mede 
AIO’s. Naast inmiddels ex-mede AIO’s, werden jullie voor mij vriendinnen, moeders, 
(grote) zussen, verdomd goeie opvoeders, en, als ik zo vrij mag zijn, m’n meisjes. Als ik 
denk aan hoe wij ooit tot elkaar zijn gekomen, moet ik altijd denken aan “een schitterend 
ongeluk”. En ik denk dat dat precies is wat het was. Zoals Amy al in haar dankwoord 
schreef, als volslagen vreemden zijn we op een kamer gezet, en als goede vriendinnen (ik 
ben tenslotte ook maar gewoon een oud wijf (toch Barbara?)) gaan we weer ieder onze 
eigen weg. Ik hoop dat we nog lang de ex-AIO-diner-date in stand zullen houden.
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Amy, wat zal ik onze zang sessies missen. Ik ben ervan overtuigd dat er nooit meer twee 
mensen zullen zijn die samen zulke excentrieke noten kunnen raken zoals wij... We heb-
ben reeds meer dan eens moeten concluderen dat menig professioneel zanger en zangeres 
zichzelf gelukkig mag prijzen dat wij besloten hebben onze zangtalenten niet te exploite-
ren. Amy en Colin, bedankt voor alle gezellige avondjes. Ik hoop dat we, ondanks onze 
drukke agenda’s, nog vaak als kolonisten het eiland Catan zullen ontdekken. Enehhh... 
Amy, even tussen jou en mij, onze kant van de kamer was inderdaad de beste! 
Wendy, het is voor mij altijd een raadsel geweest hoe je het voor elkaar hebt gekregen 
om als arts, moeder van twee jonge kinderen, en dagelijkse reistijden van ongeveer 3 
uur, er even een promotie naast te doen... en nog als eerste van ons clubje promoveren 
ook, petje af! Petje heel diep af! Bedankt voor al je gezelligheid. Ik wens je heel veel 
succes met je carrière als klinisch geneticus. 
Barbara, zelden heb ik iemand ontmoet die zo sociaal is, zo goed kan luisteren, zichzelf 
zo kan wegcijferen, en tegelijkertijd toch zo opbouwend kan bekritiseren, en zo sterk en 
uitgesproken is als jij. Als kinderarts in de maak stelde je voor mij al snel de diagnose: 
oud wijf met een belabberde slaaphygiëne. Eerlijkheidshalve dien ik toe te geven dat 
je zeer waarschijnlijk gelijk hebt. Ik wens je het allerbeste toe, en hoop je straks als 
kinderarts nog regelmatig tegen het lijf te lopen. 
Natuurlijk wil ook overige AIO’s bedanken die er later bij zijn gekomen (en soms ook 
weer vroegtijdig vetrokken). Henne, Arantza, Marrit, Judith, Pieter, Martine, Brian, 
Ines, heel veel succes met jullie onderzoek en het schrijven van jullie proefschrift en. 
Daarnaast wil ik ook onze kersverse postdocs Onno en Esther bedanken voor het ruim-
schoots op pijl houden van het gezelligheidsniveau in de “AIO-kamer” na het vertrek 
van mijn zo geliefde meisjes. Onno, ik begrijp dat deze last je teveel is geworden, en ik 
wens je dan ook heel veel succes met je nieuwe baan als proteomics specialist aan de 
Universiteit Utrecht. 
Ook wil ik graag alle oncologen van onze afdeling kinderoncologie/hematologie be-
danken voor jullie interesse in het onderzoek waar ik me de laatste jaren mee bezig 
heb gehouden. Wim, Marry, Auke en Robert, bedankt dat jullie me hebben bijgestaan 
tijdens mijn ernstigste stress momenten, namelijk wanneer er gevlogen moest worden. 
Dankzij jullie heb ik verscheidene keren mijn hevige drang om in blinde paniek door 
het vliegtuig te gaan rennen weten te onderdrukken. 
Vaak gaat het er in het leven niet om wie je bent, maar wie je kent. Jeanine (eigenlijk het 
echte hoofd van de afdeling) en Jacqueline (eigenlijk jaarlijks de echte medewerkster 
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van het jaar), ik ben daarom heel erg blij dat ik jullie ken. Bedankt voor al jullie geregel 
op de achtergrond. 
Mijn ouders wil ik bedanken dat zij het mogelijk hebben gemaakt dat ik naar hartelust 
heb kunnen studeren. Ook wil ik jullie bedanken dat jullie het uit hebben weten te 
houden met een zoon die het vaak nodig vond te beginnen met studeren als jullie het 
tijd vonden om naar bed te gaan. Lieve pa en ma, ik hoop dat het een troost voor jullie 
is dat ik nog steeds het liefst studeer als de meeste mensen slapen gaan, zonder dat jullie 
daar nog last van hebben. Hoe dan ook, ik hoop dat dit proefschrift  duidelijk maakt dat 
ik dat niet (alleen) doe voor mezelf, maar vooral voor kinderen, en hun ouders, die wel 
meer zorgen aan hun hoofd hebben dan het wel of niet op tijd gaan slapen. 
Lieve Saskia, tenslotte wil ik jou bedanken voor, tja, zo’n beetje alles. Samen hebben we 
twee prachtige kinderen, Owen en Caitlin, en toch stel ik je dagelijks voor de zware taak 
drie kinderen op te voeden. Ik kan je zeggen, met twee van de drie boek je enorm veel 
vooruitgang! Niet alleen maak je het mogelijk dat ik af en toe ´s avonds wat langer op 
het lab kan blijven, of soms eens in het weekend een experimentje kan doen, ook zie je 
kans om je binnen je eigen werk te ontwikkelen, en met succes. Ik ben waanzinnig trots 
op je, en hou enorm veel van jou, en onze kinderen. 
Ronald
